Nitrogen-containing heterocyclic compounds with MYT1 inhibitory activity

Abstract

[式中，R;4選自由可被取代的C;6-C;10芳基(R;4A)、可被取代的4~10員雜環基、以及可被取代的5~10員雜芳基(R;4HA)所組成之群組；R;5及R;6與該等所鍵結之原子一起形成可被取代的D環；D環選自由3~10員單環脂環式環、苯環、3~12員單環雜環、以及5~6員單環芳香族雜環(D;HA)所組成之群組；D環上的任意2個相鄰的取代基可與該等所鍵結之原子一起形成可被取代的E環]。;

Description

Nitrogen heterocyclic compounds having MYT1 inhibitory activity The present invention relates to a nitrogen heterocyclic compound having MYT1 inhibitory activity, or a salt thereof, or a solvate thereof. Further, the present invention relates to a medicament useful for the treatment and prevention of cancer, which contains the above as an active ingredient. Cells are exposed to exogenous or endogenous stress factors for a day and are damaged by DNA. Usually, cells damaged by DNA repair the DNA damage by activating the DDR (DNA Damage Response) pathway. In most cancers, it is known that genes and proteins related to the DDR pathway are abnormal, and treatment methods thereof are being investigated (Non-Patent Documents 1-2). One of the treatment methods for cancers in which genes and proteins related to the DDR pathway are abnormal is to use a PARP inhibitor for the treatment of cancers having a BRCA1 mutation or a BRCA2 mutation (Non-Patent Document 3). Further, at present, ATM, ATR, CHK1, DNA-PK, WEE1, etc., which are genes and proteins related to the DDR pathway, can be cited as target candidates, and a large number of studies are being conducted (Non-Patent Document 4). MYT1 is an enzyme of the WEE1 family and is known as a negative regulator of CDK1. MYT1 inactivates CDK1 by phosphorylating CDK1 and plays an important role in the regulation of the cell cycle. In recent years, new MYT1 inhibitors have been reported, and it has been reported that they cause synthetic lethality in specific cancers (Non-Patent Document 5), but there are no approved pharmaceuticals yet, and thus new therapeutic drugs are desired. [Prior Art Documents] [Non-Patent Documents] [Non-Patent Document 1] Cancers (Basel), 2020 Apr 23; 12(4): 1050. [Non-Patent Document 2] Front Pharmacol., 2021 Feb 8; 11: 629266. [Non-Patent Document 3] N. Engl. J. Med., 2018 Dec 27; 379(26): 2495 - 2505. [Non-Patent Document 4] Nat. Rev. Cancer, 2023 23, 78 - 94. [Non-Patent Document 5] Nature, 2022 Apr; 604(7907): 749 - 756. [Non-Patent Document 6] T. W. Greene, P. G. M. Wuts, Protective Groups in Organic Synthesis (5th Edition, John Wiley & Sons 2014) [Non-Patent Document 7] Tetrahedron Lett., 2019 vol.60, 151147 [Non-Patent Document 8] Chem. Rev., 1995, vol.95, no.7, p.2457 - 2483. [Non-Patent Document 9] Acc. Chem. Res., 2008, vol.41, No.11, p.1461 - 1473. [Non-Patent Document 10] Synthesis, 1992, vol.9, p.803 - 815. [Non-Patent Document 11] Org. Process Res. Dev., 2018, vol.22, no.4, p.430 - 445. [Non-Patent Document 12] Tetrahedron, 1992, vol.48, no.44, p.9577 - 9648. [Non-Patent Document 13] Aldrichimica Acta, 2005, vol.38, no.4, p.71 - 88. [Non-Patent Document 14] Chem. Soc. Rev., 2011, vol.40, p.5084 - 5121. [Non-Patent Document 15] Chem. Rev., 2016, vol.116, p.12564 - 12649. [Non-Patent Document 16] Org. Process Res. Dev., 2022, vol.26, no.6, p.1690 - 1750. [Non-Patent Document 17] J. Am. Chem. Soc., 2016, vol.138, no.26, p.8084 - 8087. [Non-Patent Document 18] ACS Med. Chem. Lett., 2020, vol.11, no.4, p.597 - 604. [Non-Patent Document 19] Nature, 2021, 598, p.451 - 456.[Non-Patent Document 20] ACS Cent. Sci. 2017, vol. 3, issue 6, p. 647 - 653. [Non-Patent Document 21] Tetrahedron 2008, vol. 64, p. 5139 - 5146. [Non-Patent Document 22] Nature. 2019 May; 569(7757): 503 - 508. [Non-Patent Document 23] PLoS Comput Biol. 2019 May 20; 15(5): e1006752. [Problems to be Solved by the Invention] An object of the present invention is to provide a new compound having inhibitory activity against MYT1, or a salt thereof, or a solvate thereof. Further, there is provided a medicament useful for the treatment and prevention of cancer, which contains these as active ingredients. [Means for Solving the Problems] That is, in one aspect of the present invention, the following inventions are provided. [A1] A compound, a salt thereof, or a solvate thereof, which is represented by the formula (1): [Chemical Formula 1] [In the formula, R 4 is selected from the group consisting of a C 6 -C 10 aryl (R 4A ), a 4 - 10 membered heterocyclic group which may be substituted, and a 5 - 10 membered heteroaryl (R 4HA ) which may be substituted; R 5 and R 6 together with the atoms to which they are bonded form a D ring which may be substituted; The D ring is selected from the group consisting of a 3 - 10 membered monocyclic alicyclic ring, a benzene ring, a 3 - 12 membered monocyclic heterocycle, and a 5 - 6 membered monocyclic aromatic heterocycle (D HA ); Any two adjacent substituents on the D ring may together with the atoms to which they are bonded form an E ring which may be substituted]. [A2] The compound, a salt thereof, or a solvate thereof according to [A1], wherein the D ring is a benzene ring or a 5 - 6 membered monocyclic aromatic heterocycle (D HA ). [A3] The compound, a salt thereof, or a solvate thereof according to [A1], wherein the D ring is a benzene ring. [A4] The compound, a salt thereof, or a solvate thereof according to [A1], wherein the D ring is a 5 - 6 membered monocyclic aromatic heterocycle (D HA )). The compound or its salt or its solvate as described in [A4], wherein the 5- to 6-membered monocyclic aromatic heterocycle (D HA ) is selected from the group consisting of a furan ring, a thiophene ring, a pyrrole ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, an oxadiazole ring, a thiadiazole ring, a triazole ring, a tetrazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, a pyrazine ring, and a triazine ring. [A6] The compound or its salt or its solvate as described in [A4], wherein the 5- to 6-membered monocyclic aromatic heterocycle (D HA ) is selected from the group consisting of a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring. [A7] The compound or its salt or its solvate as described in [A4], wherein the 5- to 6-membered monocyclic aromatic heterocycle (D HA ) is a pyridine ring. [A8] The compound or its salt or its solvate as described in any one of [A1] to [A7], wherein the D ring is unsubstituted or substituted by one or more R D , and one or more R D are each independently selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boronyl, side oxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10A group consisting of aryl and 5- to 10-membered heteroaryl, the hydroxyl group, sulfhydryl group, amino group, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may also be further substituted. [A9] The compound or its salt or their solvate according to any one of [A1] to [A7], wherein the D ring is unsubstituted or substituted by one or more R D One or more R D are each independently selected from the group consisting of halogen, cyano, hydroxyl, C 1 -C 6 alkylthio, C 1 -C 6 amide group, mono-C 1 -C 6 alkylamino, C 1 -C 6 alkylsulfonamide, C 3 -C 8 cycloalkylsulfonamide, C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy, hydroxy C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclic C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, 4- to 10-membered heterocyclic oxy, C 1 -C 6 Acyl, mono C 3 -C 8 Cycloalkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl, di C 1 -C 6 Alkylphosphonyl, C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, di C 1 -C 6 Alkylaminocarbonyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, hydroxy C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, hydroxy C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and a group consisting of 5- to 10-membered heteroaryl, the C 1 -C 6 Alkylthio, C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6Alkoxy, 4- to 10-membered heterocyclic group C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, 4- to 10-membered heterocyclic group oxy, C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and 5- to 10-membered heteroaryl may further be independently substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxyl, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, side oxy, halo C 1 -C 6 Alkyl, and C 3 -C 8 Cycloalkyl. [A10] The compound or a salt thereof or a solvate thereof according to any one of [A1] to [A7], wherein the D ring is unsubstituted or substituted via one or more R D Substituted, one or more R D Each independently is selected from the group consisting of halogen, C 1 -C 6 Alkoxy, halo C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl C 1 -C 6 alkoxy, C 3 -C 8 cycloalkoxy, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, and C 3 -C 8 a group consisting of cycloalkyl. 〔A11〕 A compound or a salt thereof or a solvate thereof as described in any one of 〔A1〕 to 〔A7〕, wherein the D ring is unsubstituted or substituted by one or more R D substituents, one or more R D each independently is selected from the group consisting of C 1 -C 6 alkoxy, C 1 -C 6 alkyl, and C 3 -C 8 a group consisting of cycloalkyl. 〔A12〕 A compound or a salt thereof or a solvate thereof as described in any one of 〔A1〕 to 〔A7〕, wherein the D ring is unsubstituted or substituted by one or more R D substituents, one or more R D Each independently is selected from the group consisting of methoxy, ethoxy, propoxy, propane-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yloxy], [(2R)-butan-2-yloxy], methyl, ethyl, propyl, propane-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl. 〔A13〕A compound or a salt thereof or a solvate thereof as described in any one of 〔A1〕 to 〔A12〕, wherein any two adjacent substituents on the D ring together with the atoms to which they are bonded form an E ring which may be substituted. 〔A14〕A compound or a salt thereof or a solvate thereof as described in any one of 〔A1〕 to 〔A13〕, wherein the E ring is selected from the group consisting of a 3- to 10-membered monocyclic alicyclic ring, a benzene ring, a 3- to 12-membered monocyclic heterocyclic ring, and a 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ). 〔A15〕A compound or a salt thereof or a solvate thereof as described in any one of 〔A1〕 to 〔A13〕, wherein the E ring is a benzene ring or a 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ). 〔A16〕A compound or a salt thereof or a solvate thereof as described in any one of 〔A1〕 to 〔A13〕, wherein the E ring is a benzene ring. 〔A17〕A compound or a salt thereof or a solvate thereof as described in any one of 〔A1〕 to 〔A13〕, wherein the E ring is a 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ). 〔A18〕A compound or a salt thereof or a solvate thereof as described in 〔A17〕, wherein the 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ) is selected from the group consisting of a furan ring, a thiophene ring, a pyrrole ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, an oxadiazole ring, a thiadiazole ring, a triazole ring, a tetrazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, a pyrazine ring, and a triazine ring. 〔A19〕A compound or a salt thereof or a solvate thereof as described in 〔A17〕, wherein the 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ) is selected from the group consisting of a thiophene ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring. 〔A20〕A compound or a salt thereof or a solvate thereof as described in 〔A17〕, wherein the 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA)Selected from the group consisting of a pyridine ring, a pyrimidine ring, a phthalazine ring, and a quinazoline ring. [A20.5] A compound or a salt thereof or a solvate thereof as described in [A17], wherein the 5- to 6-membered monocyclic aromatic heterocycle (E HA ) is a pyridine ring or a quinazoline ring. [A21] A compound or a salt thereof or a solvate thereof as described in [A17], wherein the 5- to 6-membered monocyclic aromatic heterocycle (E HA ) is a pyridine ring. [A22] A compound or a salt thereof or a solvate thereof as described in [A17], wherein the D ring and the E ring form a bicyclic ring represented by the following formula: [Chemical formula 2] (wherein, * represents the carbon atom to which R in formula (1) 5 is bonded, and ** represents the carbon atom to which R in formula (1) 6 is bonded. In the formula, the D ring is represented by "D ring" and the E ring is represented by "E ring"). [A23] A compound or a salt thereof or a solvate thereof as described in [A17], wherein the D ring and the E ring form a bicyclic ring represented by the following formula: [Chemical formula 3] (wherein, * represents the carbon atom to which R in formula (1) 5 is bonded, and ** represents the carbon atom to which R in formula (1) 6 is bonded. In the formula, the D ring is represented by "D ring" and the E ring is represented by "E ring"). [A24] A compound or a salt thereof or a solvate thereof as described in any one of [A14] to [A23], wherein the E ring is unsubstituted or substituted by one or more R E , and one or more R E are each independently selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, side oxygen group, C 1 -C 6 alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and a group consisting of 5- to 10-membered heteroaryl, the hydroxyl group, sulfhydryl group, amino group, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron group, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and 5- to 10-membered heteroaryl may also be further substituted. [A25] A compound or a salt thereof or a solvate thereof as described in any one of [A14] to [A23], wherein the E ring is unsubstituted or substituted with one or more R E s, one or more R E s are each independently selected from the group consisting of halogen, C 1 -C 6 alkyl, C 1 -C 6A group consisting of an alkoxy group and a boronic acid group. 〔A25.5〕 The compound or its salt or their solvate according to any one of 〔A14〕 to 〔A23〕, wherein the E ring is unsubstituted or substituted by one or more R E , and one or more R E are each independently selected from the group consisting of fluorine, chlorine, methoxy, dihydroxyboron, methyl, and t-butyl. 〔A26〕 The compound or its salt or their solvate according to any one of 〔A1〕 to 〔A25.5〕, wherein R 4 is a C 6 -C 10 aryl (R 4A ) or a 5- to 10-membered heteroaryl (R 4HA ) which may be substituted. 〔A27〕 The compound or its salt or their solvate according to any one of 〔A1〕 to 〔A26〕, wherein R 4 is a C 6 -C 10 aryl (R 4A ). 〔A28〕 The compound or its salt or their solvate according to 〔A26〕 or 〔A27〕, wherein C 6 -C 10 aryl (R 4A ) is phenyl. 〔A29〕 The compound or its salt or their solvate according to any one of 〔A26〕 to 〔A28〕, wherein C 6 -C 10 aryl (R 4A ) is unsubstituted or substituted by one or more R a , and one or more R a are each independently selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxyl, sulfhydryl, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boronyl, side oxy group, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and a group consisting of 5- to 10-membered heteroaryl, the hydroxyl group, sulfhydryl group, amino group, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boronyl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and 5- to 10-membered heteroaryl may also be further substituted. [A30] A compound or a salt thereof or a solvate thereof as described in any one of [A26] to [A28], wherein, C 6 -C 10 aryl (R 4A ) is unsubstituted or substituted by one or more R a , and one or more R a are each independently selected from the group consisting of halogen, cyano, hydroxyl, amino, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, hydroxy C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo C 1 -C 6 alkoxy, and C 1 -C 6 alkylsulfonamido. 〔A31〕 The compound or its salt or their solvate according to any one of 〔A26〕 to 〔A28〕, wherein C 6 -C 10 aryl (R 4A ) is unsubstituted or substituted by one or more R a , and one or more R a are each independently selected from the group consisting of halogen, hydroxyl, halo C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo C 1 -C 6 alkoxy, and C 1 -C 6 A group consisting of alkylsulfonamides. [A32] A compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A26], wherein R 4 is a 5- to 10-membered heteroaryl group which may be substituted (R 4HA ). [A33] A compound or a salt thereof or a solvate thereof as described in [A26] or [A32], wherein the 5- to 10-membered heteroaryl group (R 4HA ) is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, benzofuryl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furopyridyl. [A34] A compound or a salt thereof or a solvate thereof as described in [A26] or [A32], wherein the 5- to 10-membered heteroaryl group (R 4HA ) is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, benzofuryl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furopyridyl. [A35] A compound or a salt thereof or a solvate thereof as described in [A26] or [A32], wherein the 5- to 10-membered heteroaryl group (R 4HA ) is selected from the group consisting of pyridyl, pyrimidinyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl. [A36] A compound or a salt thereof or a solvate thereof as described in [A26] or [A32], wherein the 5- to 10-membered heteroaryl group (R 4HA ) selected from the group consisting of a pyrimidinyl group, a benzimidazolyl group, an indolyl group, an indazolyl group, and a pyrazolopyridinyl group. [A37] A compound or a salt thereof or a solvate thereof as described in [A26] or [A32], wherein the 5- to 10-membered heteroaryl group (R 4HA ) is a 1H-indazol-6-yl group or a 1H-indazol-4-yl group. [A38] A compound or a salt thereof or a solvate thereof as described in [A26] or [A32], wherein the 5- to 10-membered heteroaryl group (R 4HA ) is a 1H-indazol-4-yl group. [A39] A compound or a salt thereof or a solvate thereof as described in any one of [A32] to [A38], wherein the 5- to 10-membered heteroaryl group (R 4HA ) is unsubstituted or substituted by one or more R a , and one or more R a are each independently selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boronyl, side-oxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and a 5- to 10-membered heteroaryl group, and the hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may be further substituted. [A40] A compound or a salt thereof or a solvate thereof as described in any one of [A32] to [A38], wherein the 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or substituted with one or more R a , and one or more R a are each independently selected from the group consisting of halogen, cyano, hydroxyl, amino, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, hydroxy C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo C 1 -C 6 alkoxy, and C 1 -C 6A group consisting of alkylsulfonamides. 〔A41〕A compound or a salt thereof or a solvate thereof as described in any one of 〔A32〕 to 〔A38〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or substituted with one or more R a , and one or more R a are each independently selected from the group consisting of halogen, cyano, amino, C 1 -C 6 alkyl, and halo C 1 -C 6 alkyl. 〔A42〕A compound or a salt thereof or a solvate thereof as described in any one of 〔A32〕 to 〔A38〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) is 1H-indazol-4-yl or 1H-indazol-4-yl substituted with one or more halogens. 〔A43〕A compound or a salt thereof or a solvate thereof as described in any one of 〔A32〕 to 〔A38〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) is 1H-indazol-4-yl substituted with one or more halogens. 〔A44〕A compound or a salt thereof or a solvate thereof as described in any one of 〔A32〕 to 〔A38〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) is 1H-indazol-4-yl in which at least one of the 5th, 6th, and 7th positions is substituted with a halogen. 〔A44.5〕A compound or a salt thereof or a solvate thereof as described in any one of 〔A32〕 to 〔A38〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) is represented by the following formula: [Chemical formula 4] [In the formula, * represents the carbon bonded to R 4 in formula (1), R a5 , R a6 and R a7 are independently hydrogen or halogen, R a5 , R a6 and R a7 at least one of which is not hydrogen]. [A45] A compound or a salt thereof or a solvate thereof as described in any one of [A32] to [A38], wherein the 5- to 10-membered heteroaryl (R 4HA ) is a 1H-indazol-4-yl group in which at least one of the 5th, 6th, and 7th positions is substituted with a halogen, and the halogen is fluorine or chlorine. [A46] A compound or a salt thereof or a solvate thereof as described in any one of [A32] to [A38], wherein the 5- to 10-membered heteroaryl (R 4HA ) is a 1H-indazol-4-yl group in which at least one or two of the 5th, 6th, and 7th positions are substituted with a halogen, and the halogen is selected from the group consisting of fluorine, chlorine, a combination of fluorine and fluorine, and a combination of fluorine and chlorine. [A46.5] A compound or a salt thereof or a solvate thereof as described in any one of [A32] to [A38], wherein the 5- to 10-membered heteroaryl (R 4HA ) is a 1H-indazol-4-yl group in which at least one or two of the 5th, 6th, and 7th positions are substituted with a halogen, and the halogen is independently fluorine or chlorine. [B1] A compound or a salt thereof or a solvate thereof, which is represented by the formula (2): [Chemical formula 5] [In the formula, R 4 is selected from the group consisting of a C 6 -C 10 aryl (R 4A ), a 4- to 10-membered heterocyclic group which may be substituted, and a 5- to 10-membered heteroaryl (R 4HA ) which may be substituted; X 5 is CR x5 or N, X 6 is CR x6 or N, X 10a is CR x10a or N, R x5 、 R x6 , R 6a and R x10a are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, provided that the hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 An aryl group and a 5- to 10-membered heteroaryl group may also be further substituted, or R x5 and R x6 , R x6 and R 6a , or R 6a and R x10a may together with the atoms to which they are bonded form a substitutable E ring]. [B2] A compound or a salt thereof or a solvate thereof as described in [B1], wherein X 5 is CR x5 or N, X 6 is CR x6 , X 10a is CR x10a or N. [B3] A compound or a salt thereof or a solvate thereof as described in [B1] or [B2], wherein X 5 is CH, X 6 is CR x6 , X 10a is CR x10a . [B4] A compound or a salt thereof or a solvate thereof as described in any one of [B1] to [B3], wherein R x6 is selected from the group consisting of hydrogen, halogen, hydroxyl, C 1 -C 6 alkylthio, C 1 -C 6 amide group, mono-C 1 -C 6 alkylamino, C 1 -C 6 Alkylsulfonamido, C 3 -C 8 Cycloalkylsulfonamido, C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy, hydroxy C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclic C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, 4- to 10-membered heterocyclic oxy, C 1 -C 6 Acyl, mono C 3 -C 8 Cycloalkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl, di C 1 -C 6 Alkylphosphonyl, C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, di C 1 -C 6 Alkylamino carbonyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, hydroxy C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, hydroxy C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4-10 membered heterocyclic group, C 6 -C 10 Aryl, and a group consisting of 5-10 membered heteroaryl, the C 1 -C 6 Alkylthio, C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclic group C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, 4- to 10-membered heterocyclic group oxy, C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and 5- to 10-membered heteroaryl may be further independently substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, side oxy, halo C 1 -C 6 Alkyl, and C 3 -C 8 Cycloalkyl. [B5] The compound or a salt thereof or a solvate thereof according to any one of [B1] to [B3], wherein R x6 Selected from hydrogen, halogen, C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, and C 3 -C 8 A group consisting of cycloalkyl. [B6] A compound or a salt thereof or a solvate thereof as described in any one of [B1] to [B3], wherein R x6 Selected from the group consisting of hydrogen, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl, and C 3 -C 8 A group consisting of cycloalkyl. [B7] A compound or a salt thereof or a solvate thereof as described in any one of [B1] to [B3], wherein R x6Selected from the group consisting of hydrogen, methoxy, ethoxy, propoxy, propane-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yloxy], [(2R)-butan-2-yloxy], methyl, ethyl, propyl, propane-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl. [B8] The compound or its salt or their solvate according to any one of [B1] to [B7], wherein R x10a Selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, and C 3 -C 8 cycloalkyl. [B9] The compound or its salt or their solvate according to any one of [B1] to [B7], wherein R x10a Selected from the group consisting of hydrogen, chlorine, bromine, cyano, methyl, ethyl, propyl, propane-2-yl, vinyl, ethynyl, and cyclopropyl. [B10] The compound or its salt or their solvate according to any one of [B1] to [B9], wherein R 6a Selected from the group consisting of hydrogen, halogen, cyano, halo C 1 -C 6 alkoxy, and C 1 -C 6 alkyl. [B11] The compound or its salt or their solvate according to any one of [B1] to [B9], wherein R 6a Selected from the group consisting of hydrogen, fluorine, chlorine, bromine, cyano, difluoromethoxy, methyl, and ethyl. [B12] The compound or its salt or their solvate according to any one of [B1] to [B7], wherein R 6a and R x10a Together with the atoms bonded thereto, form a replaceable E ring. [B13] A compound or a salt thereof or a solvate thereof as described in [B12], wherein the E ring is selected from the group consisting of a 3- to 10-membered monocyclic alicyclic ring, a benzene ring, a 3- to 12-membered monocyclic heterocyclic ring, and a 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ). [B14] A compound or a salt thereof or a solvate thereof as described in [B12], wherein the E ring is a benzene ring or a 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ). [B15] A compound or a salt thereof or a solvate thereof as described in [B13] or [B14], wherein the 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ) is selected from the group consisting of a thiophene ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring. [B16] A compound or a salt thereof or a solvate thereof as described in [B13] or [B14], wherein the 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ) is selected from the group consisting of a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring. [B17] A compound or a salt thereof or a solvate thereof as described in [B13] or [B14], wherein the 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ) is a pyridine ring or a pyrazine ring. [B18] A compound or a salt thereof or a solvate thereof as described in [B13] or [B14], wherein the 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ) is a pyridine ring. [B19] A compound or a salt thereof or a solvate thereof as described in [B12], wherein the E ring is represented by the following formula: [Chemical formula 6] (In the formula, * represents the carbon bonded to R in formula (2) 6a , and ** represents the carbon bonded to R in formula (2) x10a . In the formula, the E ring is represented by "E ring"). [B20] A compound or a salt thereof or a solvate thereof as described in [B12], wherein the E ring is represented by the following formula: [Chemical formula 7] (In the formula, * represents the carbon bonded to R in formula (2) 6a , and ** represents the carbon bonded to R in formula (2) x10a Bonded carbon. In the formula, the E ring is represented by "E ring". [B21] A compound or a salt thereof or a solvate thereof as described in any one of [B12] to [B20], wherein the E ring is unsubstituted or substituted by one or more R E 's, and one or more R E each independently is selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, side oxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and a group consisting of 5- to 10-membered heteroaryl, and the hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and 5- to 10-membered heteroaryl may also be further substituted. [B22] A compound or a salt thereof or a solvate thereof as described in any one of [B12] to [B20], wherein the E ring is unsubstituted or substituted by one or more R E One or more R E Each independently is selected from the group consisting of halogen, C 1 -C 6 Alkoxy, boronic group, and C 1 -C 6 Alkyl. [B23] A compound or a salt thereof or a solvate thereof as described in any one of [B12] to [B20], wherein the E ring is unsubstituted or substituted by one or more R E One or more R E Each independently is selected from the group consisting of fluorine, chlorine, methoxy, dihydroxyboronic group, methyl, and t-butyl. [B24] A compound or a salt thereof or a solvate thereof as described in any one of [B1] to [B23], wherein R 4 Is optionally substituted C 6 -C 10 Aryl (R 4A ) or optionally substituted 5- to 10-membered heteroaryl (R 4HA ). [B25] A compound or a salt thereof or a solvate thereof as described in any one of [B1] to [B23], wherein R 4 Is optionally substituted C 6 -C 10 Aryl (R 4A)。 A compound or a salt thereof or a solvate thereof as described in [B24] or [B25], wherein C 6 -C 10 aryl (R 4A ) is phenyl. [B27] A compound or a salt thereof or a solvate thereof as described in any one of [B24] to [B26], wherein C 6 -C 10 aryl (R 4A ) is unsubstituted or substituted by one or more R a s, and one or more R a s are each independently selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, side oxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, and the hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6Alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may be further substituted. [B28] A compound or a salt thereof or a solvate thereof as described in any one of [B24] to [B26], wherein, C 6 -C 10 aryl (R 4A ) is unsubstituted or substituted by one or more R a , one or more R a are each independently selected from the group consisting of halogen, cyano, hydroxyl, amino, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, hydroxy C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo C 1 -C 6 alkoxy, and C 1 -C 6A group consisting of alkylsulfonamido groups. [B29] A compound or a salt thereof or a solvate thereof as described in any one of [B24] to [B26], wherein C 6 -C 10 aryl (R 4A ) is unsubstituted or substituted by one or more R a , and one or more R a are each independently selected from the group consisting of halogen, hydroxyl, halo C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo C 1 -C 6 alkoxy and C 1 -C 6 A group consisting of alkylsulfonamido groups. [B30] A compound or a salt thereof or a solvate thereof as described in any one of [B1] to [B23], wherein R 4 is a 5- to 10-membered heteroaryl (R 4HA ) which may be substituted. [B31] A compound or a salt thereof or a solvate thereof as described in [B24] or [B30], wherein the 5- to 10-membered heteroaryl (R 4HA ) is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, benzofuryl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furanopyridyl. [B32] A compound or a salt thereof or a solvate thereof as described in [B24] or [B30], wherein the 5- to 10-membered heteroaryl (R 4HA ) selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, benzofuryl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furanopyridyl. 〔B33〕 A compound or a salt thereof or a solvate thereof as described in 〔B24〕 or 〔B30〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) selected from the group consisting of pyridyl, pyrimidinyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl. 〔B34〕 A compound or a salt thereof or a solvate thereof as described in 〔B24〕 or 〔B30〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) selected from the group consisting of pyrimidinyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl. 〔B35〕 A compound or a salt thereof or a solvate thereof as described in 〔B24〕 or 〔B30〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) is 1H-indazol-6-yl or 1H-indazol-4-yl. 〔B36〕 A compound or a salt thereof or a solvate thereof as described in 〔B24〕 or 〔B30〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) is 1H-indazol-4-yl. 〔B37〕 A compound or a salt thereof or a solvate thereof as described in any one of 〔B31〕 to 〔B36〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or substituted by one or more R a , and one or more R a are each independently selected from the group consisting of halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, side-oxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and a group consisting of 5- to 10-membered heteroaryl, the hydroxyl group, sulfhydryl group, amino group, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may also be further substituted. [B38] A compound or a salt thereof or a solvate thereof as described in any one of [B31] to [B36], wherein, the 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or is substituted by one or more R a , one or more R aEach independently is selected from the group consisting of halogen, cyano, hydroxyl, amino, C 1 -C 6 alkyl, halo-C 1 -C 6 alkyl, hydroxy-C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo-C 1 -C 6 alkoxy and C 1 -C 6 alkylsulfonamido. [B39] The compound or its salt or their solvate as described in any one of [B31] to [B36], wherein the 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or substituted by one or more R a , and one or more R a each independently is selected from the group consisting of halogen, cyano, amino, C 1 -C 6 alkyl, halo-C 1 -C 6 alkyl. [B40] The compound or its salt or their solvate as described in any one of [B31] to [B36], wherein the 5- to 10-membered heteroaryl (R 4HA ) is 1H-indazol-4-yl or 1H-indazol-4-yl substituted by one or more halogens. [B41] The compound or its salt or their solvate as described in any one of [B31] to [B36], wherein the 5- to 10-membered heteroaryl (R 4HA) is a 1H-indazol-4-yl substituted with one or more halogens. [B42] A compound or a salt thereof or a solvate thereof as described in any one of [B31] to [B36], wherein the 5- to 10-membered heteroaryl (R 4HA ) is a 1H-indazol-4-yl in which at least one of the 5th, 6th, and 7th positions is substituted with a halogen. [B43] A compound or a salt thereof or a solvate thereof as described in any one of [B31] to [B36], wherein the 5- to 10-membered heteroaryl (R 4HA ) is a 1H-indazol-4-yl in which at least one of the 5th, 6th, and 7th positions is substituted with a halogen, and the halogen is fluorine or chlorine. [B44] A compound or a salt thereof or a solvate thereof as described in any one of [B31] to [B36], wherein the 5- to 10-membered heteroaryl (R 4HA ) is a 1H-indazol-4-yl in which at least one or two of the 5th, 6th, and 7th positions are substituted with a halogen, and the halogen is selected from the group consisting of fluorine, chlorine, a combination of fluorine and fluorine, and a combination of fluorine and chlorine. [B44.5] A compound or a salt thereof or a solvate thereof as described in any one of [B31] to [B36], wherein the 5- to 10-membered heteroaryl (R 4HA ) is a 1H-indazol-4-yl in which at least one or two of the 5th, 6th, and 7th positions are substituted with a halogen, and the halogen is independently fluorine or chlorine. [C1] A compound or a salt thereof or a solvate thereof represented by the formula (3): [Chemical formula 8] [In the formula, R 4 is selected from the group consisting of optionally substituted C 6 -C 10 aryl (R 4A ), an optionally substituted 4- to 10-membered heterocyclic group, and an optionally substituted 5- to 10-membered heteroaryl (R 4HA ); X 5 is CR x5 or N, X 6 is CR x6 or N, X 7 is CR x7 or N, X 8 is CR x8 or N, X 9 is CR x9 or N, X 10 is CR x10 or N, R x5 、 R x6 , R x7 , R x8 , R x9 and R x10 each independently is selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, and the hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may be further substituted. [C2] The compound or its salt or their solvate as described in [C1], wherein X 5 is CR x5 or N, X 6 is CR x6 , X 7 is CR x7 or N, X 8 is CR x8 or N, X 9 is CR x9 or N, X 10 is CR x10 or N. [C3] The compound or its salt or their solvate as described in [C1] or [C2], wherein X 5 is CH, X 6 is CR x6 , X 7 is CR x7 or N, X 8 is CR x8 or N, X 9 is CR x9 or N, X 10 is CR x10 or N. 〔C4〕 Such as the compound or its salt or its solvate described in any one of 〔C1〕 to 〔C3〕, wherein, X 7 is N, X 8 is CR x8 , X 9 is CR x9 , X 10 is CR x10 ; X 7 is CR x7 , X 8 is N, X 9 is CR x9 , X 10 is CR x10 ; X 7 is CR x7 , X 8 is CR x8 , X 9 is N, X 10 is CR x10 ;,, X 7 is CR x7 , X 8is CR x8 , X 9 is CR x9 , X 10 is N; X 7 is N, X 8 is CR x8 , X 9 is CR x9 , X 10 is N; X 7 is CR x7 , X 8 is N, X 9 is CR x9 , X 10 is N; or X 7 is N, X 8 is N, X 9 is CR x9 , X 10 is CR x10 . [C4.5] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C3], wherein X 7 is N, X 8 is CR x8 , X 9 is CR x9 , X 10 is CR x10 ; X 7 is CR x7 , X 8 is N, X 9 is CR x9 , X 10 is CR x10 ; X 7 is CR x7 , X 8 is CR x8 , X 9 is N, X 10 is CR x10 ; or X 7 is CR x7 , X 8 is CR x8 , X 9 is CR x9 , X 10 is N. [C5] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C4], wherein R x6 is selected from hydrogen, halogen, hydroxyl, C 1 -C 6 alkylthio, C 1 -C 6 amide group, mono-C 1 -C 6 alkylamino, C 1 -C 6 alkylsulfonamide group, C 3 -C 8Cycloalkylsulfonamido, C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy, hydroxy C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4-10 membered heterocyclic C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, 4-10 membered heterocyclic oxy, C 1 -C 6 Acyl, mono C 3 -C 8 Cycloalkylaminocarbonyl, 4-8 membered cyclic aminocarbonyl, di C 1 -C 6 Alkylphosphonyl, C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, di C 1 -C 6 Alkylaminocarbonyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, hydroxy C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, hydroxy C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and a group consisting of 5- to 10-membered heteroaryl, the C 1 -C 6 Alkylthio, C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclic group C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, 4- to 10-membered heterocyclic group oxy, C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and 5- to 10-membered heteroaryl may further be independently selected from the group consisting of halogen, cyano, hydroxy, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, side oxy, halo C 1 -C 6 Alkyl, and C 3 -C 8 Substituted with one or more substituents selected from the group consisting of cycloalkyl. [C5.1] The compound or a salt thereof or a solvate thereof according to any one of [C1] to [C3], wherein R x6 Selected from hydrogen, halogen, C 1 -C 6 Alkoxy, halo C 1 -C 6Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, and C 3 -C 8 A group consisting of cycloalkyl. 〔C5.2〕 A compound or a salt thereof or a solvate thereof as described in any one of 〔C1〕 to 〔C4〕, wherein R x6 Is selected from the group consisting of hydrogen, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl, and C 3 -C 8 A group consisting of cycloalkyl. 〔C6〕 A compound or a salt thereof or a solvate thereof as described in any one of 〔C1〕 to 〔C4〕, wherein R x6Selected from the group consisting of hydrogen, methoxy, ethoxy, propoxy, propane-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yloxy], [(2R)-butan-2-yloxy], methyl, ethyl, propyl, propane-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl. 〔C6.5〕 A compound or a salt thereof or a solvate thereof, which is represented by formula (3): [Chemical formula 9] [In the formula, R 4 is a 5- to 10-membered heteroaryl group which may be substituted (R 4HA ), the 5- to 10-membered heteroaryl group (R 4HA ) is 1H-indazol-4-yl or 1H-indazol-4-yl substituted with one or more halogens, X 5 is CR x5 or N, X 6 is CR x6 , R x6 is selected from the group consisting of hydrogen, methoxy, ethoxy, propoxy, propane-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yloxy], [(2R)-butan-2-yloxy], methyl, ethyl, propyl, propane-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl, X 7 is CR x7 or N, X 8 is CR x8 or N, X 9 is CR x9 or N, X 10 is CR x10 or N, R x5 、R x7 、R x8 、R x9 及R x10 are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, and the hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and 5- to 10-membered heteroaryl may also be further substituted. [C6.6] A compound or a salt thereof or a solvate thereof, which is represented by the formula (3): [Chemical 10] [In the formula, R 4 is 1H-indazol-4-yl, or 1H-indazol-4-yl substituted with one or more halogens, X 5 is CR x5 or N, X 6 is CR x6 , R x6 is selected from the group consisting of hydrogen, methoxy, ethoxy, propoxy, propane-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yloxy], [(2R)-butan-2-yloxy], methyl, ethyl, propyl, propane-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl, X 7 is CR x7 or N, X 8 is CR x8 or N, X 9 is CR x9 or N, X 10 is CR x10 or N, R x5 、 R x7 、R x8 、R x9 及R x10Each independently is selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and a 5- to 10-membered heteroaryl, the hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10An aryl group and a 5- to 10-membered heteroaryl group may also be further substituted. [C7] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C6.5], wherein X 7 is CR x7 . [C8] A compound or a salt thereof or a solvate thereof as described in [C7], wherein R x7 is hydrogen, a halogen, C 1 -C 6 alkoxy or C 1 -C 6 alkyl. [C9] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C6.5], wherein X 7 is N. [C10] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C9], wherein X 8 is CR x8 . [C11] A compound or a salt thereof or a solvate thereof as described in [C10], wherein R x8 is hydrogen, a halogen, C 1 -C 6 alkoxy or C 1 -C 6 alkyl. [C12] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C9], wherein X 8 is N. [C13] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C12], wherein X 9 is CR x9 . [C14] A compound or a salt thereof or a solvate thereof as described in [C13], wherein R x9 is selected from hydrogen, a halogen, C 1 -C 6 Alkoxy, C 1 -C 6 A group consisting of alkyl and boronyloxy. [C15] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C12], wherein X 9 Is N. [C16] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C15], wherein X 10 Is CR x10 . [C17] A compound or a salt thereof or a solvate thereof as described in [C16], wherein R x10 Is hydrogen, halogen, C 1 -C 6 Alkoxy or C 1 -C 6 Alkyl. [C18] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C12], wherein X 10 Is N. [C20] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C18] (however, excluding [C6.5] and [C6.6]), wherein R 4 Is optionally substituted C 6 -C 10 Aryl (R 4A ) or optionally substituted 5- to 10-membered heteroaryl (R 4HA ). [C21] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C18] (however, excluding [C6.5] and [C6.6]), wherein R 4 Is optionally substituted C 6 -C 10 Aryl (R 4A)。 [C22] A compound or a salt thereof or a solvate thereof as described in [C20] or [C21], wherein C 6 -C 10 aryl (R 4A ) is phenyl. [C23] A compound or a salt thereof or a solvate thereof as described in any one of [C20] to [C22], wherein C 6 -C 10 aryl (R 4A ) is unsubstituted or substituted by one or more R a , and one or more R a are each independently selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, side oxygen group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, and the hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6Alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may be further substituted. 〔C24〕 A compound or a salt thereof or a solvate thereof as described in any one of 〔C20〕 to 〔C22〕, wherein, C 6 -C 10 aryl(R 4A ) is unsubstituted or substituted by one or more R a , one or more R a are each independently selected from the group consisting of halogen, cyano, hydroxyl, amino, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, hydroxy C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo C 1 -C 6 alkoxy, and C 1 -C 6A group consisting of alkylsulfonamido groups. [C25] A compound or a salt thereof or a solvate thereof as described in any one of [C20] to [C22], wherein C 6 -C 10 aryl (R 4A ) is unsubstituted or substituted by one or more R a , and one or more R a are each independently selected from the group consisting of halogen, hydroxyl, halo C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo C 1 -C 6 alkoxy, and a group consisting of alkylsulfonamido groups. [C26] A compound or a salt thereof or a solvate thereof as described in any one of [C1] to [C18] (however, excluding [C6.5] and [C6.6]), wherein R 4 is a 5- to 10-membered heteroaryl (R 4HA ) which may be substituted. [C27] A compound or a salt thereof or a solvate thereof as described in [C20] or [C26], wherein the 5- to 10-membered heteroaryl (R 4HA ) is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, benzofuryl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furanopyridyl. [C28] A compound or a salt thereof or a solvate thereof as described in [C20] or [C26], wherein the 5- to 10-membered heteroaryl (R 4HA)Selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidinyl, pyridazinyl, pyridyl, triazinyl, benzofuryl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyridyl and furanopyridyl. [C29] A compound or a salt thereof or a solvate thereof as described in [C20] or [C26], wherein the 5- to 10-membered heteroaryl (R 4HA )Selected from the group consisting of pyridyl, pyrimidinyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl. [C30] A compound or a salt thereof or a solvate thereof as described in [C20] or [C26], wherein the 5- to 10-membered heteroaryl (R 4HA )Selected from the group consisting of pyrimidinyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl. [C31] A compound or a salt thereof or a solvate thereof as described in [C20] or [C26], wherein the 5- to 10-membered heteroaryl (R 4HA )Is 1H-indazol-6-yl, or 1H-indazol-4-yl. [C32] A compound or a salt thereof or a solvate thereof as described in [C20] or [C26], wherein the 5- to 10-membered heteroaryl (R 4HA )Is 1H-indazol-4-yl. [C33] A compound or a salt thereof or a solvate thereof as described in any one of [C27] to [C32], wherein the 5- to 10-membered heteroaryl (R 4HA )Is unsubstituted or substituted by one or more R a , and one or more R a Are each independently selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxyl, sulfhydryl, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, side oxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and a group consisting of 5- to 10-membered heteroaryl, the hydroxyl group, sulfhydryl group, amino group, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may also be further substituted. [C34] A compound or a salt thereof or a solvate thereof as described in any one of [C27] to [C32], wherein the 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or substituted by one or more R a , one or more R a are each independently selected from the group consisting of halogen, cyano, hydroxyl, amino, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, hydroxy C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo C 1 -C 6 a group consisting of alkoxy and alkylsulfonamide. 〔C35〕 A compound or a salt thereof or a solvate thereof as described in any one of 〔C27〕 to 〔C32〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or substituted with one or more R a , and one or more R a are each independently selected from the group consisting of halogen, cyano, amino, C 1 -C 6 alkyl, and halo C 1 -C 6 alkyl. 〔C36〕 A compound or a salt thereof or a solvate thereof as described in any one of 〔C27〕 to 〔C32〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) is 1H-indazol-4-yl or 1H-indazol-4-yl substituted with one or more halogens. 〔C37〕 A compound or a salt thereof or a solvate thereof as described in any one of 〔C27〕 to 〔C32〕, wherein the 5- to 10-membered heteroaryl (R 4HA ) is 1H-indazol-4-yl substituted with one or more halogens. 〔C38〕 A compound or a salt thereof or a solvate thereof as described in any one of 〔C27〕 to 〔C32〕, wherein the 5- to 10-membered heteroaryl (R 4HA) is a 1H-indazol-4-yl in which at least one of the 5th, 6th, and 7th positions is substituted with a halogen. [C39] The compound or its salt or their solvate as described in any one of [C27] to [C32], wherein the 5- to 10-membered heteroaryl (R 4HA ) is a 1H-indazol-4-yl in which at least one of the 5th, 6th, and 7th positions is substituted with a halogen, and the halogen is fluorine or chlorine. [C40] The compound or its salt or their solvate as described in any one of [C27] to [C32], wherein the 5- to 10-membered heteroaryl (R 4HA ) is a 1H-indazol-4-yl in which at least one or two of the 5th, 6th, and 7th positions are substituted with a halogen, and the halogen is selected from the group consisting of fluorine, chlorine, a combination of fluorine and fluorine, and a combination of fluorine and chlorine. [C40.5] The compound or its salt or their solvate as described in any one of [C27] to [C32], wherein the 5- to 10-membered heteroaryl (R 4HA) is a 1H-indazol-4-yl in which at least one or two of the 5th, 6th, and 7th positions are substituted by halogen, and the aforementioned halogen is independently fluorine or chlorine. [D1] A compound selected from the following compounds or a salt thereof or a solvate thereof: 3-amino-7-chloro-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-benzo[h]quinolin-2-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclopropyl-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methyl-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propan-2-yl-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclopropyl-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclobutyl-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-ethyl-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthroline-2-one, 3-amino-4-(5-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthroline-2-one, 3-amino-6-cyclopropyl-4-(5-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthroline-2-one, (S)-3-amino-6-cyclopropyl-4-(5-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthroline-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthroline-2-one, 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-1H-1,7-phenanthroline-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-ethyl-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-ethoxy-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthroline-2-one,3-Amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-cyclopropyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-ethoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-6-ethoxy-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-ethyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclobutyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,10-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,10-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,10-phenanthrolin-2-one, 3-amino-6-ethyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,10-phenanthrolin-2-one, 3-amino-9-fluoro-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-9-fluoro-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-9-fluoro-6-methoxy-1H-1,7-phenanthrolin-2-one3-Amino-4-(6,7-difluoro-1H-indazol-4-yl)-9-fluoro-6-methyl-1H-1,7-phenanthrolin-2-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methoxy-10H-pyrido[2,3-f]quinolin-9-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-propan-2-yloxy-10H-pyrido[2,3-f]quinolin-9-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methyl-10H-pyrido[2,3-f]quinolin-9-one, 8-amino-5-cyclopropyl-7-(7-fluoro-1H-indazol-4-yl)-10H-pyrido[2,3-f]quinolin-9-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methyl-10H-pyrido[3,2-h]quinazolin-9-one, 8-amino-5-cyclopropyl-7-(7-fluoro-1H-indazol-4-yl)-10H-pyrido[3,2-h]quinazolin-9-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,8-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5,6-dimethyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-5-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-1H-1,7-phenanthrolin-2-one, 3-amino-4-(5,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-methyl-4-(1H-pyrazolo[4,3-c]pyridin-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(1H-benzotriazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, and 3-amino-6-(tert-butyl)-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one. [D2] A 3-amino-7-chloro-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-benzo[h]quinolin-2-one or a salt thereof or a solvate thereof. [D3]A 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-benzo[h]quinolin-2-one or a salt thereof or a solvate thereof. [D4] A 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-benzo[h]quinolin-2-one or a salt thereof or a solvate thereof. [D5] A 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclopropyl-1H-benzo[h]quinolin-2-one or a salt thereof or a solvate thereof. [D6] A 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methyl-1H-benzo[h]quinolin-2-one or a salt thereof or a solvate thereof. [D7] A 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propan-2-yl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D8] A 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D9] A 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclopropyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D10] A 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclobutyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D11] A 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-ethyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D12] A 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D13] A 3-amino-4-(5-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D14] A 3-amino-6-cyclopropyl-4-(5-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D15] An (S)-3-amino-6-cyclopropyl-4-(5-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D16] A 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D16.5] A hydrochloride monohydrate of 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one. [D17]A 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D18〕 A 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-ethyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D19〕 A 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-ethoxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D20〕 A 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-(propan-2-yloxy)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D21〕 A 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-cyclopropyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D22〕 A 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D23〕 A 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D23.5〕 A hydrochloride salt of 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one. 〔D24〕 A 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propoxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D25〕 A 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D26〕 A 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-ethoxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D27〕 A 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-(propan-2-yloxy)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D28〕 A 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D29〕 A 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D30〕A 3-amino-6-ethoxy-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D31〕 A 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D31.5〕 A solvate of a 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one. 〔D32〕 A 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D32.5〕 A hydrochloride monohydrate of a 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one. 〔D33〕 A 3-amino-6-ethyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D34〕 A 3-amino-6-cyclobutyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D35〕 A 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,10-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D36〕 A 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,10-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D37〕 A 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,10-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D38〕 A 3-amino-6-ethyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,10-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D39〕 A 3-amino-9-fluoro-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D40〕 A 3-amino-9-fluoro-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D41〕 A 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-9-fluoro-6-methoxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D42〕 A 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-9-fluoro-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. 〔D43〕An 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methoxy-10H-pyrido[2,3-f]quinolin-9-one or a salt thereof or a solvate of the like. [D44] An 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-propan-2-yloxy-10H-pyrido[2,3-f]quinolin-9-one or a salt thereof or a solvate of the like. [D45] An 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methyl-10H-pyrido[2,3-f]quinolin-9-one or a salt thereof or a solvate of the like. [D46] An 8-amino-5-cyclopropyl-7-(7-fluoro-1H-indazol-4-yl)-10H-pyrido[2,3-f]quinolin-9-one or a salt thereof or a solvate of the like. [D47] An 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methyl-10H-pyrido[3,2-h]quinazolin-9-one or a salt thereof or a solvate of the like. [D48] An 8-amino-5-cyclopropyl-7-(7-fluoro-1H-indazol-4-yl)-10H-pyrido[3,2-h]quinazolin-9-one or a salt thereof or a solvate of the like. [D49] A 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,8-phenanthrolin-2-one or a salt thereof or a solvate of the like. [D49.1] A 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5,6-dimethyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate of the like. [D49.2] A 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-5-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate of the like. [D49.3] A 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate of the like. [D49.4] A 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate of the like. [D49.5] A 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate of the like. [D49.6] A 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate of the like. [D49.7] A 3-amino-4-(5,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate of the like. [D49.8]A 3-amino-6-methyl-4-(1H-pyrazolo[4,3-c]pyridin-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D49.9] A 3-amino-4-(1H-benzotriazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D49.10] A 3-amino-6-(tert-butyl)-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D50] A compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44] and [C1] to [C40], wherein the compound or a salt thereof or a solvate thereof represented by the foregoing formula (1), formula (2) and formula (3) is the compound or a salt thereof represented by the foregoing formula (1), formula (2) and formula (3). [D51] A compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44] and [C1] to [C40], wherein the compound or a salt thereof or a solvate thereof represented by the foregoing formula (1), formula (2) and formula (3) is the compound represented by the foregoing formula (1), formula (2) and formula (3). [D52] A compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44] and [C1] to [C40], wherein the compound or a salt thereof or a solvate thereof represented by the foregoing formula (1), formula (2) and formula (3) is a salt of the compound represented by the foregoing formula (1), formula (2) and formula (3). [D53] A compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44] and [C1] to [C40], wherein the compound or a salt thereof or a solvate thereof represented by the foregoing formula (1), formula (2) and formula (3) is a solvate of the compound or a salt thereof represented by the foregoing formula (1), formula (2) and formula (3). [D54] A compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44] and [C1] to [C40], wherein the compound or a salt thereof or a solvate thereof represented by the foregoing formula (1), formula (2) and formula (3) is a hydrate of the compound or a salt thereof represented by the foregoing formula (1), formula (2) and formula (3). [D55] A compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44] and [C1] to [C40], wherein the compound or a salt thereof or a solvate thereof represented by the foregoing formula (1), formula (2) and formula (3) is a hydrate of the compound or a salt thereof represented by the foregoing formula (1), formula (2) and formula (3). [D56]A compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49], wherein the compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49] is the compound or a salt thereof as described in any one of [D1] to [D49]. [D57] A compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49], wherein the compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49] is the compound as described in any one of [D1] to [D49]. [D58] A compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49], wherein the compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49] is a salt of the compound as described in any one of [D1] to [D49]. [D59] A compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49], wherein the compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49] is a solvate of the compound or a salt thereof as described in any one of [D1] to [D49]. [D60] A compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49], wherein the compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49] is a hydrate of the compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49]. [D61] A compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49], wherein the compound or a salt thereof or a solvate thereof as described in any one of [D1] to [D49] is a hydrate of the compound or a salt thereof as described in any one of [D1] to [D49]. [E1] A pharmaceutical composition comprising a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61] as an active ingredient. [E2] A prophylactic agent and / or therapeutic agent for cancer, comprising a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61] as an active ingredient. [E3] An inhibitor of MYT1, comprising a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61]. [E4] A method for preventing and / or treating cancer, which comprises administering an effective amount of a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61] to a subject. [E5]A compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61] for use in the prevention and / or treatment of cancer. [E6] Use of a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61] for the manufacture of a pharmaceutical composition for the prevention and / or treatment of cancer. [E6.2] A pharmaceutical composition, a preventive and / or therapeutic agent for cancer, an inhibitor of MYT1, a method, a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61], or a use as described in any one of [E1] to [E6], which is used in combination with a chemotherapeutic agent. [E7] A pharmaceutical composition which is combined with a chemotherapeutic agent and contains, as an active ingredient, an inhibitor of MYT1 for treating or preventing cancer in a cancer patient who is positive for detection of an RB1 gene mutation or has a low expression of the RB1 gene or protein, wherein the inhibitor of MYT1 is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61]. [E7.2] A pharmaceutical composition which is combined with a chemotherapeutic agent and contains, as an active ingredient, an inhibitor of MYT1 for treating or preventing cancer in a cancer patient who has a positive occurrence of an RB1 gene mutation or has a low expression of the RB1 gene or protein, wherein the inhibitor of MYT1 is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61]. [E7.5] A pharmaceutical composition which is combined with an inhibitor of MYT1 and contains, as an active ingredient, a chemotherapeutic agent for treating or preventing cancer in a cancer patient who is positive for detection of an RB1 gene mutation or has a low expression of the RB1 gene or protein, wherein the inhibitor of MYT1 is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61]. [E7.7] A pharmaceutical composition which is combined with an inhibitor of MYT1 and contains, as an active ingredient, a chemotherapeutic agent for treating or preventing cancer in a cancer patient who has a positive occurrence of an RB1 gene mutation or has a low expression of the RB1 gene or protein, wherein the inhibitor of MYT1 is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61]. [E8]A method for treating or preventing cancer in a cancer patient who tests positive for an RB1 gene mutation or has reduced expression of the RB1 gene or protein, comprising the steps of: combining a chemotherapeutic agent with a MYT1 inhibitor and administering the combination to the cancer patient, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E8.1] A method for treating or preventing cancer, comprising the steps of: detecting in a biological sample derived from a cancer patient that the cancer patient tests positive for an RB1 gene mutation, or has reduced expression of the RB1 gene or protein, or performing a test on a third party; combining a chemotherapeutic agent with a MYT1 inhibitor and administering the combination to the cancer patient, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E8.2] A method for treating or preventing a cancer patient who has a positive RB1 gene mutation or has reduced expression of the RB1 gene or protein, comprising the steps of: combining a chemotherapeutic agent with a MYT1 inhibitor and administering the combination to the cancer patient, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E9] A method for inhibiting cancer cell proliferation in a cancer patient who tests positive for an RB1 gene mutation or has reduced expression of the RB1 gene or protein, comprising the steps of: contacting the cancer cells with a MYT1 inhibitor and a chemotherapeutic agent, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E9.1] A method for inhibiting cancer cell proliferation, comprising the steps of: detecting in a biological sample derived from a cancer patient that the cancer patient tests positive for an RB1 gene mutation, or has reduced expression of the RB1 gene or protein, or performing a test on a third party; and contacting the cancer cells with a MYT1 inhibitor and a chemotherapeutic agent, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E9.2] A method for inhibiting cancer cell proliferation in a cancer patient who has a positive RB1 gene mutation or has reduced expression of the RB1 gene or protein, comprising:The step of contacting a MYT1 inhibitor and a chemotherapeutic agent with the aforementioned cancer cells, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61]. [E10] A method for enhancing the responsiveness of cancer treatment by a chemotherapeutic agent, wherein the cancer is a cancer of a cancer patient positive for RB1 gene mutation or with reduced expression of RB1 gene or protein, and the method comprises the step of administering a chemotherapeutic agent together with a MYT1 inhibitor to the cancer patient, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61]. [E10.1] A method for enhancing the responsiveness of cancer treatment by a chemotherapeutic agent, which comprises: detecting in a biological sample derived from a cancer patient the presence of a positive RB1 gene mutation in the cancer patient, or reduced expression of RB1 gene or protein, or performing detection on a third party, and the step of administering a chemotherapeutic agent together with a MYT1 inhibitor to the cancer patient, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61]. [E10.2] A method for enhancing the responsiveness of cancer treatment by a chemotherapeutic agent, wherein the cancer is a cancer of a cancer patient with a positive RB1 gene mutation or with reduced expression of RB1 gene or protein, and the method comprises the step of administering a chemotherapeutic agent together with a MYT1 inhibitor to the cancer patient, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61]. [E11] A method for predicting the responsiveness of a combination of a MYT1 inhibitor and a chemotherapeutic agent to cancer treatment, which comprises: detecting in a biological sample derived from a cancer patient the presence or absence of an RB1 gene mutation or the presence or absence of reduced expression of RB1 gene or protein, or performing detection on a third party, and when the aforementioned RB1 gene mutation is positive, or when the RB1 gene or protein expression is reduced, determining that the aforementioned patient is responsive to cancer treatment by the combination of the MYT1 inhibitor and the chemotherapeutic agent, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61]. [E12]A method, which is a method for cancer patients in whom combined administration of a MYT1 inhibitor and a chemotherapeutic agent is more effective than single-agent administration of the MYT1 inhibitor or / and the chemotherapeutic agent, comprising: a step of detecting the presence or absence of an RB1 gene mutation or the presence or absence of reduced expression of the RB1 gene or protein in a biological sample derived from a cancer patient, or detecting a third party, and a step of determining, based on the presence of the mutation or the reduced expression, that the cancer patient is a cancer patient in whom combined administration with a chemotherapeutic agent is more effective than single-agent administration of the MYT1 inhibitor or / and the chemotherapeutic agent, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E13] A screening method for a compound effective for treating or preventing cancer in a cancer patient detected to be positive for an RB1 gene mutation or having reduced expression of the RB1 gene or protein, comprising: a step of measuring the MYT1 inhibitory activity of a candidate compound, and a step of selecting the candidate compound having MYT1 inhibitory activity as a compound effective for cancer treatment. [E13.2] A screening method for a compound effective for treating or preventing cancer in a cancer patient in whom an RB1 gene mutation has occurred or having reduced expression of the RB1 gene or protein, comprising: a step of measuring the MYT1 inhibitory activity of a candidate compound, and a step of selecting the candidate compound having MYT1 inhibitory activity as a compound effective for cancer treatment. [E14] A MYT1 inhibitor, which is a MYT1 inhibitor for use in combination with a chemotherapeutic agent in treating or preventing cancer in a cancer patient detected to be positive for an RB1 gene mutation or having reduced expression of the RB1 gene or protein, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E14.2] A MYT1 inhibitor, which is a MYT1 inhibitor for use in combination with a chemotherapeutic agent in treating or preventing cancer in a cancer patient in whom an RB1 gene mutation has occurred or having reduced expression of the RB1 gene or protein, wherein the MYT1 inhibitor is a compound or a salt thereof or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E15] A chemotherapeutic agent, which is a chemotherapeutic agent for use in combination with a MYT1 inhibitor in treating or preventing cancer in a cancer patient detected to be positive for an RB1 gene mutation or having reduced expression of the RB1 gene or protein,The aforementioned MYT1 inhibitor is a compound or its salt or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E15.2] A chemotherapeutic agent, which is used in combination with an MYT1 inhibitor in the treatment or prevention of cancer in cancer patients who test positive for RB1 gene mutations or have reduced expression of the RB1 gene or protein, and the aforementioned MYT1 inhibitor is a compound or its salt or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E16] A use, which is the use of an MYT1 inhibitor for manufacturing a pharmaceutical composition for treating or preventing cancer in cancer patients who test positive for RB1 gene mutations or have reduced expression of the RB1 gene or protein, and is administered in combination with a chemotherapeutic agent, and the aforementioned MYT1 inhibitor is a compound or its salt or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E16.2] A use, which is the use of an MYT1 inhibitor for manufacturing a pharmaceutical composition for treating or preventing cancer in cancer patients who have a positive RB1 gene mutation or have reduced expression of the RB1 gene or protein, and is administered in combination with a chemotherapeutic agent, and the aforementioned MYT1 inhibitor is a compound or its salt or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E17] A use, which is the use of a chemotherapeutic agent for manufacturing a pharmaceutical composition for treating or preventing cancer in cancer patients who test positive for RB1 gene mutations or have reduced expression of the RB1 gene or protein, and is administered in combination with an MYT1 inhibitor, and the aforementioned MYT1 inhibitor is a compound or its salt or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E17.2] A use, which is the use of a chemotherapeutic agent for manufacturing a pharmaceutical composition for treating or preventing cancer in cancer patients who have a positive RB1 gene mutation or have reduced expression of the RB1 gene or protein, and is administered in combination with an MYT1 inhibitor, and the aforementioned MYT1 inhibitor is a compound or its salt or a solvate thereof as described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E18] The pharmaceutical composition, method, MYT1 inhibitor used, chemotherapeutic agent used, or use as described in any one of [E7] to [E17], wherein the aforementioned chemotherapeutic agent is an antimetabolite. [E19]The pharmaceutical composition, method, MYT1 inhibitor used, chemotherapeutic agent used, or use as described in [E18], wherein the antimetabolite is a folic acid antimetabolite. [E20] The pharmaceutical composition, method, MYT1 inhibitor used, chemotherapeutic agent used, or use as described in [E19], wherein the antimetabolite is pemetrexed. [E21] The pharmaceutical composition, method, MYT1 inhibitor used, chemotherapeutic agent used, or use as described in any one of [E7] to [E20], wherein the cancer is lung cancer. In the above numbers, unless otherwise specified, the numbers cited in the dependent claims include different numbers below the decimal point of that number. For example, [C6] cited in the dependent claims means including [C6] and [C6.5]. The same applies to other numbers. [Advantages of the Invention] According to the present invention, a novel compound having inhibitory activity against MYT1 or a salt thereof or a solvate thereof can be provided. Further, a medicine useful for cancer treatment and prevention containing these as active ingredients can be provided. [Modes for Carrying Out the Invention] The following shows the definitions of symbols, terms, etc. described in this specification, embodiments of the present invention, etc., to explain the present invention in detail. In this specification, "halogen" means fluorine, chlorine, bromine, or iodine. In this specification, "mercapto (thiol)" means -SH. In this specification, "amino group" means -NRR', wherein R and R' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, and heteroaryl, or R and R' together with the nitrogen atom to which they are bonded form a ring. As the amino group, -NH is preferably exemplified. 2 、mono C 1 -C 6 alkylamino (hereinafter "C p -C q " means having p to q carbon atoms), di C 1 -C 6 alkylamino, 4- to 8-membered cyclic amino group. In this specification, "alkoxy" means an oxy group bonded to "alkyl" as defined in this specification. As the alkoxy group, C is preferably exemplified. 1 -C 6 Alkoxy group, preferably C 1 -C 4 alkoxy group. As the alkoxy group, specifically, examples thereof include methoxy group, ethoxy group, 1-propoxy group, 2-propoxy group, n-butoxy group, i-butoxy group, s-butoxy group, t-butoxy group, pentyloxy group, 3-methylbutoxy group and the like. In this specification, the "alkylthio group" refers to the "mercapto" group bonded to the "alkyl group" defined in this specification. As the alkylthio group, preferably C 1 -C 6 alkylthio group, more preferably C 1 -C 4 alkylthio group. As the alkylthio group, specifically, examples thereof include methylthio group, ethylthio group, 1-propylthio group, 2-propylthio group, n-butylthio group, i-butylthio group, s-butylthio group, t-butylthio group and the like. In this specification, the "sulfonyl group" refers to -S(=O) 2 -R, wherein R is selected from the group consisting of a hydroxyl group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group. As the sulfonyl group, preferably C 1 -C 6 alkylsulfonyl group. In this specification, the "phosphonyl group" refers to -P(=O)RR', wherein R and R' are each independently selected from the group consisting of an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group. As the phosphonyl group, preferably mono C 1 -C 6 alkylphosphonyl group, di C 1 -C 6 alkylphosphonyl group. The "boronyloxy group" in this specification refers to -BRR', wherein R and R' are each independently selected from the group consisting of hydrogen, a hydroxyl group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, or R and R' together with the boron atom to which they are bonded form a ring. As the boronyloxy group, preferably dihydroxyboronyl group, mono C 1 -C 6 Alkylboron group, di-C 1 -C 6 Alkylboron group, 4- to 8-membered cyclic oxaboron group. As the oxaboron group, specifically, examples include dihydroxyoxaboron group, pinacolato boryl, neopentanediolate boryl, catecholato boryl, 9-borabicyclo[3.3.1]nonan-9-yl, etc. In this specification, "alkyl" refers to a monovalent group derived by removing one arbitrary hydrogen atom from an aliphatic hydrocarbon, and the skeleton does not contain heteroatoms (atoms other than carbon and hydrogen atoms) or unsaturated carbon-carbon bonds, and has a partial collection of hydrocarbon groups or hydrocarbon group structures containing hydrogen and carbon atoms. Alkyl includes not only linear but also branched chains. As the alkyl, preferably C 1 -C 6 Alkyl, more preferably C 1 -C 4 Alkyl. As the alkyl, specifically, examples include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, isobutyl (2-methylpropyl), n-pentyl, s-pentyl (1-methylbutyl), t-pentyl (1,1-dimethylpropyl), neopentyl (2,2-dimethylpropyl), isopentyl (3-methylbutyl), 3-pentyl (1-ethylpropyl), 1,2-dimethylpropyl, 2-methylbutyl, n-hexyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1,1,2,2-tetramethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, etc. In this specification, "alkenyl" refers to a monovalent group having at least one double bond (two adjacent SP 2 Carbon atoms). Depending on the configuration of the double bond and the substitution part (if any), the geometric form of the double bond can be opposite (E) or same side (Z), cis or trans configuration. Alkenyl includes not only linear but also branched chains. As the alkenyl, preferably C 2 -C 6 Alkenyl, more preferably C 2 -C 4 Alkenyl. As the alkenyl, specifically, for example, vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl (including cis, trans), 3-butenyl, pentenyl, 3-methyl-2-butenyl, hexenyl, etc. can be cited. In this specification, "alkynyl" refers to a monovalent group having at least one triple bond (two adjacent SP carbon atoms). The alkynyl includes not only linear but also branched forms. As the alkynyl, preferably C 2 -C 6 alkynyl, more preferably C 2 -C 4 alkynyl. As the alkynyl, specifically, for example, ethynyl, 1-propynyl, propargyl, 3-butynyl, pentynyl, hexynyl, 3-phenyl-2-propynyl, 3-(2'-fluorophenyl)-2-propynyl, 2-hydroxy-2-propynyl, 3-(3-fluorophenyl)-2-propynyl, 3-methyl-(5-phenyl)-4-pentynyl, etc. can be cited. In this specification, "cycloalkyl" refers to a saturated or partially saturated cyclic monovalent aliphatic hydrocarbon group, including monocyclic, bicyclic, and spiro rings. As the cycloalkyl, preferably C 3 -C 8 cycloalkyl. As the cycloalkyl, specifically, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, spiro[3.3]heptyl, spiro[2.3]hexyl, spiro[4.5]decyl, etc. can be cited. In this specification, "aryl" refers to a monovalent aromatic hydrocarbon ring, that is, an aromatic hydrocarbon ring group. As the aryl, preferably C 6 -C 10 aryl. As the aryl, specifically, for example, phenyl, naphthyl (e.g., 1-naphthyl, 2-naphthyl), etc. can be cited. In this specification, the "heterocyclic group" refers to a non-aromatic cyclic monovalent group containing 1 to 5 heteroatoms in addition to carbon atoms. The heterocyclic group may have double bonds and / or triple bonds in the ring, and the carbon atoms in the ring may be oxidized to form carbonyl groups, and includes monocyclic, condensed rings, and spiro rings. In the case of condensed rings, aromatic rings such as benzene rings, pyridine rings, and pyrimidine rings may also form condensed rings with saturated alicyclic rings such as cyclopentane rings and cyclohexane rings, or saturated heterocycles such as tetrahydropyran rings, dioxane rings, and pyrrolidine rings. As the number of atoms in the ring constituting the heterocyclic group, preferably 4 to 10 (4- to 10-membered heterocyclic group), more preferably 4 to 7 (4- to 7-membered heterocyclic group). Specific examples of the heterocyclic group include, for example, azetidinyl, oxoazetidinyl, oxiranyl, oxetanyl, azetidinyl, dihydrofuryl, tetrahydrofuryl (oxolan-2-yl, oxolan-3-yl), dihydropyranyl, tetrahydropyranyl (oxan-4-yl), tetrahydropyridyl, tetrahydropyrimidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, oxopyrrolidinyl, piperidyl, piperazinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, 1,2-thiazinane, thiadiazolidinyl, oxazolidonyl, benzodioxanyl, benzoxazolyl, dioxolanyl, dioxanyl, tetrahydropyrrolo[1,2-c]imidazolyl, thietanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octyl1]octanyl), 2,4,5-trimethylpiperazin-1-yl, sultam, 2-oxaspiro[3.3]heptyl, 6,7-dihydro-pyrrolo[1,2-a]imidazolyl, 4,5,6, 7-tetrahydropyrazolo[1,5-a]pyrrolidino, azepanyl, dioxepane, 5,9-dioxaspiro[3.5]nonyl, 1,1-dioxo-1,4-thiazol-4-yl, carbonylazolidine, acetylpiperidinyl, 2-oxa-6-azaspiro[3.3]heptane-6-yl, 2-oxa-7-azaspiro[3.3]heptane-6-yl Spiro[3.4]octan-7-yl, 3-oxa-6-azabicyclo[3.1.1]heptane-6-yl, 6-oxa-3-azabicyclo[3.1.1]heptane-3-yl, (9aR)-3,4,6,7,9,9a-hexahydro-1H-pyrro[2,1-c][1,4]oxa-8-yl ((9aR)-3,4,6,7,9,9a-hexahydro-1H-pyrro[2,1-c][1,4]oxa-8-yl dro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl), 3-(azacyclobutane-1-yl)azacyclobutane-1-yl, 1-(oxacyclobutane-3-yl)piperidin-4-yl, 1-(oxacyclohexane-4-yl)piperidin-4-yl, 4-pyrrolidin-1-ylpiperidin-1-yl, 4-oxo-4-ylpiperidin-1-yl, etc. In the present specification, "heteroaryl" refers to an aromatic monovalent cyclic group containing 1 to 5 heteroatoms in addition to carbon atoms, that is, an aromatic heterocyclic group. The ring may be a monocyclic ring or a condensed ring with other rings. The number of atoms constituting the ring of the heteroaryl group is preferably 5 to 10 (5-10 membered heteroaryl group), and more preferably 5 to 7 (5-7 membered heteroaryl group). Specific examples of the heteroaryl group include furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrimidinyl, pyrimidinyl, trithiocarbyl, benzofuranyl, benzothiophenyl, benzothiadiazolyl, benzo In some embodiments, the present invention includes but is not limited to thiazolyl, benzoxazolyl, benzodiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinolinyl, indolizinyl, imidazopyridinyl, pyrazolopyridinyl, triazolopyridinyl, pyrrolopyridinyl, furopyridinyl and the like. In the present specification, "alkylsulfonyl" refers to a "sulfonyl" group bonded to an "alkyl" or "cycloalkyl" group as defined in the present specification. Preferred examples of the alkylsulfonyl group include C 1 -C 6 Alkylsulfonyl, C 3 -C 8 Cycloalkylsulfonyl, preferably C 1 -C 4 Alkylsulfonyl, C 3 -C 6 Cycloalkylsulfonyl. As the alkylsulfonyl, specifically, for example, methylsulfonyl, ethylsulfonyl, 1-propylsulfonyl, 2-propylsulfonyl, n-butylsulfonyl, i-butylsulfonyl, s-butylsulfonyl, t-butylsulfonyl and the like can be mentioned. In this specification, the "amide group" means that in the "amine group" defined in this specification, R is hydrogen and R' is the group of the "acyl group" defined in this specification. As the amide group, preferably C 1 -C 6 Amide group, more preferably C 1 -C 4 Amide group. As the amide group, specifically, for example, acetamide group and the like can be mentioned. In this specification, the "monoalkylamino group" means that in the "amine group" defined in this specification, R is hydrogen and R' is the group of the "alkyl" defined in this specification. As the monoalkylamino group, preferably mono-C 1 -C 6 Alkylamino group, more preferably mono-C 1 -C 4 Alkylamino group. As the monoalkylamino group, specifically, for example, methylamino group, ethylamino group, n-propylamino group, i-propylamino group, n-butylamino group, s-butylamino group, t-butylamino group and the like can be mentioned. In this specification, the "alkylsulfonamide group" means that in the "amine group" defined in this specification, R is hydrogen and R' is the group of the "alkylsulfonyl" defined in this specification. As the alkylsulfonamide group, preferably C 1 -C 6 Alkylsulfonamide group, C 3 -C 8 Cycloalkylsulfonamido, more preferably C 1 -C 4 Alkylsulfonylamino, C 3 -C 6 Cycloalkylsulfonamido. As the alkylsulfonamido, specifically, examples include methylsulfonylamino, ethylsulfonylamino, cyclopropylsulfonylamino, and the like. In this specification, "haloalkoxy" refers to a group in which one or more hydrogens of the "alkoxy" defined in this specification are replaced by "halogen". As the haloalkoxy, preferably halo C 1 -C 6 Alkoxy, more preferably halo C 1 -C 4 Alkoxy. As the haloalkoxy, specifically, examples include difluoromethoxy, trifluoromethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 3-fluoropropoxy, 2,2-difluoropropoxy, 3,3-difluoropropoxy, (2R)-2-fluoropropoxy, [(2S)-1,1,1-trifluoropropan-2-yl]oxy, [(2R)-1,1,1-trifluoropropan-2-yl]oxy, 3,3,3-trifluoro-2,2-dimethylpropoxy, and the like. In this specification, "hydroxyalkoxy" refers to a group in which one or more hydrogens of the "alkoxy" defined in this specification are replaced by a hydroxy group (hydroxyl). As the hydroxyalkoxy, preferably hydroxy C 1 -C 6 Alkoxy, more preferably hydroxy C 1 -C 4 Alkoxy. As the hydroxyalkoxy, specifically, examples include 2-hydroxy-2-methylpropoxy, 3-hydroxy-3-methylbutoxy, 4-hydroxybutoxy, and the like. In this specification, "alkoxyalkoxy" refers to a group in which the "alkoxy" defined in this specification is bonded to the "alkoxy". As the alkoxyalkoxy, preferably C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, preferably C 1 -C 4 Alkoxy C 1 -C 4 Alkoxy. As the alkoxyalkoxy, specifically, for example, 2-methoxyethoxy, (2S)-2-methoxypropoxy, (2R)-2-methoxypropoxy, etc. can be mentioned. In this specification, "cycloalkylalkoxy" refers to an oxy group to which "cycloalkylalkyl" defined in this specification is bonded. As the cycloalkylalkoxy, preferably C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, more preferably C 3- C 6 Cycloalkyl C 1 -C 4 Alkoxy. As the cycloalkylalkoxy, specifically, for example, cyclopropylmethoxy, cyclobutanylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, 1-bicyclo[1.1.1]pentenylmethoxy, etc. can be mentioned. In this specification, "heterocyclic group alkoxy" refers to an oxy group to which the "heterocyclic group" defined in this specification is bonded via "alkyl". As the heterocyclic group alkoxy, preferably 4- to 10-membered heterocyclic group C 1 -C 6 Alkoxy, more preferably 4- to 7-membered heterocyclic group C 1 -C 4 Alkoxy. As the heterocyclic group alkoxy, specifically, for example, (1,1-dioxothian-4-yl)oxy, oxolane-2-ylmethoxy, oxolane-3-ylmethoxy, oxane-4-ylmethoxy, 1,4-dioxan-2-ylmethoxy, (1-methylpiperidin-4-yl)methoxy, 3-morpholin-4-ylpropoxy, (oxetane-3-yl)methoxy, etc. can be mentioned. In this specification, "cycloalkyloxy" refers to an oxy group bonded to a "cycloalkyl" as defined in this specification. As the cycloalkyloxy, preferably C 3 -C 8 cycloalkyloxy, more preferably C 3- C 6 cycloalkyloxy. Specifically, as the cycloalkyloxy, examples include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, etc. In this specification, "heterocyclic group oxy" refers to an oxy group bonded to a "heterocyclic group" as defined in this specification. The number of atoms in the ring constituting the heterocyclic group is preferably 4 to 10 (4- to 10-membered heterocyclic group oxy), more preferably 4 to 7 (4- to 7-membered heterocyclic group oxy). Specifically, as the heterocyclic group oxy, examples include azetidinyloxy, epoxyethanyloxy, oxetanyloxy, azetidinyloxy, dihydrofuranyloxy, tetrahydrofuranyloxy ((3R)-oxolan-3-yloxy, (3S)-oxolan-3-yloxy), dihydropyranyloxy, tetrahydropyranyloxy (oxan-4-yloxy), ((3S)-oxan-3-yloxy), ((3R)-oxan-3-yloxy)), tetrahydropyridyl oxy, tetrahydropyrimidinyl oxy, morpholinyl oxy, thiomorpholinyl oxy, pyrrolidinyl oxy, piperidinyl oxy, piperazinyl oxy, pyrazolidinyl oxy, imidazolinyl oxy, imidazolidinyl oxy, oxazolidinyl oxy, isoxazolidinyl oxy, tetrahydrothiazolyl oxy, isotetrahydrothiazolyl oxy, 1,2-thiazinyl oxy, thiadiazolyl oxy, oxazolidinoneyl oxy, benzodioxolanyl oxy, benzoxazolyl oxy, dioxolanyl oxy, dioxanyl oxy, tetrahydropyrrolo[1,2-c]imidazolyl oxy, thietanyl oxy, 3,6-diazabicyclo[3.1.1]heptyl oxy, 2,5-diazabicyclo[2.2.1]heptyl oxy, 3-oxa-8-azabicyclo[3.2.1]octyl oxy, sultamyl oxy, 2-oxaspiro[3.3]heptyl oxy, tetrahydrothiopyranyl oxy, etc. In this specification, "acyl (alkanoyl)" refers to a group in which a carbonyl group is bonded to hydrogen or an "alkyl" as defined in this specification. As the acyl, preferably C 1 -C 6 acyl, more preferably C ２ -C ４Acyl group. As the acyl group, specifically, for example, formyl group, acetyl group, propionyl group, butyryl group, etc. can be mentioned. The "aminocarbonyl" in this specification means the "amino" group defined in this specification bonded to the carbonyl group. As the aminocarbonyl, preferably -CONH 2 , mono C 1 -C 6 alkylaminocarbonyl, mono C 3 -C 8 cycloalkylaminocarbonyl, di C 1 -C 6 alkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl. As the aminocarbonyl, specifically, for example, -CONH 2 , dimethylaminocarbonyl, 1-azetidinylcarbonyl, 1-pyrrolidinylcarbonyl, 1-piperidinylcarbonyl, 1-piperazinylcarbonyl, 4-morpholinylcarbonyl, 3-oxazolidinylcarbonyl, 1,1-dioxosulfomorpholin-4-ylcarbonyl, 3-oxa-8-azabicyclo[3.2.1]oct-8-ylcarbonyl, N-cyclopropylaminocarbonyl, etc. The "alkylphosphonyl" in this specification means the "phosphonyl" group bonded to the "alkyl" defined in this specification. As the alkylphosphonyl, mono C 1 -C 6 alkylphosphonyl, di C 1 -C 6 alkylphosphonyl, preferably mono C 1 -C 4 alkylphosphonyl, di C 1 -C 4 alkylphosphonyl. As the alkylphosphonyl, specifically, for example, methylphosphonyl, ethylphosphonyl, dimethylphosphonyl, diethylphosphonyl, etc. can be mentioned. The "haloalkyl" in this specification means a group in which one or more hydrogens of the "alkyl" defined in this specification are replaced by "halogen". As the haloalkyl, preferably halo-substituted C 1 -C 6 Alkyl, more preferably halo C 1 -C 4 alkyl. As the haloalkyl, specifically, for example, difluoromethyl, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3-fluoropropyl, 3,3-difluoropropyl, 3,3,3-trifluoropropyl, 1,1,1-trifluoro-2-propyl, 4,4-difluorobutyl, 5,5-difluoropentyl and the like can be mentioned. "Hydroxyalkyl" in this specification means a group in which one or plural hydrogens of "alkyl" defined in this specification are replaced by a hydroxy group (hydroxyl). As the hydroxyalkyl, preferably hydroxy C 1 -C 6 alkyl, more preferably hydroxy C 1 -C 4 alkyl. As the hydroxyalkyl, specifically, for example, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, 5-hydroxypentyl and the like can be mentioned. "Aminecarbonylalkyl" in this specification means a group in which one or plural hydrogens of "alkyl" defined in this specification are replaced by "aminecarbonyl" defined in this specification. As the aminecarbonylalkyl, preferably aminecarbonyl C 1 -C 6 alkyl, mono C 1 -C 6 alkylaminocarbonyl C 1 -C 6 alkyl, di C 1 -C 6 alkylaminocarbonyl C 1 -C 6 alkyl, more preferably aminecarbonyl C 1 -C 4 alkyl, mono C 1 -C 4 alkylaminocarbonyl C 1 -C 4 alkyl, di-C 1 -C 4 alkylaminocarbonyl C 1 -C 4 alkyl. As the aminocarbonylalkyl, specifically, for example, methylaminocarbonylmethyl, dimethylaminocarbonylmethyl, t-butylaminocarbonylmethyl, 1-azetidinylcarbonylmethyl, 1-pyrrolidinylcarbonylmethyl, 1-piperidinylcarbonylmethyl, 4-morpholinylcarbonylmethyl, 2-(methylaminocarbonyl)ethyl, 2-(dimethylaminocarbonyl)ethyl, 2-(1-azetidinylcarbonyl)ethyl, 2-(1-pyrrolidinylcarbonyl)ethyl, 2-(4-morpholinylcarbonyl)ethyl, 3-(dimethylaminocarbonyl)propyl, 4-(dimethylaminocarbonyl)butyl, etc. can be mentioned. The "cycloalkylalkyl" in this specification means a group in which one or a plurality of hydrogens of the "alkyl" defined above are replaced by the "cycloalkyl" defined above. As the cycloalkylalkyl, preferably C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, more preferably C 3- C 6 cycloalkyl C 1 -C 4 alkyl. As the cycloalkylalkyl, specifically, for example, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, etc. can be mentioned. The "hydroxyalkenyl" in this specification means a group in which one or a plurality of hydrogens of the "alkenyl" defined in this specification are replaced by a hydroxy group (hydroxyl). As the hydroxyalkenyl, preferably hydroxy C 2 -C 6 alkenyl, more preferably hydroxy C 2 -C 4 alkenyl. As the hydroxyalkenyl, specifically, for example, (E)-4-hydroxybut-1-enyl, etc. can be mentioned. In this specification, "hydroxyalkynyl" refers to a group in which one or more hydrogens of "alkynyl" as defined in this specification are replaced by a hydroxyl group (hydroxy). Preferred examples of the hydroxyalkynyl group include hydroxy C 2 -C 6 alkynyl, more preferably hydroxy C 2 -C 4 alkynyl. Specific examples of the hydroxyalkynyl group include, for example, 3-hydroxy-3-methylbut-1-ynyl. The "alicyclic ring" in this specification refers to a non-aromatic hydrocarbon ring. The alicyclic ring may also have an unsaturated bond in the ring. The carbon atoms constituting the ring may also be oxidized to form a carbonyl group. The alicyclic ring may be a monocyclic ring (referred to as a monocyclic alicyclic ring in this specification) or may form a condensed ring with a saturated alicyclic ring such as a cyclopentane ring or a cyclohexane ring, or an aromatic hydrocarbon ring such as a benzene ring or a naphthalene ring. Preferred examples of the alicyclic ring include 3- to 10-membered alicyclic rings. Specific examples of the alicyclic ring include, for example, a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a cycloheptane ring, a cyclooctane ring, a bicyclo[2.2.1]heptane ring, etc. The "aromatic hydrocarbon ring" in this specification refers to a hydrocarbon ring composed of a monocyclic ring or a condensed ring that exhibits aromaticity. Preferred examples of the aromatic hydrocarbon ring include 6- to 10-membered aromatic hydrocarbon rings. Specific examples of the aromatic hydrocarbon ring include, for example, a benzene ring, a naphthalene ring, etc. The "heterocyclic ring" in this specification refers to a non-aromatic heterocyclic ring containing preferably 1 to 5, more preferably 1 to 3 heteroatoms among the atoms constituting the ring. The heterocyclic ring may have double bonds and / or triple bonds in the ring, and the carbon atoms in the ring may also be oxidized to form carbonyl groups. The heterocyclic ring may be a monocyclic ring (referred to as a monocyclic heterocyclic ring in this specification), or may form a condensed ring or a spiro ring with a saturated alicyclic ring such as a cyclopentane ring or a cyclohexane ring, or a saturated heterocyclic ring such as a tetrahydropyran ring, a dioxane ring, or a pyrrolidine ring. The number of atoms in the ring constituting the heterocyclic ring is preferably 3 to 12 (3- to 12-membered heterocyclic ring), more preferably 4 to 10 (4- to 10-membered heterocyclic ring). Specific examples of the heterocyclic ring include, for example, an azetidine ring, an oxetane ring, a tetrahydrofuran ring, a tetrahydropyran ring, a morpholine ring, a thiomorpholine ring, a pyrrolidine ring, a 4-oxopyrrolidine ring, a piperidine ring, a 4-oxopiperidine ring, a piperazine ring, a pyrazolidine ring, an imidazolidine ring, an oxazolidine ring, an isoxazolidine ring, a thiazolidine ring, an isothiazolidine ring, a thiadiazolidine ring, an oxazolidinone ring, a dioxolane ring, a dioxane ring, a thietane ring, an octahydroindole ring, a 6,7-dihydro-pyrrolo[1,2-a]imidazole ring, an azocane ring, a 4,5,6,7-tetrahydropyrazolo[1,5-a]piperazine ring, an azepane ring, a dioxepane ring, a 5,9-dioxaspiro[3.5]nonane ring, or a ring in which one or more single bonds in these saturated heterocyclic rings are replaced by double bonds or triple bonds, etc. The "aromatic heterocycle" in this specification refers to a cyclic compound composed of a monocyclic or condensed ring that contains one or more heteroatoms and exhibits aromaticity. The cyclic compound composed of a monocyclic ring that exhibits aromaticity in this specification is called a monocyclic aromatic heterocycle. As the aromatic heterocycle, preferably a 5- to 10-membered aromatic heterocycle can be mentioned. Specifically, as the aromatic heterocycle, for example, a furan ring, a thiophene ring, a pyrrole ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, an oxadiazole ring, a thiadiazole ring, a triazole ring, a tetrazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, a pyrazine ring, a triazine ring, a benzofuran ring, a benzothiophene ring, a benzothiadiazoline ring, a benzothiazoline ring, a benzoxazoline ring, a benzoxadiazoline ring, a benzimidazole ring, a benzotriazole ring, an indole ring, an isoindole ring, an indazole ring, a carbazole ring, a quinoline ring, an isoquinoline ring, a cinnoline ring, a quinazoline ring, a quinoxaline ring, a benzodioxole ring, an indolizine ring, an imidazopyridine ring, a pyrazolopyridine ring, an imidazopyridine ring, a triazolopyridine ring, a pyrrolopyrazine ring, a furopyridine ring, etc. can be mentioned. "May also be substituted" in this specification means that a certain group may not be substituted or may also be substituted by one or more substituents. In the case of being substituted by a plurality of substituents, these substituents may be the same or may be different from each other. Furthermore, each of these may also be given a substituent, and there is no limitation to these substituents. For example, one or two or more can be independently and freely selected from any substituents including a halogen atom, an oxygen atom, a sulfur atom, a nitrogen atom, a boron atom, a silicon atom, or a phosphorus atom. As this substituent, for example, deuterium, a halogen, a cyano group, a nitro group, a hydroxyl group, a sulfhydryl group, an amino group, C 1 -C 6 alkoxy, C 1 -C 6Alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron group, side oxy group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, etc. "One or plural" in this specification means one or more than two. When "one or plural" is used in the context related to the substituents of a certain group, this term means the number from one to the maximum number of substituents allowed for the group. In this specification, the "~" indicating a range includes the values at both ends. For example, "A~B" represents a numerical range of A or more and B or less. In this specification, the term "about", when used in combination with a numerical value, means a value range of +10% and -10% of the numerical value. The term "and / or" in this specification includes any combination of appropriately combining "and" and "or". Specifically, for example, "A, B, and / or C" includes the following 7 variations: (i) A, (ii) B, (iii) C, (iv) A and B, (v) A and C, (vi) B and C, (vii) A, B, and C. One embodiment of the present invention is a compound represented by the general formula (1) (hereinafter, also referred to as "compound (1)") or a salt thereof or a solvate thereof. In compound (1), R 4 is selected from the group consisting of optionally substituted C 6 -C 10 aryl (R 4A ), optionally substituted 4- to 10-membered heterocyclic group, and optionally substituted 5- to 10-membered heteroaryl (R 4HA ). As R 4 , preferably a C that can be substituted 6 -C 10 aryl (R 4A ) or a 5- to 10-membered heteroaryl (R 4HA ) that can be substituted. R 4 is a C that can be substituted 6 -C 10 aryl (R 4A ) when, as R 4A preferably a phenyl group. As C 6 -C 10 aryl (R 4A ) in a preferred embodiment (i), R 4A is not substituted, or is substituted by one or more R a , one or more R a are each independently selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boryl, side oxy group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and a group consisting of 5- to 10-membered heteroaryl, the hydroxyl group, sulfhydryl group, amino group, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may also be further substituted. As a preferred embodiment (ii) of C 6 -C 10 aryl (R 4A ), R 4A is unsubstituted, or is substituted by one or more R a , one or more R a each independently is selected from the group consisting of halogen, cyano, hydroxyl, amino, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, hydroxy C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo-C 1 -C 6 alkoxy, and C 1 -C 6 a group consisting of alkylsulfonamido. As C 6 -C 10 aryl (R 4A ), a preferred embodiment (iii), R 4A is unsubstituted or substituted by one or more R a 's, one or more R a each independently is selected from the group consisting of halogen, hydroxyl, halo-C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo-C 1 -C 6 alkoxy, and C 1 -C 6 a group consisting of alkylsulfonamido. R 4 is a 5- to 10-membered heteroaryl (R 4HA ) that can be substituted. When it is, as R 4HAPreferably selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrimidyl, triazinyl, benzofuryl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrimidyl, and furylpyridyl, more preferably selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidinyl, pyridazinyl, pyrimidyl, triazinyl, benzofuryl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrimidyl and furylpyridyl, still more preferably selected from the group consisting of pyridyl, pyrimidinyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl, yet still more preferably selected from the group consisting of pyrimidinyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl, particularly preferably 1H-indazol-6-yl, or 1H-indazol-4-yl, most preferably 1H-indazol-4-yl. As a preferred embodiment (i) of the 5- to 10-membered heteroaryl (R 4HA ), R 4HA is unsubstituted or substituted by one or more R a s, and one or more R a s are each independently selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, side oxy, C 1 -C 6 alkyl, C 2-C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and the group consisting of 5- to 10-membered heteroaryl, the hydroxyl group, sulfhydryl group, amino group, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may also be further substituted. As a preferred embodiment (ii) of the 5- to 10-membered heteroaryl (R 4HA ), R 4HA is unsubstituted, or is substituted by one or more R a s, and one or more R a s are each independently selected from the group consisting of halogen, cyano, hydroxyl, amino, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, hydroxy C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo C 1 -C 6 alkoxy, and C 1 -C 6 a group consisting of alkylsulfonamido. As a preferred embodiment (iii) of a 5- to 10-membered heteroaryl (R 4HA ), R 4HA is unsubstituted or substituted with one or more R a , one or more R a each independently being selected from the group consisting of halogen, cyano, amino, C 1 -C 6 alkyl, and halo C 1 -C 6 alkyl. As a preferred embodiment (iv) of a 5- to 10-membered heteroaryl (R 4HA ), R 4HA is 1H-indazol-4-yl or 1H-indazol-4-yl substituted with one or more halogens. As a preferred embodiment (v) of a 5- to 10-membered heteroaryl (R 4HA ), R 4HA is 1H-indazol-4-yl substituted with one or more halogens. As a preferred embodiment (vi) of a 5- to 10-membered heteroaryl (R 4HA ), R 4HAis a 1H-indazol-4-yl in which at least one of the 5th, 6th, and 7th positions is substituted by a halogen. As a preferred embodiment (vii) of a 5- to 10-membered heteroaryl (R 4HA ), R 4HA is a 1H-indazol-4-yl in which at least one of the 5th, 6th, and 7th positions is substituted by a halogen, and the halogen is fluorine or chlorine. As a preferred embodiment (viii) of a 5- to 10-membered heteroaryl (R 4HA ), R 4HA is a 1H-indazol-4-yl in which any one or two of the 5th, 6th, and 7th positions are substituted by a halogen, and the halogen is selected from the group consisting of fluorine, chlorine, a combination of fluorine and fluorine, and a combination of fluorine and chlorine. In compound (1), R 5 and R 6 together with the atoms to which they are bonded form an optionally substituted D ring, and the D ring is selected from the group consisting of a 3- to 10-membered monocyclic alicyclic ring, a benzene ring, a 3- to 12-membered monocyclic heterocyclic ring, and a 5- to 6-membered monocyclic aromatic heterocyclic ring (D HA ), and any two adjacent substituents on the D ring can together with the atoms to which they are bonded form an optionally substituted E ring. As the D ring, a benzene ring or a 5- to 6-membered monocyclic aromatic heterocyclic ring (D HA ) is preferred. When the D ring is a 5- to 6-membered monocyclic aromatic heterocyclic ring (D HA ), as D HA it is preferably selected from the group consisting of a furan ring, a thiophene ring, a pyrrole ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, an oxadiazole ring, a thiadiazole ring, a triazole ring, a tetrazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, a pyrazine ring, and a triazine ring, more preferably selected from the group consisting of a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring, and still more preferably a pyridine ring. As a preferred embodiment (i) of the D ring, the D ring is unsubstituted or substituted by one or more R D s, and one or more R D s are each independently selected from the group consisting of deuterium, a halogen, a cyano group, a nitro group, a hydroxyl group, a sulfhydryl group, an amino group, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boronyl, side oxy group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and a group consisting of 5- to 10-membered heteroaryl, the hydroxyl group, sulfhydryl group, amino group, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boronyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may also be further substituted. As a preferred aspect (ii) of the D ring, the D ring is unsubstituted or is substituted by one or more R D is substituted, and one or more Rs D are each independently selected from the group consisting of halogen, cyano, hydroxyl, C 1 -C 6 alkylthio, C 1 -C 6 amide group, mono-C 1 -C 6 alkylamino, C 1 -C 6 alkylsulfonamide group, C 3 -C 8 cycloalkylsulfonamide group, C 1 -C 6 alkoxy, halo-C 1 -C 6 alkoxy, hydroxy-C 1 -C 6 alkoxy, C 1 -C 6 alkoxy-C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl-C 1 -C 6 alkoxy, 4- to 10-membered heterocyclic group-C 1 -C 6 alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclic oxy, C 1 -C 6 Acyl, single C 3 -C 8 Cycloalkylaminocarbonyl, 4-8 membered cyclic aminocarbonyl, di C 1 -C 6 Alkylphosphonyl, C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, di C 1 -C 6 Alkylaminocarbonyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, hydroxy C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, hydroxy C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4-10 membered heterocyclic group, C 6 -C 10 A group consisting of aryl and 5- to 10-membered heteroaryl, the C 1 -C 6 alkylthio, C 1 -C 6 alkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl C 1 -C 6 alkoxy, 4- to 10-membered heterocyclic group C 1 -C 6 alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclic group oxy, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl and 5- to 10-membered heteroaryl may further independently be selected from the group consisting of halogen, cyano, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, side oxy, halo C 1 -C 6 alkyl, and C 3 -C 8 substituted by one or more substituents from the group consisting of cycloalkyl. As a preferred embodiment (iii) of the D ring, the D ring is unsubstituted or substituted via one or more R D substituents, one or more R D each independently selected from the group consisting of halogen, C 1 -C 6 alkoxy, halo C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl C 1 -C 6 alkoxy, C 3 -C 8 cycloalkoxy, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, and C 3 -C 8 group consisting of cycloalkyl. As a preferred embodiment (iv) of the D ring, the D ring is unsubstituted or substituted via one or more R D substituted, one or more Rs D each independently is selected from the group consisting of C 1 -C 6 alkoxy, C 1 -C 6 alkyl, and C 3 -C 8 cycloalkyl. As a preferred aspect (v) of the D ring, the D ring is unsubstituted or substituted via one or more Rs D substituted, one or more Rs D each independently is selected from the group consisting of methoxy, ethoxy, propoxy, propane-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yloxy], [(2R)-butan-2-yloxy], methyl, ethyl, propyl, propane-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl. As an aspect of compound (1), any two adjacent substituents on the D ring together with the atoms to which they are bonded form an optionally substituted E ring. In this case, the E ring is preferably selected from the group consisting of a 3- to 10-membered monocyclic alicyclic ring, a benzene ring, a 3- to 12-membered monocyclic heterocyclic ring, and a 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ) and more preferably a benzene ring or a 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ). When the E ring in compound (1) is a 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ) as E HAPreferably selected from the group consisting of a furan ring, a thiophene ring, a pyrrole ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, an oxadiazole ring, a thiadiazole ring, a triazole ring, a tetrazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, a pyrazine ring, and a triazine ring, more preferably selected from the group consisting of a thiophene ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring, still more preferably selected from the group consisting of a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring, particularly preferably a pyridine ring or a pyrazine ring, and most preferably a pyridine ring. As an aspect of the present invention, in compound (1), the D ring and the E ring form a bicyclic ring represented by the following formula: [Chemical Formula 11] (In the formula, * represents the carbon to which R in formula (1) 5 is bonded, and ** represents the carbon to which R in formula (1) 6 is bonded. In the formula, the D ring is represented by "D ring" and the E ring is represented by "E ring".) As a preferred aspect of the present invention, in compound (1), the D ring and the E ring form a bicyclic ring represented by the following formula: [Chemical Formula 12] (In the formula, * represents the carbon to which R in formula (1) 5 is bonded, and ** represents the carbon to which R in formula (1) 6 is bonded. In the formula, the D ring is represented by "D ring" and the E ring is represented by "E ring".) As a preferred aspect (i) of the E ring in compound (1), the E ring is unsubstituted or substituted by one or more R E substituents, and one or more R E are each independently selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, side oxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and the group consisting of 5- to 10-membered heteroaryl, the hydroxyl group, sulfhydryl group, amino group, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may also be further substituted. As a preferred aspect (ii) of the E ring in compound (1), the E ring is unsubstituted or substituted by one or more R E one or more R E each independently selected from the group consisting of halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and borono group. As a preferred aspect (iii) of the E-ring in compound (1), the E-ring is unsubstituted or substituted by one or more R E groups, and one or more R E are each independently selected from the group consisting of fluorine, chlorine, methoxy, dihydroxyboron, methyl, and t-butyl. Another embodiment of the present invention is a compound represented by the general formula (2) (hereinafter, also referred to as "compound (2)") or a salt thereof or a solvate thereof. R in compound (2) 4 has the same meaning as R in the above compound (1). 4 In compound (2), X 5 is CR x5 or N. As X 5 , preferably CR x5 , more preferably CH. In compound (2), X 6 is CR x6 or N. As X 6 , preferably CR x6 . In compound (2), X 10a is CR x10a or N. As X 10a , preferably CR x10a . In compound (2), R x5 、 R x6 , R 6a and R x10a are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, hydroxy, mercapto, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and a group consisting of 5- to 10-membered heteroaryl, the hydroxyl, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and 5- to 10-membered heteroaryl may be further substituted, or R x5 And R x6 、R x6 and R 6a or R 6a and R x10a may together with the atoms to which they are bonded form a substitutable E ring. As a preferred embodiment (i) of R x6 R x6 is selected from the group consisting of hydrogen, halogen, hydroxyl, C 1 -C 6 alkylthio, C 1 -C 6 amide group, mono C 1 -C 6 alkylamino, C 1 -C 6 alkylsulfonamide group, C 3 -C 8 cycloalkylsulfonamide group, C 1 -C 6 alkoxy, halo C 1 -C 6 alkoxy, hydroxy C 1 -C 6 alkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl C 1 -C 6 alkoxy, 4- to 10-membered heterocyclic group C 1 -C 6 alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclic oxy, C 1 -C 6 acyl, mono C 3 -C 8 cycloalkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl, di C 1 -C 6 alkylphosphonyl, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, hydroxy C 1 -C 6 alkyl, di C 1 -C 6 alkylaminocarbonyl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, C 2 -C 6 alkenyl, hydroxy C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, hydroxy C 2-C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and a group consisting of 5- to 10-membered heteroaryl, the C 1 -C 6 Alkylthio, C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclic group C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, 4- to 10-membered heterocyclic group oxy, C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 An aryl group and a 5- to 10-membered heteroaryl group may also be further independently substituted by one or more substituents selected from the group consisting of halogen, cyano, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, side oxygen group, halo C 1 -C 6 alkyl, and C 3 -C 8 alkyl, and C As a preferred embodiment (ii) of R x6 , R x6 is selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkoxy, halo C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl C 1 -C 6 alkoxy C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkoxy, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, and C 3 -C 8 a group consisting of cycloalkyl. As a preferred aspect (iii) of R x6 , R x6 is selected from the group consisting of hydrogen, C 1 -C 6 alkoxy, C 1 -C 6 alkyl, and C 3 -C 8 a group consisting of cycloalkyl. As a preferred aspect (iv) of R x6 , R x6 is selected from the group consisting of hydrogen, methoxy, ethoxy, propoxy, propane-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yloxy], [(2R)-butan-2-yloxy], methyl, ethyl, propyl, propane-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl. As a preferred aspect (i) of R x10a , R x10a is selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, and C 3 -C 8A group consisting of cycloalkyl groups. As R x10a In a preferred embodiment (ii), R x10a is selected from the group consisting of hydrogen, chlorine, bromine, cyano, methyl, ethyl, propyl, propane-2-yl, vinyl, ethynyl, and cyclopropyl. As R 6a In a preferred embodiment (i), R 6a is selected from the group consisting of hydrogen, halogen, cyano, halo-C 1 -C 6 alkoxy, and C 1 -C 6 alkyl. As R 6a In a preferred embodiment (ii), R 6a is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, cyano, difluoromethoxy, methyl, and ethyl. As an embodiment of compound (2), R 6a and R x10a together with the atoms to which they are bonded form an optionally substituted E-ring. In this case, the E-ring is preferably selected from the group consisting of 3- to 10-membered monocyclic alicyclic rings, benzene rings, 3- to 12-membered monocyclic heterocycles, and 5- to 6-membered monocyclic aromatic heterocycles (E HA ), more preferably a benzene ring or a 5- to 6-membered monocyclic aromatic heterocycle (E HA ). When the E-ring is a 5- to 6-membered monocyclic aromatic heterocycle (E HA ), as E HA is preferably selected from the group consisting of a thiophene ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring, more preferably selected from the group consisting of a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring, still more preferably a pyridine ring or a pyrazine ring, and most preferably a pyridine ring. As a preferred embodiment of the present invention, the E-ring in compound (2) is represented by the following formula: [Chemical formula 13] (In the formula, * represents R in formula (2) 6a bonded carbon, ** represents R in formula (2) x10a bonded carbon. In the formula, the E ring is represented by "E ring".) As a preferred embodiment of the present invention, the E ring in compound (2) is represented by the following formula: [Chemical 14] (wherein, * represents R in formula (2) 6a bonded carbon, ** represents R in formula (2) x10a bonded carbon. In the formula, the E ring is represented by "E ring".) As a preferred embodiment (i) of the E ring in compound (2), the E ring is unsubstituted or substituted via one or more R E substituents, and one or more R E are each independently selected from the group consisting of deuterium, halogen, cyano, nitro, hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, side oxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and a group consisting of 5- to 10-membered heteroaryl, the hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boronic group, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may also be further substituted. As a preferred aspect (ii) of the E ring in compound (2), the E ring is unsubstituted or substituted via one or more R E substituents, and one or more R E are each independently selected from the group consisting of halogen, C 1 -C 6 alkoxy, boronic group, and C 1 -C 6 alkyl. As a preferred aspect (iii) of the E ring in compound (2), the E ring is unsubstituted or substituted via one or more R E substituents, and one or more R E are each independently selected from the group consisting of fluorine, chlorine, methoxy, dihydroxyboronic group, methyl, and t-butyl. Another embodiment of the present invention is a compound represented by the general formula (3) (hereinafter, also referred to as "compound (3)") or a salt thereof or a solvate thereof. R in compound (3) 4 has the same meaning as R in the above compound (1), and X in compound (3) 4 has the same meaning as X in the above compound (1), and Y in compound (3) 5and X 6 and X in the above compound (2) 5 and X 6 have the same meaning. In compound (3), X 7 is CR x7 or N. In compound (3), X 8 is CR x8 or N. In compound (3), X 9 is CR x9 or N. In compound (3), X 10 is CR x10 or N. In compound (3), as the combination of X 7 、X 8 、X 9 and X 10 with X 7 being N, X 8 being CR x8 ,X 9 being CR x9 ,X 10 being CR x10 ;X 7 being CR x7 ,X 8 being N, X 9 being CR x9 ,X 10 being CR x10 ; X 7 is CR x7 ,X 8 is CR x8 ,X 9 is N, X 10 is CR x10 ; X 7 is CR x7 ,X 8 is CR x8 ,X 9 is CR x9 ,X 10 is N; X 7 is N, X 8 is CR x8 ,X 9 is CR x9 ,X 10 is N; X 7 is CR x7 ,X 8 is N, X 9 is CR x9 ,X 10 is N; or X 7 is N, X 8 is N, X 9 is CR x9 ,X 10 is CR x10 is preferred. In compound (3), as X 7 、X 8 、X 9 and X 10 's combination, with X 7 being N, X 8 being CR x8 ,X 9 being CR x9 ,X 10 being CR x10 ;X 7 being CR x7 ,X 8 being N, X 9 being CR x9 ,X 10 being CR x10 ;X 7 being CR x7 ,X 8 being CR x8 ,X 9 being N, X 10 being CR x10 ;or X 7 being CR x7 ,X 8 being CR x8 ,X 9 being CR x9 ,X 10 It is better for N. In compound (3), R x7 , R x8 , R x9 and R x10 are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, and the hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and 5- to 10-membered heteroaryl may be further substituted. R x7 Preferably selected from the group consisting of hydrogen, halogen, C 1 -C 6 Alkoxy and C 1 -C 6 Alkyl. R x8 Preferably selected from the group consisting of hydrogen, halogen, C 1 -C 6 Alkoxy and C 1 -C 6 Alkyl. R x9 Preferably selected from the group consisting of hydrogen, halogen, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl, and borono group. R x10 Preferably selected from the group consisting of hydrogen, halogen, C 1 -C 6 Alkoxy and C 1 -C 6 Alkyl. Another embodiment of the present invention is the compound or its salt or their solvate described in Table 11 below. [Table 11] In this specification, "a compound or its salt or a solvate thereof" includes a compound, a salt of the compound, a solvate of the compound, and a solvate of the salt of the compound. The compound or its salt described in this specification is preferably a pharmaceutically acceptable salt thereof. The compound or its salt described in this specification may be a solvate thereof, preferably a pharmaceutically acceptable solvate thereof. Examples of salts of a compound include hydrochloride; hydrobromide; hydroiodide; phosphate; phosphonate; sulfate; sulfonates such as methanesulfonate, p-toluenesulfonate, etc.; carboxylates such as acetate, citrate, malate, tartrate, succinate, salicylate, etc.; or alkali metal salts such as sodium salt, potassium salt, etc.; alkaline earth metal salts such as magnesium salt, calcium salt, etc.; ammonium salts such as ammonium salt, alkylammonium salt, dialkylammonium salt, trialkylammonium salt, tetraalkylammonium salt, etc. These salts are produced, for example, by contacting the compound with an acid or a base. In this specification, a solvate means that a compound and a solvent form a molecular aggregate together, and there is no particular limitation as long as it is a solvate formed with a solvent that permits ingestion accompanying pharmaceutical administration. As an example of this, there may be mentioned solvates with a single solvent such as only hydrates, alcoholates (ethanolate, methanolate, 1-propanol, 2-propanol, etc.), dimethylformamide, etc., and also include solvates formed with plural solvents relative to one compound molecule, or solvates formed with plural types of solvents relative to one compound molecule. When the solvent is water, it is called a hydrate. As the solvate of the present invention, a hydrate is preferred, and specific examples of such hydrates include hydrates of 1 to 10, preferably hydrates of 1 to 5, more preferably hydrates of 1 to 3. When the compound of the present invention can be obtained in a free form, the compound can be converted into a state of a salt or a hydrate or a solvate that the compound can form according to a usual method. For example, there may be mentioned a hydrate, an ethanolate, etc. of the compound represented by formula (1) or its salt. Specifically, there may be mentioned a hemihydrate, a monohydrate, a dihydrate, a trihydrate, a tetrahydrate, a pentahydrate, a hexahydrate, a heptahydrate, an octahydrate, a nonahydrate, a decahydrate or a 1-ethanolate of the compound represented by formula (1), or a hemihydrate, a monohydrate, a dihydrate, a trihydrate, a tetrahydrate, a pentahydrate, a hexahydrate, a heptahydrate, an octahydrate, a nonahydrate, a decahydrate or a 1-ethanolate of the sodium salt of the compound represented by formula (1), or a hydrate or an ethanolate of the hydrochloride salt of the compound represented by formula (1), etc., but it is not limited to these. The hydrate or solvate can be produced in a crystalline form or an amorphous form, and in the case of a crystalline form, it may have crystal polymorphism. As a method for producing a hydrate or a solvate, a hydrate or a solvate can be obtained, for example, by adding a solvent such as ethanol and / or water to the compound represented by formula (1) and performing usual methods such as stirring, cooling, concentration, and / or drying. Furthermore, when the compound of the present invention can be obtained as a salt, hydrate or solvate of the compound, the compound can be converted into its free form according to a conventional method. The compounds described in this specification may contain atoms of unnatural proportions of isotopes in one or more atoms constituting these compounds. By substituting any atom in the compound with an isotope atom having the same atomic number (number of protons) and a different mass number (sum of the number of protons and neutrons), a compound substituted with an isotope in a ratio different from the natural abundance ratio of the isotope, that is, a compound labeled with an isotope atom is also included in the present invention. Examples of the isotope elements included in the compounds in this specification are hydrogen atoms, carbon atoms, nitrogen atoms, oxygen atoms, phosphorus atoms, sulfur atoms, fluorine atoms, chlorine atoms, etc., and respectively include 2 H, 3 H, 13 C, 14 C, 15 N, 17 O, 18 O, 32 P, 35 S, 18 F, 36 Cl, etc. The compounds labeled with isotope atoms can be used as therapeutic or prophylactic agents, research reagents (e.g., analytical reagents), and diagnostic agents (e.g., in vivo imaging diagnostic agents). The compounds in this specification containing all proportions of radioactive or non-radioactive isotope elements are included in the scope of the present invention. The compounds labeled with isotope atoms can be produced by the same method as the production method of the unlabeled compound, using reagents or solvents containing the corresponding isotope atoms. Among the compounds, salts or solvates thereof described in this specification, all of these stereoisomers (e.g., enantiomers, diastereomers (including cis and trans geometric isomers)), racemates of the aforementioned isomers, and other mixtures are included. For example, the compounds of the present invention may have one or more asymmetric points, and the present invention includes racemic mixtures, diastereomeric mixtures, and enantiomers of such compounds. Also, for example, the compounds of the present invention may have axial asymmetry, and the present invention may include the respective stereoisomers of such compounds and mixtures thereof. <General Preparation Method> Examples of the manufacturing method of the compound represented by Formula (1) to Formula (3), its salt, or its solvate are described by the following process groups. The compounds of the present invention can be synthesized by various methods. The following manufacturing method is for illustration, and the present invention is not limited to the specified chemical reactions and conditions. In the following process of the manufacturing method, some substituents are omitted for clarity, but this is not intended to limit the disclosure of the process. The representative compounds of the present invention can be synthesized using appropriate intermediates, known compounds, and reagents. In the following general synthesis method, the variable groups represented by R 1 , R 2 etc., and the variables represented by n etc., unless otherwise specified, are the same as the variable groups represented by R 1 , R 2 etc. in the compounds represented by the general formula defined in this specification and the variables represented by n etc. Furthermore, when the starting material or the target product of a certain step undergoes an undesired chemical transformation under the reaction conditions of that step, the target product of that step can be obtained by, for example, protecting and deprotecting functional groups. Regarding the selection of protecting groups and the selection of methods for protection and deprotection, reference can be made to, for example, T. W. Greene, P. G. M. Wuts, Protective Groups in Organic Synthesis (5th Edition, John Wiley & Sons 2014) (Non-Patent Document 6). A part of the protection and deprotection of functional groups is also described in the following process. The compounds obtained in each step can be separated by general techniques and purified by crystallization or chromatography as needed. Examples of abbreviations used in this specification and their meanings are listed below. Boc: tert-Butoxycarbonyl DMA: N,N-Dimethylacetamide DMF: N,N-Dimethylformamide DMSO: Dimethyl sulfoxide EtOH: Ethanol MeOH: Methanol NMP: N-Methyl-2-pyrrolidone TFA: Trifluoroacetic acid THF: Tetrahydrofuran TBME: tert-Butyl methyl ether TFE: 2,2,2-Trifluoroethanol HATU: O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate DIPEA: N,N-Diisopropylethylamine XPhos Pd G3: (2-Dicyclohexylphosphino-2’,4’,6’-triisopropyl-1,1’-biphenyl)(2-(2’-amino-1,1’-biphenyl)) palladium(II) methanesulfonate (CAS No.: 1445085-55-1) XPhos Pd G4: (2-Dicyclohexylphosphino-2’,4’,6’-triisopropyl-1,1’-biphenyl)(2-(2’-(N-methyl)amino-1,1’-biphenyl)) palladium(II) methanesulfonate (CAS No.: 1599466-81-5) DPPF Pd G4: (1,1’-Bis(diphenylphosphino)ferrocene)(2-(2’-(N-methyl)amino-1,1’-biphenyl)) palladium(II) methanesulfonate (CAS No.: 1621274-17-6) CPhos Pd G3: (2-Dicyclohexylphosphino-2’,6’-bis(N,N-dimethylamino)biphenyl)(2-(2’-amino-1,1-biphenyl)) palladium(II) methanesulfonate (CAS No.: 1447963-73-6) CPhos Pd G2: Chloro[(2-dicyclohexylphosphino-2’,6’-bis(N,N-dimethylamino)-1,1’-biphenyl)-2-(2’-amino-1,1’-biphenyl)]palladium(II) (CAS No.: 2230788-62-0) tBuBrettPhos Pd G3: [(2-Di-tert-butylphosphino-3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1’-biphenyl)-2-(2’-amino-1,1’-biphenyl)] palladium(II) methanesulfonate (CAS No.: 1536473-72-9) BINAP Pd G4: [(±)-2,2’-Bis(diphenylphosphino)-1,1’-binaphthyl](2’-methylamino-1,1’-biphenyl-2-yl) palladium(II) methanesulfonate (CAS No.: 1599466-90-6) Xantphos Pd G3: [9,9-Dimethyl-4,5-Bis(diphenylphosphino)xanthene(2’-amino-1,1’-biphenyl-2-yl)palladium(II) methanesulfonate (CAS No.: 1445085-97-1) Xantphos Pd G4: [9,9-Dimethyl-4,5-bis(diphenylphosphino)xanthene](2’-methylamino-1,1’-biphenyl-2-yl)palladium(II) methanesulfonate (CAS No.: 1621274-19-8) tBuXPhos Pd G3: [(2-Di-tert-butylphosphino-2’,4’,6’-triisopropyl-1,1’-biphenyl)-2-(2’-amino-1,1’-biphenyl)]palladium(II) methanesulfonate (CAS No.: 1447963-75-8) DCC: N,N’-Dicyclohexylcarbodiimide EDC: N-Ethyl-N’-(3-dimethylaminopropyl)carbodiimide COMU: (1-Cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-𠰌olinium hexafluorophosphate LiHMDS: Lithium hexamethyldisilazide NaHMDS: Sodium hexamethyldisilazide KHMDS: Potassium hexamethyldisilazide LDA: Lithium diisopropylamide DIAD: Diisopropyl azodicarboxylate CMMP: (Cyanomethylene)trimethylphosphorane CMBP: (Cyanomethylene)tributylphosphorane DCE: 1,2-Dichloroethane FA: Formic acid, The compounds of the present invention can be synthesized, for example, by the production methods shown below. (General Production Method 1-1) General Production Method 1-1 is a preferred production method for compounds represented by General Formulas (1) to (3) in which R 4 is a C 6 -C 10 aryl, or a 5- to 10-membered heteroaryl that may be substituted. [Chemical Formula 15] Step 1-1 This step is the formylation step of aromatic bromide 1a. Compound 1b can be prepared by reacting the aromatic bromide 1a with a metal species and then with a formylating agent. Examples of the metal species include metals such as magnesium and lithium, and organometallic reagents. Examples of the organometallic reagents include isopropylmagnesium bromide, isopropylmagnesium chloride-lithium chloride complex, n-butyllithium, and sec-butyllithium, with isopropylmagnesium chloride-lithium chloride complex being preferred. The formylating agent is selected from N-formamides and orthoformates. As the N-formamide, DMF is preferred. As the orthoformate, trimethyl orthoformate is preferred. Examples of the solvent used in this step include aprotic solvents such as n-hexane, cyclohexane, ethers (dialkyl ethers exemplified by diethyl ether, etc., cyclic ethers such as 1,2-dimethoxyethane, THF, and 2-methyltetrahydrofuran), toluene, and mixed solvents thereof, with THF, 1,2-dimethoxyethane, toluene, and mixed solvents thereof being preferred. Step 1-2 This step is the step of preparing an aromatic ester from aromatic bromide 1a. Aromatic ester 1c (wherein R represents C 1 -C 6 alkyl, 2,4,6-trichlorophenyl, or 2,5-dioxopyrrolidin-1-yl) can be prepared by reacting the aromatic bromide 1a with a carbonylating agent in the presence of a Pd catalyst and a base. This step can be carried out with reference to, for example, the method described in Tetrahedron Lett., 2019 vol. 60, 151147 (Non-Patent Document 7). Examples of the carbonylating agent include formates, oxalates, and their salts, with 2,4,6-trichlorophenyl formate being preferred. Examples of the base include tertiary amines, with triethylamine and DIPEA being preferred. Examples of the solvent used in this step include aprotic solvents such as toluene, acetonitrile, THF, DMF, and mixed solvents thereof, with toluene being preferred. As the Pd catalyst, the combination of palladium acetate and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, Xantphos Pd G4, and Xantphos Pd G3 are preferred. This step can be carried out at a reaction temperature from -20°C to near the boiling point of the solvent, preferably at a temperature from 60°C to near the boiling point of the solvent. Step 1-3 This step is the hydrolysis step of aromatic ester 1c. Aromatic carboxylic acid 1d can be prepared by reacting the aromatic ester 1c with a hydroxide. Examples of the hydroxide include those selected from the group consisting of sodium hydroxide, lithium hydroxide, potassium hydroxide, and barium hydroxide. Examples of the solvent used in this step include polar solvents such as water, ethers, alcohols, DMSO, and mixed solvents thereof, with the mixed solvent of THF and water and the mixed solvent of methanol and water being preferred. Steps 1-4 This step is the amidation step of aromatic carboxylic acid 1d. Aromatic amide 1e (wherein X represents methyl(methoxy)amino or morpholino) can be produced by reacting aromatic carboxylic acid 1d with an amine or amine salt in the presence of a condensing agent. As the condensing agent, for example, a group selected from DCC, EDC, EDC hydrochloride, HATU, COMU, and propylphosphonic anhydride (cyclic trimer) can be chosen, and HATU is preferred. Also, as the additive in this step, a base can be used. Examples of the base include DIPEA, triethylamine, and diazabicycloundecane, etc., and DIPEA is preferred. As the solvent used in this step, for example, DMF, DMA, NMP, DCM, THF, 1,4-dioxane, 1,2-dimethoxyethane, ethyl acetate, acetonitrile, and a mixed solvent thereof can be mentioned. As the amine or amine salt, for example, N,O-dimethylhydroxylamine hydrochloride and morpholine can be mentioned, and N,O-dimethylhydroxylamine hydrochloride is preferred. Steps 1-5 This step is another method for synthesizing aromatic amide 1e and is the step of performing an ester-amide exchange reaction of aromatic ester 1c. This step can be carried out when R of aromatic ester 1c is 2,4,6-trichlorophenyl, 2,5-dioxopyrrolidin-1-yl, etc. Aromatic amide 1e (wherein X represents methyl(methoxy)amino or morpholino) can be produced by reacting aromatic ester 1c with an amine. As the amine, morpholine is preferred. As the solvent used in this step, for example, toluene, DMF, DMA, THF, 1,4-dioxane, 1,2-dimethoxyethane, acetonitrile, and a mixed solvent thereof can be mentioned, and toluene is preferred. This step can be carried out at a reaction temperature from -20°C to near the boiling point of the solvent, preferably at a temperature from 60°C to near the boiling point of the solvent. (General Preparation Method 1-2) General Preparation Method 1-2 is a preferred production method for compounds represented by general formulas (1) to (3), wherein R 4 is a C that can be substituted 6 -C 10 aryl, or a 5- to 10-membered heteroaryl that can be substituted. [Chemical Formula 16] [Chemical Formula 17] Step 1-6 This step is the step of iodinating aromatic amine 1f. Aromatic amine 1g can be produced by reacting aromatic amine 1f with an iodinating reagent. Examples of the iodinating reagent include iodine, N-iodosuccinimide, 1,3-diiodo-5,5-dimethylhydantoin, N-iodosaccharin, and iodine chloride, with N-iodosuccinimide being preferred. Examples of the solvent used in this step include DCM, acetonitrile, ethyl acetate, DMSO, and acetic acid, with DCM and DMSO being preferred. As additives in this step, acids such as TFA, acetic acid, sulfuric acid, methanesulfonic acid, and trifluoromethanesulfonic acid can be appropriately used. Step 1-7 This step is the step of converting the amino group of aromatic amine 1g using an N,N-dimethylformamidine reagent. Aromatic iodine compound 1h can be produced by converting the amino group of aromatic amine 1g into an N,N-dimethylformamidinyl group. Examples of the N,N-dimethylformamidine reagent include N,N-dimethylformamide dimethyl acetal, N,N-dimethylformamide di-tert-butyl acetal, and a combination of DMF and phosphorus oxychloride (V), with N,N-dimethylformamide dimethyl acetal being preferred. Examples of the solvent used in this step include alcohols, DMSO, THF, DMF, DMA, NMP, toluene, 1,4-dioxane, 1,2-dimethoxyethane, ethyl acetate, acetonitrile, and mixed solvents thereof, with ethanol and DMSO being preferred. This step can be carried out at a reaction temperature from -20°C to near the boiling point of the solvent, preferably at a temperature from 40°C to near the boiling point of the solvent. Step 1-8 This step is the step of synthesizing ketone 1i by reacting aromatic iodine compound 1h with a metal species and then with aromatic amide 1e (wherein X represents methyl (methoxy)amino or morpholino). Examples of the metal species include metals such as magnesium and lithium, and organometallic reagents. Examples of the organometallic reagent include isopropylmagnesium bromide, isopropylmagnesium chloride-lithium chloride complex, n-butyllithium, and sec-butyllithium, with isopropylmagnesium chloride-lithium chloride complex being preferred. Examples of the solvent used in this step include non-protic solvents such as n-hexane, cyclohexane, ethers, and toluene, and mixed solvents thereof, with THF, 1,2-dimethoxyethane, toluene, and mixed solvents thereof being preferred. Also, as additives, hexamethylphosphoric triamide, N,N'-dimethylpropyleneurea, or crown ether can be optionally added, with N,N'-dimethylpropyleneurea being preferred as the additive. Step 1-9 This step is a step of converting dimethylformamidine 1i into aniline 1j by means of a hydrolysis reaction. Aniline 1j can be produced by reacting a dimethylformamidine compound 1i with a hydroxide. Examples of the hydroxide include sodium hydroxide, lithium hydroxide, potassium hydroxide, and barium hydroxide, with sodium hydroxide being preferred. Examples of the solvent used in this step include polar solvents such as THF, alcohol, and DMSO, with DMSO being preferred. Step 1-10 This step is a step of reacting an aromatic iodine compound 1h with a metal species and then reacting with an aromatic aldehyde 1b to produce an alcohol. Examples of the metal species include metals such as magnesium and lithium, and organometallic reagents. Examples of the organometallic reagent include, for example, isopropylmagnesium bromide, isopropylmagnesium chloride-lithium chloride complex, n-butyllithium, and sec-butyllithium, with isopropylmagnesium chloride-lithium chloride complex being preferred. Examples of the solvent used in this step include aprotic solvents such as n-hexane, cyclohexane, ethers, toluene, and mixed solvents thereof, with THF, 1,2-dimethoxyethane, toluene, and mixed solvents thereof being preferred. Further, as an additive, hexamethylphosphoric triamide, N,N'-dimethylpropyleneurea, or crown ether can be added, and as the additive, N,N'-dimethylpropyleneurea is preferred. Further, an acid and a base can be sequentially added to the reaction mixture to convert the N,N-dimethylformamidyl group into an amino group. As the acid, formic acid is preferred. As the base, ethylenediamine is preferred. Step 1-11 This step is a step of converting benzyl alcohol 1o into a ketone by an oxidation reaction. Aromatic amine 1j can be produced by reacting benzyl alcohol 1o with an oxidizing agent. Examples of the oxidizing agent include, for example, manganese dioxide, Dess-Martin periodinane, chromium(IV) oxide, and pyridinium dichromate, with manganese dioxide being preferred. Examples of the solvent used in this step include aprotic solvents such as DCM, chloroform, acetonitrile, ethyl acetate, and mixed solvents thereof, with DCM being preferred. Step 1-12 This step is the step of haloacetylating aromatic amine 1j. This step can be carried out following Method-1 or Method-2 below. Method-1: Haloacetamide 1k (wherein Y represents a halogen) can be produced by reacting aromatic amine 1j with a haloacetylating agent. As the haloacetylating agent, for example, chloroacetyl chloride or bromoacetyl chloride can be used. In this step, a base can be appropriately used. As the base, organic bases such as DIPEA, triethylamine, and pyridine can be used. As the solvent used in this step, for example, DCM, acetonitrile, THF, DMF, DMA, and NMP can be mentioned, with DCM and DMA being preferred. Method-2: Haloacetamide 1k (wherein Y represents a halogen) can be produced by reacting aromatic amine 1j with haloacetic acid in the presence of a condensing agent. As the haloacetic acid, chloroacetic acid and bromoacetic acid can be used. As the condensing agent, for example, DCC, EDC, EDC hydrochloride, HATU, COMU, and propylphosphonic anhydride (cyclic trimer) can be mentioned, with HATU and propylphosphonic anhydride (cyclic trimer) being preferred. As the base, DIPEA and triethylamine etc. can be mentioned, with DIPEA being preferred. As the solvent used in this step, for example, DMF, DMA, NMP, DCM, acetone, THF, 1,4-dioxane, 1,2-dimethoxyethane, ethyl acetate, acetonitrile and mixed solvents thereof can be mentioned, with DMF being preferred. Step 1-13 This step is the step of constructing a pyridone skeleton from haloacetamide 1k (wherein Y represents a halogen) by a cyclization reaction. Pyridinium ylide 1l (wherein Y represents a halogen) can be produced by reacting haloacetamide 1k with pyridine. Pyridine can be used as the solvent for this step. Also, the reaction mixture of Step 1-12 can be reacted with pyridine. This step can be carried out at a reaction temperature from -20°C to near the boiling point of the solvent, preferably at a temperature from 40°C to near the boiling point of the solvent. Step 1-14 This step is the deprotection step of pyridinium ylide 1l. 3-Aminopyridone compound 1n1 can be produced by reacting pyridinium ylide 1l with a nucleophile. As the nucleophile, for example, hydrazine, hydrazine hydrochloride, hydrazine monohydrate, and hydroxylamine etc. can be mentioned, with hydrazine monohydrate and hydrazine hydrochloride being preferred. Also, the reaction mixture of Step 1-13 can be directly used. This step can be carried out at a reaction temperature from -20°C to near the boiling point of the solvent, preferably at a temperature from 40°C to near the boiling point of the solvent. Step 1-15 This step is at the R of 3-aminopyridone compound 1n1 4 In the case of having a protecting group such as 2-tetrahydropyranyl which can be removed by an acid, an acid is added to the 3-aminopyridone compound 1n1 to remove the protecting group such as 2-tetrahydropyranyl which can be removed by an acid. Examples of the acid include sulfuric acid, hydrochloric acid, sulfonic acids, and carboxylic acids, and trifluoroacetic acid (TFA) is preferred. Examples of the solvent used in this step include alcohols (such as alkyl alcohols or fluoroalkyl alcohols), water, and dichloromethane (DCM). Also, in the alcohols used as the solvent, an acid can be generated, for example, with trimethylchlorosilane (TMSCl) to remove the protecting group such as 2-tetrahydropyranyl which can be removed by an acid. As the combination of the acid and the solvent, the combination of TMSCl and 2,2,2-trifluoroethanol (TFE), the combination of TFA and DCM, and the combination of TFA and water are preferred. (General Preparation Method 2) General Preparation Method 2 is another preferred method for synthesizing the 3-aminopyridone compound 1n2. General Preparation Method 2 is a preferred manufacturing method for compounds where R in the compounds represented by the general formulas (1) to (3) is a C 4 that can be substituted C 6 -C 10 aryl, or a 5- to 10-membered heteroaryl that can be substituted. [Chemical Formula 18] [Chemical Formula 19] Step 2-1 Step 2-1 is a step of condensing an acid chloride 2a-1 (wherein X represents chlorine) or a carboxylic acid 2a-2 (wherein X represents a hydroxyl group) with a glycine alkyl ester or a salt of a glycine alkyl ester. This step can be carried out following Method-1 or Method-2 below. Method-1: The amide 2b can, in the presence of a base, react the acid chloride 2a-1 with a glycine alkyl ester or a salt of a glycine alkyl ester (wherein R is a C 1 -C 6It is produced by reacting with an alkyl group). As the salt of glycine alkyl ester, glycine alkyl ester hydrochloride is preferred. As the base, organic bases such as DIPEA, triethylamine, and pyridine, carbonates, and inorganic salts such as sodium hydroxide can be cited, and triethylamine or DIPEA is preferred. As the solvent used in this step, DCM, acetonitrile, THF, DMF, DMA, NMP, and water can be cited, and DCM and THF are preferred. Method - 2: Amide 2b can be produced by reacting carboxylic acid 2a - 2 with glycine alkyl ester or a salt of glycine alkyl ester in the presence of a condensing agent. As the salt of glycine alkyl ester, glycine alkyl ester hydrochloride is preferred. As the condensing agent, for example, DCC, EDC, EDC hydrochloride, HATU, COMU, and propylphosphonic anhydride (cyclic trimer) can be cited, and HATU and propylphosphonic anhydride (cyclic trimer) are preferred. Also, as the additive in this step, a base can be used. As the base, DIPEA, triethylamine, etc. can be cited, and DIPEA is preferred. As the solvent used in this step, for example, a solvent selected from the group consisting of DMF, DMA, NMP, DCM, acetone, THF, 1,4 - dioxane, 1,2 - dimethoxyethane, ethyl acetate, and acetonitrile, or a mixed solvent thereof can be cited, and DMF is preferred. Step 2 - 2 This step is the step of protecting amide 2b with Boc. The Boc - protected compound 2c can be produced by reacting amide 2b with a Boc - reagent. In this step, a base and a catalyst can be appropriately used. As the base, DIPEA, triethylamine, and diazabicycloundecene can be cited. As the catalyst, DMAP can be cited. As the solvent used in this step, for example, a solvent selected from the group consisting of DMF, DMA, DCM, acetone, THF, 1,4 - dioxane, 1,2 - dimethoxyethane, ethyl acetate, and acetonitrile, or a mixed solvent thereof can be cited, and DMF is preferred. Step 2 - 3 This step is the step of acyl - rearrangement of the Boc - protected compound 2c in the presence of a base. As the base, a base selected from the group consisting of sodium tert - butoxide, potassium tert - butoxide, LiHMDS, NaHMDS, KHMDS, and LDA can be used alone or in combination, and potassium tert - butoxide, LiHMDS, and a mixture thereof are preferred. As the solvent used in this step, a solvent selected from the group consisting of toluene, xylene, n - hexane, cyclohexane, THF, 1,2 - dimethoxyethane, N,N’ - dimethylpropyleneurea, and hexamethylphosphoric triamide, or a mixed solvent thereof can be cited, and THF is preferred. Step 2-4 This step is the step of tosylating the ketone compound 2d with a base. As the base, a base selected from the group consisting of, for example, sodium tert-butoxide, potassium tert-butoxide, LiHMDS, NaHMDS, KHMDS, LDA, DIPEA, triethylamine, and diazabicycloundecene, or a combination of these bases can be used. LDA, LiHMDS, DIPEA, and triethylamine are preferred. As the solvent used in this step, solvents selected from the group consisting of toluene, xylene, n-hexane, cyclohexane, THF, 1,2-dimethoxyethane, acetonitrile, and DCM, or a mixed solvent thereof can be cited. THF is preferred. Also, the reaction mixture of Step 2-3 can be directly used for the reaction. Step 2-5 This step is a cross-coupling step and a cyclization condensation step using a Pd catalyst. In the presence of a Pd catalyst, compound 2e is reacted with the corresponding organoboron compound (wherein R' is exemplified by hydrogen, alkyl, or alkylene), or an organotin compound (wherein R' is exemplified by hydrogen, alkyl, or alkylene) is reacted. The organoboron compound or organotin compound used has an amino group at the ortho position of boron or tin, and a cyclization condensation step occurs after the cross-coupling step. This step can be carried out following Method-1 or Method-2 below. Method-1 (Suzuki-Miyaura cross-coupling): Method-1 can be carried out, for example, according to the methods described in Chem. Rev. 1995, vol. 95, no. 7, p. 2457-2483. (Non-Patent Document 8), Acc. Chem. Res. 2008, vol. 41, No. 11, p. 1461-1473. (Non-Patent Document 9). As the base used in the present invention, inorganic salts such as carbonates, phosphates, and hydroxides, and amines such as triethylamine and DIPEA can be cited. Cesium carbonate, potassium carbonate, and triethylamine are preferred. As the solvent used in this method, polar solvents such as toluene, xylene, THF, 2-methyltetrahydrofuran, 4-methyltetrahydropyran, 1,4-dioxane, DMF, DMA, NMP, water, etc., and a mixed solvent thereof can be cited. A mixed solvent of 2-methyltetrahydrofuran, 4-methyltetrahydropyran, and water is preferred. As the Pd catalyst, PdCl 2 (PPh 3 ) 2 、Pd(PPh 3 ) 4, and dichloropalladium(II) bis(1,1'-bis(diphenylphosphino)ferrocene), dichloropalladium(II) 1,4-bis(diphenylphosphino)butane, XPhos Pd G3, and XPhos Pd G4, with dichloropalladium(II) bis(1,1'-bis(diphenylphosphino)ferrocene), dichloropalladium(II) 1,4-bis(diphenylphosphino)butane, XPhos Pd G3, and XPhos Pd G4 being preferred. This step can be carried out at a reaction temperature ranging from -20 °C to near the boiling point of the solvent, preferably at a temperature of 80 °C or higher to near the boiling point of the solvent. Method -2 (Stille cross-coupling): Method -2 can be carried out, for example, according to the method described in Synthesis 1992, vol. 9, p. 803-815. (Non-patent Document 10). As the Pd catalyst, examples include PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4 , and dichloropalladium(II) bis(1,1'-bis(diphenylphosphino)ferrocene), and dichloropalladium(II) 1,4-bis(diphenylphosphino)butane, etc., with Pd(PPh 3 ) 4 being preferred. As the solvent used in this method, examples include toluene, xylene, THF, 2-methyltetrahydrofuran, 4-methyltetrahydropyran, 1,4-dioxane, DMF, DMA, and NMP, etc., with toluene being preferred. This step can be carried out at a reaction temperature ranging from -20 °C to near the boiling point of the solvent, preferably at a temperature of 80 °C to near the boiling point of the solvent. Step 2-6 This step is to deprotect the Boc of the Boc-protected compound 2f. It can be carried out under the same conditions as in Step 1-15. Step 2-7 This step is to carry out the Wittig reaction on the formyl compound 2g. The α,β-unsaturated ester compound 2h can be prepared by reacting the formyl compound 2g with a phosphorus reagent in the presence of a base. As the phosphorus reagent, examples include 2-(BOC-amino)-2-(dimethoxyphosphoryl)acetate and its equivalents (wherein R is C 1 -C 6(Alkyl), and potassium 2-(BOC-amino)-2-(dimethoxyphosphoryl)acetate is preferred. As the base, a base selected from the group consisting of sodium tert-butoxide, potassium tert-butoxide, LiHMDS, NaHMDS, KHMDS, LDA, and 1,4-diazabicyclo[2.2.2]octane, or a mixture thereof can be mentioned. As the solvent used in this method, toluene, THF, 1,2-dimethoxyethane, acetonitrile, DCM, etc. can be mentioned. Step 2-8 This step is the bromination step of the α,β-unsaturated ester compound 2h. The aromatic nitro compound 2i can be produced by reacting the α,β-unsaturated ester 2h with a brominating agent and further isomerizing in the presence of a base. As the brominating agent, NBS, 1,3-dibromo-5,5'-dimethylhydantoin, N-bromosaccharin, etc. can be mentioned, and NBS is preferred. As the base, 1,4-diazabicyclo[2.2.2]octane, diazabicycloundecene, sodium tert-butoxide, potassium tert-butoxide, LiHMDS, NaHMDS, KHMDS, etc. can be mentioned, and 1,4-diazabicyclo[2.2.2]octane and diazabicycloundecene are preferred. As the solvent used in this method, acetonitrile, DCM, etc. can be mentioned. Step 2-9 This step is the reduction step and consecutive cyclization step of the aromatic nitro compound 2i. Regarding the reduction step, it can be carried out, for example, by the method described in Org. Process Res. Dev. 2018, vol. 22, no. 4, p. 430-445. (Non-Patent Document 11), especially in solvents such as methanol and ethyl acetate, by Pd(OH) 2 / H 2 combination, or by reacting in ethanol with a combination of Fe / NH 4 Cl is preferred. By carrying out the reaction at a reaction temperature from room temperature to near the boiling point, the cyclization step can be carried out continuously. Step 2-10 This step is the cross-coupling step using a Pd catalyst. React the compound 2i or 2j with the corresponding organoboron compound (R 4- B(OR) 2 、R 4- BF 3 K) or organotin compound (R 4- SnR 3 )(wherein, R is exemplified as hydrogen, alkyl). It can be carried out under the same conditions as in Step 2-5. (General Preparation Method 3) General Preparation Method 3 can be carried out in the 3-aminopyridinone compound 1n1 or 1n2, where X 6 is CR x6 and R x6 is a halogen. [Chemical Formula 20] Step 3-1 This step is to introduce the substituent R into the 3-aminopyridinone compound 1n1 or 1n2 in the presence of a metal catalyst x6 . This step can be carried out according to any of the following Methods -1 to -6. Method -1 (Suzuki-Miyaura Cross-Coupling): React the 3-aminopyridinone compound 1n1 or 1n2 with the corresponding organoboron compound (R x6 -B(OR) 2 , R x6 -BF 3 K) or organotin compound (R x6 -SnR 3 )(wherein R is exemplified by hydrogen, alkyl). It can be carried out under the same conditions as Method -1 in Step 2-5. Method -2 (Alkylation or Vinylation by Negishi Cross-Coupling): The 3-aminopyridinone compound 3a can be prepared by reacting the 3-aminopyridinone compound 1n1 or 1n2 with the corresponding organozinc reagent (R x6 -ZnX) (wherein X is a halogen) in the presence of Pd or Ni. Method -2 can be carried out, for example, according to the methods described in Tetrahedron. 1992, vol. 48, no. 44, p. 9577-9648. (Non-Patent Document 12) or Aldrichimica Acta. 2005, vol. 38, p. 71-88. (Non-Patent Document 13). As the solvent used in this step, polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, etc., or a mixed solvent thereof can be exemplified, and THF is preferred. As Pd or Ni, those described in Tetrahedron. 1992, vol. 48, no. 44, p. 9577-9648. (Non-Patent Document 12) or Aldrichimica Acta. 2005, vol. 38, p. 71-88. (Non-Patent Document 13), as well as PdCl 2(PPh 3 ) 2 、Pd(PPh 3 ) 4 、 and dichloropalladium(II) bis(diphenylphosphino)ferrocene, with PdCl 2 (PPh 3 ) 2 、Pd(PPh 3 ) 4 、 and dichloropalladium(II) bis(diphenylphosphino)ferrocene being preferred. Method - 3 (Sonogashira cross - coupling): The 3 - aminopyridone compound 3a can be prepared by reacting the 3 - aminopyridone compound 1n1 or 1n2 with the corresponding alkyne (R - C≡C - H, where R - C≡C - is represented as R x6 -) in the presence of Pd, Cu, and a base. Method - 3 can be carried out, for example, according to the method described in Chem.Soc.Rev.2011, vol.40, p.5084 - 5121. (Non - patent document 14). The corresponding alkyne may also have a silyl group, for example, trimethylsilylacetylene can be cited. As the base, amines such as triethylamine, DIPEA, diazabicycloundecene, and inorganic bases such as sodium acetate can be cited, with triethylamine and DIPEA being preferred. As Pd, for example, PdCl 2 (PPh 3 ) 2 、Pd(PPh 3 ) 4 、 dichloropalladium(II) bis(diphenylphosphino)ferrocene, Pd(OAc) 2 、 and Pd 2 (dba) 3 , with PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4 , and dichloropalladium(II) bis[1,1'-bis(diphenylphosphino)ferrocene] are preferred. As Cu, for example, copper iodide, copper bromide, and copper chloride can be mentioned, and copper iodide is preferred. As the solvent used in this step, for example, polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, DMSO, methanol, ethanol, 2-propanol, and mixed solvents thereof can be mentioned, and DMSO, DMF, DMA, and NMP are preferred. Method - 4 (thiolation): The 3-aminopyridinone compound 3a can be produced by reacting the 3-aminopyridinone compound 1n1 or 1n2 with the corresponding thiol or thiolate in the presence of Pd and a base. As the thiol, for example, 2-ethylhexyl 2-ethylhexanoate and mercaptopropionic acid can be mentioned. As the base, for example, amines such as triethylamine, DIPEA, diazabicycloundecene, and piperidine can be mentioned, and triethylamine and DIPEA are preferred. As Pd, for example, zerovalent Pd complexes such as Pd(PPh 3 ) 4 etc. can be mentioned, and Xantphos Pd G3 is preferred. As the solvent used in this step, for example, polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, DMSO, methanol, ethanol, 2-propanol, and mixed solvents thereof can be mentioned, and 1,4-dioxane is preferred. Method - 5 (etherification or hydroxylation): The 3-aminopyridinone compound 3a can be produced by reacting the 3-aminopyridinone compound 1n1 or 1n2 with the corresponding alcohol or water in the presence of Pd. In the case of etherification, as the base, for example, the sodium salt and potassium salt of the corresponding alcohol can be used. Also, in the case of hydroxylation, for example, sodium hydroxide and potassium hydroxide can be used. As Pd, for example, Pd(PPh 3 ) 4Equivalent Pd complexes, preferably tBuBrettPhos Pd G3. As the solvent used in this step, polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, etc. can be cited, and 1,4-dioxane is preferred. Method - 6 (amination): The 3-aminopyridone compound 3a can be prepared by reacting the 3-aminopyridone compound 1n1 or 1n2 with the corresponding amine in the presence of Pd or Cu and a base. When using Pd, it can be carried out by the method described in, for example, Chem.Rev.2016, vol.116, p.12564 - 12649. (Non-patent Document 15). Examples of Pd include Pd(PPh 3 ) 4 Equivalent Pd complexes, preferably Xantphos Pd G3, Xantphos Pd G4, and tBuXPhos Pd G3. Examples of the base include carbonates, phosphates, sodium tert-butoxide, potassium, and tert-butanol, etc., and sodium tert-butoxide is preferred. As the solvent used in this step, polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, DMSO, etc. and mixed solvents thereof can be cited, and 1,4-dioxane is preferred. Also, when using Cu, it can be carried out by the method described in, for example, Org. Process Res. Dev.2022, vol.26, no.6, p.1690 - 1750. (Non-patent Document 16). Examples of Cu include copper iodide, copper bromide, and copper chloride, and copper iodide is preferred. Examples of the ligand of Cu include 1,10-phenanthroline, L-proline, and 2-((2,6-dimethylphenyl)amino)-2-oxoacetic acid (DMPAO), etc., and 2-((2,6-dimethylphenyl)amino)-2-oxoacetic acid (DMPAO) is preferred. Examples of the base include carbonates, phosphates, sodium tert-butoxide, and potassium tert-butoxide, etc., and cesium carbonate, potassium carbonate, and tripotassium phosphate are preferred. As the solvent used in this step, polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, DMSO, etc. and mixed solvents thereof can be cited, and DMSO is preferred. Step 3 - 2 This step is a step of deprotecting the Boc group, 2-tetrahydropyranyl group, or both when the 3-aminopyridone compound 3a has a Boc group, 2-tetrahydropyranyl group, or both. It can be carried out under the same conditions as in Step 1 - 15. Steps 3 - 3 - 1, 3 - 3 - 2, and 3 - 3 - 3 are all steps of protecting the 3-aminopyridone compound 1n1 or 1n2 with a protecting group. Step 3-3-1: Protection by Bocylation This step is the step of protecting the 3-aminopyridinone compound 1n1 or 1n2 with a Boc group. The protected compound 3c of 3-aminopyridinone can be prepared by reacting the 3-aminopyridinone compound 1n1 or 1n2 with a Bocylation reagent. In this step, a base and a catalyst can be appropriately used. In this step, in the formula, P 1 is a Boc group, P 3 is a Boc group or H. This step can be carried out under the same conditions as step 2-2. Step 3-3-2: Protection by p-methoxybenzylation This step is the step of carrying out p-methoxybenzylation by reacting the 3-aminopyridinone compound 1n1 or 1n2 with a p-methoxybenzylation reagent in the presence of a base. In this step, in the formula, P 1 is p-methoxybenzyl, P 3 is H. Examples of the p-methoxybenzylation reagent include p-methoxybenzyl chloride and p-methoxybenzyl bromide. Examples of the base include inorganic bases such as potassium carbonate, silver carbonate, cesium carbonate, and sodium hydroxide, with potassium carbonate and silver carbonate being preferred. Examples of the solvent used in this step include aprotic solvents such as DMF, DMA, NMP, THF, DCM, and DCE, with DMF, DMA, or DCE being preferred. Step 3-3-3: Protection by 2-(trimethylsilyl)ethoxymethylation This step is the step of carrying out 2-(trimethylsilyl)ethoxymethylation by reacting the 3-aminopyridinone compound 1n1 or 1n2 with a 2-(trimethylsilyl)ethoxymethylation reagent in the presence of a base. In this step, in the formula, P 1 is 2-(trimethylsilyl)ethoxymethyl, P 3 is H. Examples of the 2-(trimethylsilyl)ethoxymethylation reagent include 2-(trimethylsilyl)ethoxymethyl chloride, etc. Examples of the base include inorganic bases such as potassium carbonate, silver carbonate, cesium carbonate, and sodium hydroxide, with potassium carbonate or cesium carbonate being preferred. Examples of the solvent used in this step include aprotic solvents such as DMF, DMA, NMP, THF, DCM, and 1,2-dichloroethane, with DMF and DMA being preferred. Step 3-4 This step is the alkylation step of the protected body 3c of 3-aminopyridinone. In the presence of a photoredox catalyst, the protected body 3c of 3-aminopyridinone is reacted with an alcohol (R x6 -OH) or a haloalkyl (R x6 -X, where X is a halogen), alkylation can be carried out. It can be carried out according to the methods described in JACS. 2016, vol.138, no.26, p.8084-8087. (Non-patent document 17), ACS Med.Chem.Lett.2020, 11, 597-604. (Non-patent document 18) and Nature 2021, vol.598, p.451-456. (Non-patent document 19), etc. Steps 3-5 This step is to deprotect the Boc group or 2-tetrahydropyranyl group when the 3-aminopyridinone 3d has a Boc group or 2-tetrahydropyranyl group. It can be carried out under the same conditions as in Step 1-15. Steps 3-6 This step is the hydroxylation step of the protected body 3c of 3-aminopyridinone. It can be carried out under the same conditions as the hydroxylation in Method 5 of Step 3-1. Steps 3-7 This step is the alkylation step of the hydroxy compound 3e. This step can be carried out according to the following Method-1 or Method-2. Method-1 (Nucleophilic substitution reaction): The alkylated compound 3f (wherein R x6a O represents R x6 ) can be prepared by reacting the hydroxy compound 3e with the corresponding haloalkyl, alkyl triflate or alkyl nonaflate in the presence of a base. Examples of the base include inorganic bases such as carbonates and phosphates, and cesium carbonate and potassium carbonate are preferred. Also, examples of the solvent used in this step include THF, 1,4-dioxane, DMF, DMA, and NMP, etc. Method-2 (Mitsunobu reaction): The alkylated product 3f (wherein R x6a O represents R x6 ) can be prepared by reacting the hydroxy compound 3e with the corresponding alcohol in the presence of a Mitsunobu reagent. Examples of the Mitsunobu reagent include the combination of triphenylphosphine and DIAD, CMMP, and CMBP, etc. Examples of the solvent used in this step include non-protic solvents such as toluene, DCM, THF, n-hexane, cyclohexane, ethyl acetate, DMA, DMF, NMP, and 1,4-dioxane, etc., and DCM and THF are preferred. Steps 3-8 This step is to deprotect the 2-(trimethylsilyl)ethoxymethyl, p-methoxybenzyl, or 2-tetrahydropyranyl group when the alkylated compound 3f has a 2-(trimethylsilyl)ethoxymethyl, p-methoxybenzyl, or 2-tetrahydropyranyl group. It can be carried out under the same conditions as in Step 1-15. Step 3-9 This step is the p-methoxybenzylation step of the 3-aminopyridone compound 1n1 or 1n2. Step 3-9 can be carried out under the same conditions as Step 3-3-2. In the formula, P 2 represents p-methoxybenzyl. Step 3-10 This step is the hydroxylation step of the p-methoxybenzyl-protected compound 3g. It can be carried out under the same conditions as the hydroxylation in Method 5 of Step 3-1. Step 3-11 This step is the alkylation step of the hydroxy compound 3h. It can be carried out under the same conditions as Step 3-7. (In the formula of compound 3i, R x6a O represents R x6 ) Step 3-12 When the compound 3i has p-methoxybenzyl or 2-tetrahydropyranyl, this step is the deprotection step of p-methoxybenzyl 2-tetrahydropyranyl. It can be carried out under the same conditions as Step 1-15. (General Preparation Method 4) General Preparation Method 4 is a preferred production method for compounds in which R in the compounds represented by the general formulas (1) to (3) 4 is a 4- to 10-membered heterocyclic group that can be substituted. [Chemical Formula 21] Step 4-1 This step is the nitration step of the 4-hydroxypyridone compound 4a. The 3-nitropyridone compound 4b can be produced by reacting the 4-hydroxypyridone compound 4a with a nitrating agent under acidic conditions. Examples of the nitrating agent include nitric acid and nitrates. Examples of the solvent used in this step include acetic acid, sulfuric acid, and nitric acid. Step 4-2 This step is the chlorination step of the 3-nitropyridone compound 4b. The 4-chloropyridone compound 4c can be produced by reacting the 3-nitropyridone compound 4b with a chlorinating agent. Examples of the chlorinating agent include, for example, phosphorus oxychloride, thionyl chloride, and oxalyl chloride. These chlorinating agents can also be used with a certain amount of solvent. As the catalyst in this step, DMF can also be used. Step 4-3 This step is the step of carrying out an aromatic nucleophilic substitution reaction of the 4-chloropyridone compound 4c. The 3-nitropyridone compound 4d can be produced by reacting the 4-chloropyridone compound 4c with the corresponding amine (for example, piperidine can be mentioned). Examples of the solvent used in this step include, for example, aprotic solvents such as toluene, THF, n-hexane, cyclohexane, ethyl acetate, DMA, DMF, NMP, 1,4-dioxane, and DMSO, and DMF is preferred. Step 4-4 This step is the reduction step of the 3-nitropyridone compound 4d. The 3-aminopyridone compound 4e can be produced by reacting the 3-nitropyridone compound 4d with a reducing agent. This step can be carried out, for example, by the method described in Org. Process Res. Dev. 2018, vol. 22, no. 4, p. 430-445. (Non-Patent Document 11), in a solvent such as methanol or ethyl acetate, using a combination of Pd(OH) 2 / H 2 or, in ethanol, a combination of Fe / NH 4 Cl is preferred. <Pharmaceutical Composition> The present invention provides a pharmaceutical composition (hereinafter, also referred to as "the pharmaceutical composition of the present invention") containing the compound represented by formula (1) of the present invention or a salt thereof or a solvate thereof (the first component). In addition to the compound represented by formula (1) of the present invention or a salt thereof or a solvate thereof, the pharmaceutical composition of the present invention can be formulated by introducing a pharmaceutically acceptable carrier by a known method. For formulation, commonly used excipients, binders, lubricants, coloring agents, flavoring agents, or, if necessary, stabilizers, emulsifiers, absorption promoters, surfactants, pH adjusters, preservatives, antioxidants, etc. can be used, and components used as raw materials for general pharmaceutical preparations are combined and formulated according to conventional methods. Formulation can process the active ingredient used in pharmaceuticals into the most appropriate shape or form, that is, dosage form, according to the method of use or purpose of use by a known method. As commonly used dosage forms, for example, liquid pharmaceutical preparations (liquid preparations) such as injections, suspensions, emulsions, eye drops, etc., or solid pharmaceutical preparations (solid preparations) such as tablets, powders, fine granules, granules, coated tablets, capsules, dry syrups, buccal tablets, suppositories, etc. are exemplified, but are not limited thereto. For example, in the manufacture of a liquid preparation, after appropriately combining and adding a pharmacologically acceptable carrier or vehicle, specifically, sterilized water or physiological saline, vegetable oil, emulsifier, suspending agent, surfactant, stabilizer, flavoring agent, excipient, vehicle, preservative, binder, etc., additives commonly used in the field of pharmaceutical preparations, to the compound represented by formula (1) of the present invention or a salt thereof or a solvate thereof, it is formulated by mixing in the unit dosage form required by generally recognized pharmaceutical practice. Alternatively, a solid preparation for preparing a liquid preparation can be dissolved in an appropriate solvent, such as sterilized water or physiological saline, immediately before administration and then administered. Such a liquid preparation can also be parenterally used, for example, in the form of an injection of a sterile solution of water or a pharmaceutically acceptable liquid other than water, or a suspension. For example, it can be appropriately combined with a pharmacologically acceptable carrier or medium, specifically, with sterilized water or physiological saline, vegetable oil, emulsifier, suspending agent, surfactant, stabilizer, flavoring agent, excipient, vehicle, preservative, binder, etc., and formulated by mixing in the unit dosage form required by generally recognized pharmaceutical practices. Specifically, examples of the carrier include light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, calcium carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl acetal diethylaminoacetate, polyvinylpyrrolidone, gelatin, medium-chain triglyceride, polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethyl cellulose, corn starch, inorganic salts, etc. The effective ingredient amount of these preparations can be set to an appropriate volume within the range that can obtain the indication. The sterile composition for injection can be formulated according to the usual pharmaceutical practices using a vehicle such as distilled water for injection. Examples of the aqueous injection solution include isotonic solutions containing physiological saline or other adjuvants, such as D-sorbitol, D-mannose, D-mannitol, sodium chloride, and can also be used in combination with appropriate solubilizing adjuvants, such as alcohols, specifically, ethanol, polyols such as propylene glycol, polyethylene glycol, and nonionic surfactants, such as Polysorbate80 (registered trademark), HCO-50. Examples of the oily liquid include sesame oil, soybean oil, and can also be used in combination with benzyl benzoate and benzyl alcohol as solubilizing adjuvants. Further, a buffer, such as phosphate buffer, sodium acetate buffer, a pain reliever, such as procaine hydrochloride, a stabilizer, such as benzyl alcohol, phenol, and an antioxidant can also be incorporated. The prepared injection is usually filled in an appropriate ampoule. For example, in the manufacture of solid preparations, after appropriately combining the compound represented by formula (1) of the present invention or its salt or its solvate with an excipient, and further adding pharmaceutically acceptable additives commonly used in the pharmaceutical field, such as a binder, disintegrant, lubricant, coloring agent, flavoring agent, etc., as needed, it is made into tablets, powders, fine granules, granules, coated tablets, capsules, dry syrups, buccal tablets, suppositories, etc. by the usual methods. Examples of pharmaceutically acceptable additives used in such solid preparations include animal and vegetable oils such as soybean oil, beef tallow, and synthetic glycerides; hydrocarbons such as liquid paraffin, squalane, and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; higher alcohols such as cetostearyl alcohol and behenyl alcohol; silicone resin; silicone oil; surfactants such as polyoxyethylene fatty acid esters, sorbitan fatty acid esters, glycerol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, and polyoxyethylene-polyoxypropylene block copolymers; water-soluble polymers such as hydroxyethyl cellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene glycol, polyvinylpyrrolidone, and methyl cellulose; lower alcohols such as ethanol and isopropyl alcohol; polyhydric alcohols such as glycerin, propylene glycol, dipropylene glycol, and sorbitol; sugars such as lactose, lactose hydrate, fructose, and sucrose; inorganic powders such as anhydrous silicic acid, magnesium aluminum silicate, and aluminum silicate; and pure water, etc. Examples of excipients include saccharides (such as lactose, lactose hydrate, fructose, sucrose, etc.), sugar alcohols (such as mannitol, etc.), starches (corn starch, potato starch, wheat starch, rice starch, partially pregelatinized (alpha) starch, pregelatinized starch, etc.), cellulose (such as crystalline cellulose), inorganic salts (such as calcium silicate, anhydrous calcium hydrogen phosphate, precipitated calcium carbonate, etc.), etc. Examples of binders include polyvinyl alcohol, polyvinyl ether, methyl cellulose, ethyl cellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polypropylene glycol - polyoxyethylene - block polymer, etc. Examples of disintegrants include croscarmellose sodium, sodium carboxymethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, calcium carboxymethyl cellulose, methyl cellulose, crystalline cellulose, sodium lauryl sulfate, povidone, or polysorbitol, etc. Examples of lubricants include magnesium stearate, calcium stearate, talc, sucrose fatty acid ester, sodium stearyl fumarate, hydrogenated oil, etc. As coloring agents that are allowable to be added to pharmaceuticals, as flavoring and odor-masking agents, cocoa powder, menthol, aromatic powder, peppermint oil, borneol, cinnamon bark powder, etc. can be used. Such tablets and granules can also be appropriately coated with sugar coating or other appropriate substances. Furthermore, when preparing liquid preparations such as syrups and injectable preparations, pH adjusters, solubilizers, isotonic agents, etc. can be added to the compounds of the present invention or their pharmacologically acceptable salts, and solubilizing agents, stabilizers, etc. can be added as needed, and the preparations can be formulated according to the usual methods. <Cancer treatment or prevention of cancer patients with positive detection of RB1 gene mutation, or decreased expression of RB1 gene or protein, and cancer patients with positive occurrence of RB1 gene mutation, or decreased expression of RB1 gene or protein> The MYT1 inhibitor is for the purpose of cancer treatment or prevention of cancer patients with positive detection of RB1 gene mutation, decreased expression of RB1 gene or protein, or cancer patients with positive occurrence of RB1 gene mutation, or decreased expression of RB1 gene or protein, and can be used alone or in combination with chemotherapeutic agents. "Combined use" means using two or more components in combination. For example, the combined use of a MYT1 inhibitor (hereinafter, also referred to as "the first component") and a chemotherapeutic agent (hereinafter, also referred to as "the second component") includes "the aspect of preparing a single preparation containing the first component and the second component for administration" (that is, the aspect of using the first component and the second component as a combined preparation), and "the aspect of preparing the first component and the second component into individual preparations for simultaneous or separate administration". In the latter aspect, the preparation containing the first component can be administered first, or the preparation containing the second component can be administered first. The latter aspect can be made into "the aspect of formulating the first component and the second component into individual preparations and administering them simultaneously through the same administration route", "the aspect of formulating the first component and the second component into individual preparations and administering them separately with a time difference through the same administration route", "the aspect of formulating the first component and the second component into individual preparations and administering them simultaneously through different administration routes (administering to different parts of the same patient)", and "the aspect of formulating the first component and the second component into individual preparations and administering them separately with a time difference through different administration routes". In the case of "the aspect of formulating the first component and the second component into individual preparations and administering them simultaneously through the same route", the two preparations can be mixed before administration. "Separate" means that one preparation is administered before or after the administration of the other preparation. In other words, "combined use" also refers to a method of use in which one component is present in the patient's body and then the other component is made to be present in the patient's body. That is, it is preferably administered in such a way that the first component and the second component are present in the patient's body, such as in the blood, at the same time, and it is preferably administered to the patient in such a way that a certain preparation is administered simultaneously, or another preparation is administered within 48 hours after the administration of a certain preparation. "Cancer treatment" in the present invention refers to reducing the number of cancer cells in an individual, inhibiting the proliferation of cancer cells, reducing tumor volume, reducing tumor weight, inhibiting the metastasis of cancer cells, or improving various symptoms caused by cancer, and combinations thereof. In addition, "cancer prevention" in the present invention refers to preventing the occurrence of new cancer cells, preventing an increase in the number of cancer cells caused by the re-proliferation of reduced cancer cells, preventing the re-proliferation of cancer cells with inhibited proliferation, preventing the re-increase in the volume or weight of a reduced tumor, and combinations thereof. 〔First Embodiment Regarding Cancer Treatment or Prevention〕 One embodiment of the present invention is a pharmaceutical composition that is combined with a chemotherapeutic agent and contains a MYT1 inhibitor as an active ingredient, which is used for treating or preventing cancer in patients who test positive for an RB1 gene mutation or have a low expression of the RB1 gene or protein. One embodiment of the present invention is a pharmaceutical composition that is combined with a chemotherapeutic agent and contains a MYT1 inhibitor as an active ingredient, which is used for treating or preventing cancer in cancer patients who test positive for an RB1 gene mutation or have a low expression of the RB1 gene or protein. RB1 (retinoblastoma gene, also known as Rb or RB) is a gene that encodes the representative cell cycle control factor RB1 protein, which is related to the G1 / S checkpoint. The RB1 protein (also known as RB1 or pRb) forms a complex with the transcription factor E2F to inhibit the function of E2F, which is responsible for inducing the expression of genes involved in the transition of the cell cycle from the G1 phase to the S phase. When the function of E2F is inhibited, the transition from the G1 phase to the S phase is blocked. In the cell cycle, generally, cell proliferation stimulates the synthesis of cyclin D (Cyclin D), which binds to CDK4 to form a complex. The complex is phosphorylated (activated) by CAK, phosphorylating the RB protein. When the RB protein is phosphorylated, the transcription factor E2F bound to the RB protein is released, inducing the expression of a gene group required for S-phase progression or DNA replication. Among the induced genes is cyclin E, which forms a complex with CDK2 and further phosphorylates RB1, further inactivating the RB1 protein. When the RB1 gene has a mutation (especially a mutation that impairs the function of the RB1 protein) or the expression level of the RB1 gene or protein is low, the cell cycle proceeds. In this specification, "positive for RB1 gene mutation" means that when analyzing the base sequence corresponding to the RB1 gene of the subject, any mutation is found in the base sequence relative to the base sequence of the wild-type RB1 gene (for example, a mutation with at least one amino acid residue insertion, substitution, deletion, and / or addition relative to the wild-type RB1 protein), or when the mutation in the base sequence of the RB1 gene is reflected in the base change in the transcription product or the amino acid change in the translation product, such a change is detected in the transcription product or the translation product. In a specific embodiment, positive for RB1 gene mutation is a mutation detected in a biological sample (for example, cancer cells) derived from a cancer patient. In this specification, "detecting a mutation" generally refers to detecting a mutation in genomic DNA, but also includes the case where the mutation in the genomic DNA is reflected in the base change in the transcription product or the amino acid change in the translation product, and such a change is detected in the transcription product or the translation product (that is, indirectly detected). A preferred aspect of the method of this specification is a method of detecting a mutation by directly determining the base sequence of the RB1 gene region of cancer cells. The method for detecting positive for RB1 gene mutation is not particularly limited. For example, it can be confirmed and determined by NGS (next-generation sequencing). In the present invention, the "RB1 gene region" refers to a certain region on the genomic DNA containing the RB1 gene. In this region, each gene expression control region (for example, promoter region, enhancer region) other than the respective independent translation regions is also included as a non-translation region or the 3' untranslated region of each gene, etc. In this method, first, a DNA sample is prepared from a biological sample. Examples of the DNA sample include a genomic DNA sample and a cDNA sample prepared by reverse transcription of RNA. The method for extracting genomic DNA or RNA from a biological sample is not particularly limited, and a known method can be appropriately selected and used. For example, as a method for extracting genomic DNA, the SDS-phenol method can be mentioned (a method in which tissues stored in a solution containing urea or ethanol are treated with proteinase K, surfactant (SDS), and phenol to denature the proteins in the tissues, and DNA is precipitated from the tissues with ethanol for extraction), Clean Columns (registered trademark, manufactured by NexTec), AquaPure (registered trademark, manufactured by Bio-Rad), ZR Plant / Seed DNA Kit (manufactured by Zymo Research), AquaGenomicSolution (registered trademark, manufactured by Mo Bi Tec), prepGEM (registered trademark, manufactured by ZyGEM), BuccalQuick (registered trademark, manufactured by TrimGen) DNA extraction methods. Furthermore, the method for preparing RNA extracted from a biological sample and the method for preparing cDNA from the extracted RNA are not particularly limited, and known methods can be appropriately selected and used. For example, an extraction method using phenol and a chaotropic salt (more specifically, an extraction method using a commercially available kit such as TRIzol (manufactured by Invitrogen) or ISOGEN (manufactured by Wako Pure Chemical Industries, Ltd.)), or a method using other commercially available kits (RNAPrep Total RNA extraction kit (manufactured by Beckman Coulter), RNeasy Mini (manufactured by QIAGEN), RNA Extraction Kit (manufactured by Pharmacia Biotech), etc.) can be cited. In addition, the reverse transcriptase used for preparing cDNA from the extracted RNA is not particularly limited, and examples include reverse transcriptases derived from retroviruses such as RAV (Rous associated virus) or AMV (Avian myeloblastosis virus), or reverse transcriptases derived from murine retroviruses such as MMLV (Moloney murine leukemia virus). In this aspect, next, the DNA containing the RB1 gene region is isolated, and the base sequence of the isolated DNA is determined. The isolation of this DNA can be carried out, for example, by using a pair of oligonucleotide primers designed to sandwich all or a part of the RB1 gene region, and performing PCR using genomic DNA or RNA as a template. The determination of the base sequence of the isolated DNA can be carried out by methods well-known to those of ordinary skill in the art such as the Maxam-Gilbert method or the Sanger method, or next-generation sequencing capable of rapidly and comprehensively reading and analyzing the base sequence of a gene can also be used. By comparing the determined base sequence of the DNA or cDNA with a control (for example, in the case where the biological sample is a sample from a cancer patient, the base sequence of DNA or cDNA from a non-cancerous tissue from the same patient or a publicly known database), it can be determined whether there is a mutation in the RB1 gene region in the cancer cells of the biological sample. The method for detecting a mutation in the RB1 gene region can be carried out by various methods capable of detecting a mutation, in addition to the method of directly determining the base sequence of DNA or cDNA. For example, the mutation detection in the present invention can also be carried out by the following method. First, prepare a DNA or cDNA sample from a biological sample. Next, prepare an oligonucleotide probe with a base sequence complementary to the mutated portion of the base sequence containing the RB1 gene region and labeled with a reporter fluorescent dye and a quenching fluorescent dye. Then, hybridize the aforementioned DNA or cDNA sample with the aforementioned oligonucleotide probe, and further use the aforementioned DNA or cDNA hybridized with the aforementioned oligonucleotide probe as a template to amplify the base sequence of the aforementioned mutated site containing the RB1 gene region. And, by decomposing the oligonucleotide probe along with the aforementioned amplification, the fluorescence emitted by the aforementioned reporter fluorescent dye is detected, and then the detected fluorescence is compared with a control. As such a method, the dual-dye probe method, namely the so-called TaqMan (registered trademark) probe method, can be cited. In another method, prepare a DNA or cDNA sample from a biological sample. Next, in a reaction system containing intercalators that emit fluorescence when inserted between the DNA strands, use the aforementioned DNA or cDNA sample as a template to amplify the base sequence of the mutated site containing the RB1 gene region. And, change the temperature of the aforementioned reaction system to detect the change in the fluorescence intensity emitted by the aforementioned intercalators, and compare the detected change in the fluorescence intensity accompanying the aforementioned temperature change with a control. As such a method, the HRM (high resolution melting) method can be cited. In another method, first prepare a DNA or cDNA sample from a biological sample. Next, amplify the DNA containing all or a part of the RB1 gene region. And, cut the amplified DNA with a restriction enzyme. Next, separate the DNA fragments according to their sizes. Then, compare the sizes of the detected DNA fragments with a control. As such a method, for example, the method using restriction fragment length polymorphism (RFLP) or the PCR-RFLP method, etc., can be cited. In another method, first prepare a DNA or cDNA sample from a biological sample. Next, amplify the DNA containing all or a part of the RB1 gene region. And, dissociate the amplified DNA into single-stranded DNA. Next, separate the dissociated single-stranded DNA on a non-denaturing gel. Compare the migration degree of the separated single-stranded DNA on the gel with a control. As such a method, for example, the PCR-SSCP (single-strand conformation polymorphism) method can be cited. In another method, first, a DNA or cDNA sample is prepared from a biological sample. Next, DNA containing all or a part of the RB1 gene region is amplified. Then, the amplified DNA is separated on a gel with a gradually increasing concentration of a DNA denaturant. Next, the degree of migration of the separated DNA on the gel is compared with a control. As such a method, for example, the denaturant gradient gel electrophoresis (DGGE) method can be cited. As another method, there is a method using DNA containing a mutation site in the RB1 gene region prepared from a biological sample and a substrate on which an oligonucleotide probe hybridizing with the DNA is immobilized. As such a method, for example, the DNA array method or the like can be cited. In another method, first, a DNA or cDNA sample is prepared from a biological sample. And, an oligonucleotide primer is prepared which "has a base on the 3'-side of one base of all or a part of the bases in the RB1 gene region and a base sequence complementary to the base sequence on the 3'-side". Next, using this primer with the DNA as a template, a ddNTP primer extension reaction is carried out. Next, the primer extension reaction product is added to a mass analyzer for mass measurement. Next, the genotype is determined from the result of the mass measurement. Next, the determined genotype is compared with a control. As such a method, for example, the MALDI-TOF / MS method can be cited. In another method, first, a DNA or cDNA sample is prepared from a biological sample. Next, an oligonucleotide probe composed of 5'- "bases of all or a part of the RB1 gene region and a base sequence complementary to the base sequence on the 5'-side" - "a base on the 3'-side of one base of all or a part of the RB1 gene region and a base sequence that does not hybridize with the base sequence on the 3'-side" - 3' (FLAP) is prepared. And, an oligonucleotide probe "having bases of all or a part of the RB1 gene region and a base sequence complementary to the base sequence on the 3'-side" is prepared. Next, the prepared DNA or cDNA sample is hybridized with the above two kinds of oligonucleotide probes. Next, the hybridized DNA is cleaved with a single-stranded DNA cleavage enzyme to release the FLAP. The single-stranded DNA cleavage enzyme is not particularly limited, and for example, cleavase can be cited. In this method, next, an oligonucleotide probe having a complementary sequence to the FLAP and labeled with a reporter fluorescence and a quenching fluorescence is hybridized with the FLAP. Next, the emitted fluorescence intensity is measured. Next, the measured fluorescence intensity is compared with a control. As such a method, for example, the Invader method can be cited. In another method, first, a DNA or cDNA sample is prepared from a biological sample. Next, DNA containing all or a part of the RB1 gene region is amplified. Then, the amplified DNA is dissociated into single strands, and only one of the dissociated single-stranded DNAs is separated. Next, an extension reaction is performed one base at a time near the bases of all or a part of the RB1 gene region. At this time, the generated pyrophosphate is catalyzed to emit light, and the luminescence intensity is measured. Then, the measured fluorescence intensity is compared with a control. As such a method, for example, the Pyrosequencing method can be mentioned. In another method, first, a DNA or cDNA sample is prepared from a biological sample. Next, DNA containing all or a part of the RB1 gene region is amplified. Next, an oligonucleotide primer "having a base on the 3'-side of one base of the bases of all or a part of the RB1 gene region and a base sequence complementary to the base sequence of the 3'-side base" is prepared. Next, in the presence of a fluorescently labeled nucleotide, using the amplified DNA as a template, the prepared primer is used for a single-base extension reaction. Then, the polarization degree of fluorescence is measured. Next, the measured polarization degree of fluorescence is compared with a control. As such a method, for example, the AcycloPrime method can be mentioned. In another method, first, a DNA or cDNA sample is prepared from a biological sample. Next, DNA containing all or a part of the RB1 gene region is amplified. Next, an oligonucleotide primer "having a base on the 3'-side of one base of the bases of all or a part of the RB1 gene region and a base sequence complementary to the base sequence of the 3'-side base" is prepared. Next, in the presence of a fluorescently labeled nucleotide, using the amplified DNA as a template, the prepared primer is used for a single-base extension reaction. Next, the type of base used in the single-base extension reaction is determined. Then, the determined type of base is compared with a control. As such a method, for example, the SNuPE method can be mentioned. Furthermore, if the mutation is accompanied by an amino acid change in the RB1 protein, the sample prepared from the biological sample can also be a protein. In this case, for detecting the mutation, methods using a molecule (for example, an antibody) that specifically binds to the site where the amino acid change occurs due to the above mutation, peptide mass fingerprinting (PMF), a protein sequencer (Edman degradation method), etc. can be used. In this specification, "decreased expression of the RB1 gene or protein" means that when analyzing the RB1 gene or protein in the subject of analysis, the expression level of the RB1 gene or protein is lower than that in a control (for example, the expression level in a healthy subject or non-cancerous tissue of the same patient). In a specific embodiment, a decreased expression level of the RB1 gene or protein is detected in a biological sample (for example, cancer cells) derived from a cancer patient. The method for detecting the decreased expression of the RB1 gene is not particularly limited, and examples thereof include a method of detecting the expression level of RB1 at the transcriptional level or translational level and comparing it with the aforementioned control. In the method for detecting the expression level of the RB1 gene at the transcriptional level, first, RNA or cDNA is prepared from a biological sample. The method for extracting RNA from a biological sample and the method for preparing cDNA from the extracted RNA are not particularly limited, and known methods can be appropriately selected and used. Examples thereof include an extraction method using phenol and chaotropic salts (more specifically, an extraction method using commercially available kits such as TRIzol (manufactured by Invitrogen), ISOGEN (manufactured by Wako Pure Chemical Industries, Ltd.), etc.), and methods using other commercially available kits (RNAPrep Total RNA extraction kit (manufactured by Beckman Coulter), RNeasy Mini (manufactured by QIAGEN), RNA Extraction Kit (manufactured by Pharmacia Biotech), etc.). In addition, the reverse transcriptase used for preparing cDNA from the extracted RNA is not particularly limited, and examples thereof include reverse transcriptases derived from retroviruses such as RAV (Rous associated virus) or AMV (Avian myeloblastosis virus), or reverse transcriptases derived from murine retroviruses such as MMLV (Moloney murine leukemia virus). Next, oligonucleotide primers or oligonucleotide probes are used for amplification reactions or hybridization reactions, respectively, and their amplification products or hybridization products are detected. As such methods, for example, RT-PCR method, Northern blotting method, dot blotting method, DNA array method, in situ hybridization method, ribonuclease protection assays method, mRNA-seq, etc. can be used. Those of ordinary skill in the art can set oligonucleotide primers or oligonucleotide probes suitable for each method according to the general method based on the nucleotide sequence of the cDNA of RB1. It is known in the art that hypermethylation of promoters is one of the main causes of decreased gene expression. Therefore, in the detection of whether RB1 has functional inhibition, one can consider detecting the methylation of the gene promoter of RB1 as an indicator. For the detection of promoter methylation, known methods can be used, such as a method of directly detecting the change in the nucleotide sequence after bisulfite treatment having the activity of converting methylated cytosine into uracil by nucleotide sequencing, or an indirect detection method using a restriction endonuclease that can recognize the nucleotide sequence (cleavable) before bisulfite treatment but cannot recognize the nucleotide sequence (non-cleavable) after bisulfite treatment, etc. The method for detecting the reduced expression of the RB1 protein is not particularly limited, and can be confirmed and determined, for example, by IHC (immunohistochemical staining) using an antibody specific to the RB1 protein. In the method for detecting a protein using an antibody, first, a protein sample is prepared from a biological sample. Next, an antibody specific to the RB1 protein is used and the antigen-antibody reaction is utilized to detect the RB1 protein. When the antibody specific to the RB1 protein is labeled, the RB1 protein can be directly detected. When it is not labeled, it can be further reacted with a labeled molecule (for example, a secondary antibody or protein A) that recognizes the antibody, and the RB1 protein can be indirectly detected using the label of the molecule. As such a method, for example, immunohistochemistry (immunostaining) method, Western blotting method, ELISA method, flow cytometry, image cytometry, radioimmunoassay, immunoprecipitation method, analysis method using an antibody array, etc. can be used. In this method, immunohistochemistry also has the advantage of simultaneously obtaining additional information such as the morphology or distribution state of cancer cells in the tissue. The type or source of the antibody used is not particularly limited, and a monoclonal antibody is preferably used. As long as it can sufficiently specifically detect the RB1 protein, a polyclonal antibody (a mixture of several to dozens of antibodies) or a polyclonal antibody can also be used. Also, Fab, Fab’, F(ab’) 2 , Fv, scFv, sc(Fv) 2 , dsFv, and antibody functional fragments or their polymers (for example, dimers, trimers, tetramers, polymers) of diabody can be used. As the anti-RB1 protein antibody, it can be a commercially available product. The detection of the RB1 protein can also be carried out using a mass spectrometry (MS). In particular, the analysis by a mass spectrometer (LC / MS) linked to liquid chromatography is sensitive and advantageous. The detection by mass spectrometry can be carried out, for example, by labeling the protein in the aforementioned protein sample, fractionating the labeled protein, subjecting the fractionated protein to mass spectrometry, and confirming the RB1 protein from the mass spectrometry value. As the label, a known isotope labeling reagent in the technical field can be used, and an appropriate labeling reagent can be obtained as a commercially available product. Also, fractionation can be carried out using a known method in the technical field, for example, a commercially available ion exchange column, etc. can be used. In this specification, the amplification of the copy number of the CCNE1 gene can be determined at the time of diagnosis or prognostic analysis by evaluating the copy number of the CCNE1 gene (for example, next-generation sequencing, digital PCR, array CGH method or FISH method) using a biological sample from a cancer patient. In this specification, the "patient" can be a mouse, a rat, a guinea pig, a monkey, a dog, a sheep, a horse, or a human. The "cancer patient" in the present invention not only refers to a patient suffering from cancer, but can also be a patient suspected of suffering from cancer. In a specific embodiment, the subject of treatment or prevention is a cancer patient in whom an increase in the CCNE1 gene is not detected as compared with a control. Further, in a specific embodiment, the subject of treatment or prevention is not a mouse transplanted with OVCAR3. The pharmaceutical composition is preferably used for humans. In this specification, the "biological sample derived from a cancer patient" is a biological sample in which the presence or absence of an RB1 gene mutation or the presence or absence of a decrease in the expression of the RB1 gene or protein can be detected, and is not particularly limited, and is preferably a cancer biopsy specimen, blood, urine, body cavity fluid, a specimen such as circulating tumor DNA (ctDNA) derived from tumor cell circulation, etc. Further, it can be a protein extract or a nucleic acid extract (mRNA extract, cDNA preparation or cRNA preparation prepared from the mRNA extract, etc.) obtained from the aforementioned specimen. In this specification, the "biological sample" can include a sample derived from a cancer patient and a sample derived from a cancer cell culture. The RB1 gene mutation can include a mutation in which at least one amino acid residue is inserted, deleted, added, or an existing amino acid residue is substituted, as compared with the wild-type RB1 protein. Further, the RB1 gene mutation can be a nonsense mutation, a frameshift mutation, a splice site mutation, a heterozygous deletion, or a homozygous deletion. The RB1 gene mutation is preferably a mutation that reduces RB1 function. The "mutation that reduces RB1 function" can be confirmed, for example, by the URL: https: / / www.oncokb.org / gene / RB1 [searched on February 20, 2023]. The nucleotide sequence of the typical DNA (cDNA) of the human wild-type RB1 gene is shown in SEQ ID NO: 1 (NCBI reference number: NM_000321.3), and the typical amino acid sequence of the human wild-type RB1 protein is shown in SEQ ID NO: 2 (NCBI reference number: NP_000312.2). In the case of the human RB1 gene, RB1 gene mutations may include mutations having a nucleotide sequence different from the genomic sequence of human RB1 set forth in NCBI reference number NC_13.11 from position 48,303,751 to position 48,481,890, a nucleotide sequence different from the nucleotide sequence of human RB1 set forth in NCBI reference number NG_9009.1 from position 4921 to position 5161, or an amino acid sequence different from the amino acid sequence of the human RB1 protein set forth in SEQ ID NO: 2, and may be mutations having at least one of the following (1) to (5). Furthermore, even in the case of non-mutated RB1, individual differences may occur in the sequence due to polymorphisms or the like. (1) The codon corresponding to the serine residue (S) at position 82 of the amino acid sequence of SEQ ID NO: 2 is substituted with a stop codon. (2) The codon corresponding to the arginine residue (R) at position 467 of the amino acid sequence of SEQ ID NO: 2 is substituted with a stop codon. (3) In the codon corresponding to the amino acid residue at position 182 of the amino acid sequence of SEQ ID NO: 2, at least one base is inserted or deleted, and a new reading frame is formed starting from the isoleucine residue (I), and the third reading frame therefrom is a stop codon. (4) The glutamic acid residue (E) at position 837 of the amino acid sequence of SEQ ID NO: 2 is substituted with a lysine residue (K), and a part of the RB1 gene is homozygous deletion. (5) The glycine residue (G) at position 449 of the amino acid sequence of SEQ ID NO: 2 is substituted with a glutamic acid residue (E), and a part of the RB1 gene is homozygous deletion. In the present specification, the reduced expression of the RB1 gene or protein includes the reduced gene expression caused by methylation of the RB1 gene or microRNA (MicroRNA). The pharmaceutical composition of the present invention can be used for treating or preventing cancer, and is particularly suitable for treating or preventing cancer in cancer patients who are positive for the detection of RB1 gene mutations, have reduced expression of the RB1 gene or protein, or have positive RB1 gene mutations or reduced expression of the RB1 gene or protein. The pharmaceutical composition of the present invention can be used alone or in combination with a chemotherapeutic agent. In a specific embodiment, the cancer is lung cancer. The pharmaceutical composition of the present invention is more suitable for the treatment or prevention of cancer, particularly for the treatment or prevention of lung cancer. In one aspect, the compound represented by the formula (1) to (3) of the present invention or a salt thereof or a solvate thereof can be used as a MYT1 inhibitor. The pharmaceutical composition (hereinafter, also referred to as "the pharmaceutical composition of the present invention") containing a compound represented by the formula (1) to (3), its salt, or a solvate thereof (the first component) as an active ingredient can be used in combination with a chemotherapeutic agent (the second component). In one embodiment, the pharmaceutical composition of the present invention can be administered simultaneously or separately with the chemotherapeutic agent. In another embodiment, the pharmaceutical composition of the present invention can be administered as a combination preparation with the chemotherapeutic agent. The chemotherapeutic agent is a substance having anti-cancer activity (also referred to as anti-tumor activity). The chemotherapeutic agent can be, for example, an antimetabolite. An antimetabolite is a substance having a chemical structure similar to a metabolite (e.g., folic acid) and antagonizing or inhibiting the metabolic mechanism of an organism. As an antimetabolite, for example, a folic acid antimetabolite can be mentioned. A folic acid antimetabolite is a substance that inhibits or blocks the function of an enzyme that reduces folic acid to the activated folic acid necessary for nucleic acid synthesis, thereby hindering DNA biosynthesis. As a folic acid antimetabolite, for example, methotrexate, pemetrexed can be mentioned. A preferred folic acid antimetabolite is pemetrexed. In this embodiment, a preferred combination of the MYT1 inhibitor and the chemotherapeutic agent, the MYT1 inhibitor is the compound represented by the formula (1) to (3) of the present invention, its salt, or a solvate thereof, and the chemotherapeutic agent is pemetrexed. The dosage of the compound represented by the formula (1) to (3) of the present invention, its salt, or a solvate thereof is preferably 0.001 to 50 mg (0.001 to 50 mg / kg / day) per 1 kg of the body weight of the administration subject per day, more preferably 0.001 to 20 mg / kg / day, and even more preferably 0.002 to 10 mg / kg / day. When the dosage of the compound represented by the formula (1) to (3) of the present invention, its salt, or a solvate thereof is within these ranges, the therapeutic or preventive effect on cancer is further improved. The number of administrations of the compound represented by the formula (1) to (3) of the present invention, its salt, or a solvate thereof can be, for example, more than once a week, can be twice a week, can be once a day, or can be twice a day. The dosage of the chemotherapeutic agent is preferably 0.005 to 300 mg (0.005 to 300 mg / kg / day) per 1 kg of the body weight of the administration subject per day, more preferably 0.01 to 250 mg / kg / day, and even more preferably 0.02 to 200 mg / kg / day. When the dosage of the chemotherapeutic agent is within these ranges, the therapeutic or preventive effect on cancer is further improved. The number of administrations of the chemotherapeutic agent can be, for example, more than once a week, can be twice a week, can be once a day, or can be twice a day. The dosage of the compound represented by the formula (1) to (3), its salt or its solvate (the first component) and the chemotherapeutic agent (the second component) of the present invention is preferably 0.0001 to 50 mg / kg / day for the first component and 0.005 to 300 mg / kg / day for the second component per 1 kg of the body weight of the administration subject, more preferably 0.001 to 20 mg / kg / day for the first component and 0.01 to 250 mg / kg / day for the second component, and still more preferably 0.002 to 10 mg / kg / day for the first component and 0.02 to 200 mg / kg / day for the second component. When the dosages of the first component and the second component are within these ranges, the therapeutic or prophylactic effect on cancer is further enhanced. In the present invention, examples of the administration method include oral, rectal, parenteral (intravenous, intramuscular, subcutaneous, percutaneous absorption), intracisternal, intravaginal, intraperitoneal, intravesical, or local (injection, drip, powder, ointment, gel or cream) administration and inhalation (intraoral or nasal spray), etc. Examples of such administration forms include, for example, tablets, capsules, granules, powders, fine granules, pills, aqueous or non-aqueous oral solutions and suspensions, and parenteral solutions filled into containers suitable for subdividing into respective dosages. Further, the administration form may also be suitable for various administration methods including formulations with controlled release such as subcutaneous implants. The first component can be administered, for example, by any of the above-described administration methods, and the second component can be administered, for example, by an administration method that is the same as or different from the administration method of the first component. The administration interval between the first component and the second component can be set, for example, to an interval of 0 days to 14 days, an interval of 0 days to 10 days, or an interval of 0 days to 7 days. The administration interval can be determined, for example, using AUC, Cmax, Tmax, elimination half-life, or the health status of the subject as an indicator. For example, the first component can be administered orally (tablets, capsules, etc.) and the second component can be administered by intravenous drip. For example, both the first component and the second component can also be administered orally (tablets, capsules, etc.). For example, the first component can also be administered by intravenous drip and the second component can be administered orally (tablets, capsules, etc.). For example, both the first component and the second component can also be administered by intravenous drip. In this case, the first component and the second component can be administered at any interval, such as 3 times a day, 2 times a day, 1 time a day, once a week, once every two weeks, etc. More specifically, both the first component and the second component can be administered once a day. In this case, it can be administered before a meal, during a meal, or after a meal. Before a meal, with a meal, or after a meal can be before, during, or after any one of breakfast, lunch, dinner, midnight snack, or snacks. As long as the administration interval between the first component and the second component is within 24 hours, it becomes possible to administer both once a day. As needed, the first component and the second component may sometimes be administered 2 times a day and 1 time a day, 1 time a day and 1 time a day, 1 time a day and 2 times a day, 1 time a day and 1 time every two days, 1 time a day and 1 time every three days, 1 time a day and 1 time every seven days, as well as 3 times a day and 1 time every seven days, and 2 times a day and 1 time every seven days. As needed, it is also possible to only increase or decrease the administration interval of the second component, and / or it is also possible to only increase the administration interval of the first component. The second component can be administered starting from the start date of administration of the first component, or the start date of administration of the first component and the start date of administration of the second component can also be separated. The administration period is set to 7 days as one course, and the total number of courses can be set to 1 course or more, or can also be set to 2 courses or more. Also, each course can be carried out continuously, or a drug withdrawal period can be set. It is also possible to set a drug withdrawal period in the middle of a course. As needed, during a course, it is also possible to continuously administer only the first component and discontinue the second component, or it is also possible to discontinue the first component and continuously administer the second component. It is also possible to include the first component and the second component in the same tablet, capsule, etc. The pharmaceutical composition of this embodiment can be administered in combination (co-administered) with, for example, the pharmaceutical composition containing a MYT1 inhibitor described in the following "Second Embodiment Regarding Cancer Treatment or Prevention". In one aspect of the present embodiment, it is a MYT1 inhibitor for use in combination with a chemotherapeutic agent in the treatment or prevention of cancer in patients detected as positive for RB1 gene mutation or having reduced expression of RB1 gene or protein. In one aspect of the present embodiment, it is a MYT1 inhibitor for use in combination with a chemotherapeutic agent in the treatment or prevention of cancer in cancer patients with positive RB1 gene mutation or reduced expression of RB1 gene or protein. In another aspect of the present embodiment, it is the use of a MYT1 inhibitor for the manufacture of a medicament for the treatment or prevention of cancer in patients detected as positive for RB1 gene mutation or having reduced expression of RB1 gene or protein, which is administered in combination with a chemotherapeutic agent. In another aspect of the present embodiment, it is the use of a MYT1 inhibitor for the manufacture of a medicament for the treatment or prevention of cancer in cancer patients with positive RB1 gene mutation or reduced expression of RB1 gene or protein, which is administered in combination with a chemotherapeutic agent. 〔Second Embodiment Regarding Cancer Treatment or Prevention〕 The second embodiment of the present invention regarding cancer treatment or prevention is a pharmaceutical composition in combination with a MYT1 inhibitor and containing a chemotherapeutic agent for treating or preventing cancer in patients detected as positive for RB1 gene mutation or having reduced expression of RB1 gene or protein as an active ingredient. Each term in this specification (for example, MYT1 inhibitor, chemotherapeutic agent, RB1 gene mutation, administration method, cancer type, etc.) can refer to the definitions in the "First Embodiment Regarding Cancer Treatment or Prevention". In this specification, cancer in patients detected as positive for RB1 gene mutation or having reduced expression of RB1 gene or protein can be cancer in patients with positive RB1 gene mutation or reduced expression of RB1 gene or protein. The pharmaceutical composition of this embodiment can be administered in combination (co-administered) with, for example, the pharmaceutical composition containing a MYT1 inhibitor described in the "First Embodiment Regarding Cancer Treatment or Prevention". In a specific embodiment, the pharmaceutical composition contains a chemotherapeutic agent (second component) as an active ingredient. The pharmaceutical composition containing a chemotherapeutic agent as an active ingredient can be used in combination with a MYT1 inhibitor (first component). In one embodiment, the pharmaceutical composition containing a chemotherapeutic agent can be administered simultaneously or separately from the MYT1 inhibitor. In another embodiment, the pharmaceutical composition containing a chemotherapeutic agent can be administered as a combination preparation with the MYT1 inhibitor. In this embodiment, for a preferred combination of a MYT1 inhibitor and a chemotherapeutic agent, the MYT1 inhibitor is a compound represented by formula (1) to (3) of the present invention or a salt thereof or a solvate thereof, and the chemotherapeutic agent is pemetrexed. The dosages of the MYT1 inhibitor (the first component) and the chemotherapeutic agent (the second component) are preferably 0.0001 to 50 mg / kg / day for the first component and 0.005 to 300 mg / kg / day for the second component per 1 kg of the weight of the subject to be administered, more preferably 0.001 to 20 mg / kg / day for the first component and 0.01 to 250 mg / kg / day for the second component, and even more preferably 0.002 to 10 mg / kg / day for the first component and 0.02 to 200 mg / kg / day for the second component. When the dosages of the first component and the second component are within these ranges, the therapeutic or prophylactic effect on cancer is further enhanced. In one aspect of this embodiment, it is a chemotherapeutic agent used in combination with an MYT1 inhibitor in the treatment or prevention of cancer in a patient who tests positive for an RB1 gene mutation or shows reduced expression of the RB1 gene or protein. In another aspect of this embodiment, it is the use of a chemotherapeutic agent for the manufacture of a medicament for the treatment or prevention of cancer in a patient who tests positive for an RB1 gene mutation or shows reduced expression of the RB1 gene or protein, and is administered in combination with an MYT1 inhibitor. 〔Third Embodiment Regarding Cancer Treatment or Prevention〕 The third embodiment of the present invention regarding cancer treatment or prevention is a method for treating or preventing cancer in a patient who tests positive for an RB1 gene mutation or shows reduced expression of the RB1 gene or protein, which includes administering a chemotherapeutic agent in combination with an MYT1 inhibitor to the cancer patient. In one aspect of this embodiment, it is a method for treating or preventing cancer, which includes: a step of detecting a positive RB1 gene mutation in a cancer patient, or reduced expression of the RB1 gene or protein in a cancer patient, or detecting the same in a third party, in a biological sample derived from the cancer patient, and a step of administering a chemotherapeutic agent in combination with an MYT1 inhibitor to the cancer patient. The dosages of the MYT1 inhibitor (the first component) and the chemotherapeutic agent (the second component) are preferably 0.0001 to 50 mg / kg / day for the first component and 0.005 to 300 mg / kg / day for the second component per 1 kg of the weight of the subject to be administered, more preferably 0.001 to 20 mg / kg / day for the first component and 0.01 to 250 mg / kg / day for the second component, and even more preferably 0.002 to 10 mg / kg / day for the first component and 0.02 to 200 mg / kg / day for the second component. When the dosages of the first component and the second component are within these ranges, the therapeutic or prophylactic effect on cancer is further enhanced. When the chemotherapeutic agent and the MYT1 inhibitor are administered in combination, the MYT1 inhibitor and the chemotherapeutic agent can be administered simultaneously, or a certain dosing interval can be set for separate administration. Also, the administration routes of the MYT1 inhibitor and the chemotherapeutic agent can be the same or different. Further, a combined dosage form containing the MYT1 inhibitor and the chemotherapeutic agent can also be prepared for administration. That is, the pharmaceutical composition can also contain both the MYT1 inhibitor and the chemotherapeutic agent. 〔Fourth Embodiment Regarding Cancer Treatment or Prevention〕 The fourth embodiment of the present invention regarding cancer treatment or prevention is a method for inhibiting cancer cell proliferation in a subject in which a positive RB1 gene mutation is detected, or the expression of the RB1 gene or protein is decreased, the method comprising the step of contacting the cancer cells with an MYT1 inhibitor and a chemotherapeutic agent. In one aspect of this embodiment, it is a method for inhibiting cancer cell proliferation, the method comprising the steps of detecting a positive RB1 gene mutation in a biological sample from a cancer patient, or a decrease in the expression of the RB1 gene or protein, or detecting a third party, and contacting the cancer cells with an MYT1 inhibitor and a chemotherapeutic agent. The method of this embodiment also includes any of the in vivo, in vitro, and ex vivo forms. For example, the subject in which a positive RB1 gene mutation is detected, or the expression of the RB1 gene or protein is decreased can be an animal in which a positive RB1 gene mutation is detected, or the expression of the RB1 gene or protein is decreased, and the animal species can be a mouse, rat, guinea pig, monkey, dog, sheep, horse, or human. In the case of in vivo, cancer cell proliferation can be inhibited by administering the MYT1 inhibitor and the chemotherapeutic agent to the above-mentioned subject. In the case of in vitro, cancer cell proliferation can be inhibited by adding the MYT1 inhibitor and the chemotherapeutic agent to a system containing cancer cells taken from the above-mentioned subject. In the case of ex vivo, cancer cell proliferation can be inhibited by taking out an organ containing cancer cells (for example, the lung in the case of lung cancer) from the above-mentioned subject and administering the MYT1 inhibitor and the chemotherapeutic agent to the organ. The dosage of the first component (MYT1 inhibitor) and the second component (chemotherapeutic agent) can be appropriately set according to the amount of cancer cells and the types of the MYT1 inhibitor and the chemotherapeutic agent used. [Fifth Embodiment Regarding Cancer Treatment or Prevention] The fifth embodiment of the present invention regarding cancer treatment or prevention is a method for enhancing the responsiveness of cancer treatment by chemotherapeutic agents. The cancer is the cancer of a patient who is positive for an RB1 gene mutation or has a low expression of the RB1 gene or protein. The method includes the step of administering a chemotherapeutic agent together with a MYT1 inhibitor to the cancer patient. In one aspect of this embodiment, it is a method for enhancing the responsiveness of cancer treatment by chemotherapeutic agents. The method includes the steps of detecting, in a biological sample derived from a cancer patient, that the cancer patient is positive for an RB1 gene mutation, or has a low expression of the RB1 gene or protein, or detecting the same in a third party, and administering a chemotherapeutic agent together with a MYT1 inhibitor to the cancer patient. In the method of this embodiment, when treating the cancer of a patient who is positive for an RB1 gene mutation or has a low expression of the RB1 gene or protein, it includes the step of combining with a MYT1 inhibitor and administering a chemotherapeutic agent to the patient. By combining with a MYT1 inhibitor and administering a chemotherapeutic agent, the effectiveness of cancer treatment by chemotherapeutic agents can be enhanced. In the step of administering a chemotherapeutic agent together with a MYT1 inhibitor to the cancer patient, both the MYT1 inhibitor and the chemotherapeutic agent can be administered simultaneously, or a certain dosing interval can be set for separate administration. Also, the administration routes of the MYT1 inhibitor and the chemotherapeutic agent can be the same or different. Further, it can also be administered in the form of a combined agent containing the MYT1 inhibitor and the chemotherapeutic agent. Even in patients with insufficient therapeutic effects of existing chemotherapeutic agents, sufficient therapeutic effectiveness can be obtained by combining with a MYT1 inhibitor. Regarding the dosage of the MYT1 inhibitor (first component) and the chemotherapeutic agent (second component), per 1 kg of the weight of the subject to be administered, it is preferably 0.0001 - 50 mg / kg / day for the first component and 0.005 - 300 mg / kg / day for the second component, more preferably 0.001 - 20 mg / kg / day for the first component and 0.01 - 250 mg / kg / day for the second component, and even more preferably 0.002 - 10 mg / kg / day for the first component and 0.02 - 200 mg / kg / day for the second component. When the dosages of the first component and the second component are within these ranges, the therapeutic or preventive effect of cancer is further enhanced. Sixth Embodiment Regarding Cancer Treatment or Prevention The sixth embodiment of the present invention regarding cancer treatment or prevention is a method for predicting the responsiveness of a combination of a MYT1 inhibitor and a chemotherapeutic agent to cancer treatment. The method includes: detecting the presence or absence of an RB1 gene mutation, or the presence or absence of reduced expression of the RB1 gene or protein, or detecting a third party in cancer cells derived from a cancer patient, and determining that the cancer patient is responsive to cancer treatment by the combination of the MYT1 inhibitor and the chemotherapeutic agent in the case where the RB1 gene mutation is positive, or in the case where the RB1 gene or protein expression is reduced. In the method of this embodiment, in cancer cells taken from a cancer patient as a treatment target, the presence or absence of an RB1 gene mutation, or the presence or absence of reduced expression of the RB1 gene or protein, or a third party is detected. In the case where the RB1 gene mutation is positive, or in the case where the RB1 gene or protein expression is reduced, the cancer patient is determined to be responsive (effective) to treatment with a combination of a MYT1 inhibitor and a chemotherapeutic agent. According to the method of this embodiment, even for a patient in whom the treatment effectiveness of an existing chemotherapeutic agent is insufficient, if the cancer patient has a positive RB1 gene mutation, or reduced expression of the RB1 gene or protein, it can be determined that treatment is effective by administering a combination of a MYT1 inhibitor and a chemotherapeutic agent. Thereby, for cancer patients who cannot obtain a sufficient treatment effect with only existing chemotherapeutic agents, an effective chemotherapy can be proposed in advance. Detection of an RB1 gene mutation in cancer cells, or reduced expression of the RB1 gene or protein, can be carried out by methods well-known to those of ordinary skill in the art, such as direct sequencing, PCR, TaqMan Genotyping, next-generation sequencing, etc. In one aspect of this embodiment, it can be a method for selecting cancer patients for whom a combination of a MYT1 inhibitor and a chemotherapeutic agent is more effective. This method includes: detecting the presence or absence of an RB1 gene mutation, or the presence or absence of reduced expression of the RB1 gene or protein, or detecting a third party in cancer cells derived from a cancer patient, and determining that the cancer patient is a cancer patient for whom a combination of a MYT1 inhibitor and a chemotherapeutic agent is more effective based on the presence of the mutation. On the other hand, in this embodiment, it is a method for diagnosing that, for a specific cancer patient, the combined administration of a MYT1 inhibitor and a chemotherapeutic agent is more effective in cancer treatment than the administration of the chemotherapeutic agent alone. This method includes: in cancer cells derived from a cancer patient, detecting the presence or absence of an RB1 gene mutation, or the presence or absence of reduced expression of the RB1 gene or protein, or detecting a third party, and based on the presence of the mutation, determining that the cancer patient is a cancer patient for whom the combined administration of a MYT1 inhibitor and a chemotherapeutic agent is more effective. 〔Seventh Embodiment Regarding Cancer Treatment or Prevention〕 The seventh embodiment of the present invention regarding cancer treatment or prevention is a method for screening a compound effective for cancer treatment or prevention of a patient detected to have a positive RB1 gene mutation or reduced expression of the RB1 gene or protein, and the method includes: a step of measuring the MYT1 inhibitory activity of a candidate compound, and a step of selecting a candidate compound having MYT1 inhibitory activity as a compound effective for cancer treatment. The method of this embodiment includes: a step of measuring the MYT1 inhibitory activity of a candidate compound, and a step of selecting it as a compound effective for cancer treatment when the candidate compound has MYT1 inhibitory activity. In the present invention, a MYT1 inhibitor refers to a substance that can directly or indirectly neutralize, block, inhibit, reduce, or impede MYT1 activity. As an example of the aforementioned MYT1 protein activity, threonine kinase activity or tyrosine kinase activity can be mentioned. Whether a compound inhibits the threonine kinase activity or tyrosine kinase activity of MYT1 can be confirmed, for example, by treating a purified MYT1 protein standard with a test compound, adding ATP, and using the degree of ATP hydrolysis as an index. The degree of ATP hydrolysis can be evaluated by using Kinase-Glo (manufactured by Promega) or ADP-Glo (manufactured by Promega) (Non-Patent Document 8). When the test compound inhibits the threonine kinase activity or tyrosine kinase activity of MYT1 compared to a control (for example, the degree of ATP hydrolysis of MYT1 not treated with the test compound), a decrease in this ATP hydrolysis can be confirmed. The compound inhibits the threonine kinase activity of the MYT1 protein. For example, it can be confirmed by treating a purified MYT1 protein standard with a test compound, adding CDK1, which is a substrate of MYT1, and using the degree of phosphorylation of the Thr14 site of CDK1 as an indicator. The degree of phosphorylation of this site can be evaluated by Western blotting using an antibody (manufactured by Abcam) that specifically recognizes the phosphorylation of the Thr14 site of CDK1, by ELISA using an antibody that specifically recognizes CDK1 and an antibody that specifically recognizes the phosphorylation of the Thr14 site of CDK1, or by AlphaLISA (manufactured by PerkinElmer) using an antibody that specifically recognizes CDK1 and an antibody that specifically recognizes the phosphorylation of the Thr14 site of CDK1. When the threonine kinase activity of MYT1 is inhibited by the aforementioned test compound as compared with a control (for example, the degree of phosphorylation of the Thr14 site of CDK1 of MYT1 not treated with the test compound), a decrease in this phosphorylation can be confirmed. Also, the compound inhibits the threonine kinase activity of the MYT1 protein. For example, it can be confirmed by using the lysate of cells treated with the test compound and using the degree of phosphorylation of the Thr14 site of CDK1, which is a substrate protein of the threonine kinase activity of MYT1, as an indicator. The degree of phosphorylation of this site can be evaluated by Western blotting using an antibody (manufactured by Abcam) that specifically recognizes the phosphorylation of the Thr14 site of CDK1, by ELISA using an antibody that specifically recognizes CDK1 and an antibody that specifically recognizes the phosphorylation of the Thr14 site of CDK1, or by AlphaLISA (Non-Patent Document 8) using an antibody that specifically recognizes CDK1 and an antibody that specifically recognizes the phosphorylation of the Thr14 site of CDK1. When the threonine kinase activity of MYT1 is inhibited by the aforementioned test compound as compared with a control (for example, the degree of phosphorylation of the Thr14 site of CDK1 in the cell lysate not treated with the test compound), a decrease in this phosphorylation can be confirmed. Also, for the compound to inhibit the expression of MYT1, for example, it can be confirmed by detecting a decrease in the expression of MYT1 in cells treated with the test compound. As a method for detecting a decrease in the expression of MYT1, for example, the expression level of MYT1 is usually detected at the transcriptional level or the translational level, and it is confirmed by a method in which the expression level is lower than that of a control (for example, the expression level of cells not treated with the test compound). In the method for detecting the expression level of MYT1 at the transcriptional level, first, RNA or cDNA is prepared from cells treated with the test compound. The method for extracting RNA from the aforementioned cells is not particularly limited, and a known method can be appropriately selected and used. Examples thereof include an extraction method using phenol and chaotropic salts (more specifically, an extraction method using commercially available kits such as TRIzol (manufactured by Invitrogen), ISOGEN (manufactured by Wako Pure Chemical Industries, Ltd.), etc.), or other commercially available kits (RNAPrep Total RNA extraction kit (manufactured by Beckman Coulter), RNeasy Mini (manufactured by QIAGEN), RNA Extraction Kit (manufactured by Pharmacia Biotech), etc.). In addition, the reverse transcriptase used for preparing cDNA from the extracted RNA is not particularly limited, and examples thereof include reverse transcriptases derived from retroviruses such as RAV (Rous associated virus) or AMV (Avian myeloblastosis virus), or reverse transcriptases derived from murine retroviruses such as MMLV (Moloney murine leukemia virus). Next, oligonucleotide primers or oligonucleotide probes are used for amplification reactions or hybridization reactions, respectively, and their amplification products or hybridization products are detected. As such methods, for example, RT-PCR method, Northern blotting method, dot blotting method, DNA array method, in situ hybridization method, ribonuclease protection assay, mRNA-seq, etc. can be used. For those having ordinary knowledge in the technical field, oligonucleotide primers or oligonucleotide probes suitable for each method can be set according to the general method based on the nucleotide sequence of the cDNA of MYT1. In the method for detecting the expression level of MYT1 at the translational level, first, a protein sample is prepared from cells treated with the test compound. Next, an antigen-antibody reaction is performed using an antibody specific to the MYT1 protein to detect the MYT1 protein. For the detection method of the protein using such an antibody, for example, for the aforementioned protein sample, an antibody specific to the MYT1 protein is added and an antigen-antibody reaction is performed to detect the binding of the aforementioned antibody to the MYT1 protein. When the antibody specific to the MYT1 protein is labeled, the MYT1 protein can be directly detected. When it is not labeled, it can be further reacted with a labeled molecule (e.g., secondary antibody or protein A) that recognizes the antibody, and the MYT1 protein can be indirectly detected using the label of the molecule. As such methods, for example, immunohistochemistry (immunostaining) method, Western blotting method, ELISA method, flow cytometry, image cytometry, radioimmunoassay, immunoprecipitation method, analysis method using antibody array, etc. can be used. The type or source of the antibody used is not particularly limited, and a monoclonal antibody is preferably used. As long as it can specifically detect the MYT1 protein sufficiently, a polyclonal antibody (a mixture of several to dozens of antibodies) or a polyclonal antibody can also be used. Also, Fab, Fab’, F(ab’) 2 , Fv, scFv, sc(Fv) 2 , dsFv, and antibody functional fragments or their polymers (e.g., dimers, trimers, tetramers, polymers) of bispecific antibodies. As such an anti-MYT1 protein antibody, it can be a commercially available product. Also, the detection of the MYT1 protein can also be carried out using a mass spectrometry method (MS). In particular, analysis by a mass spectrometer (LC / MS) linked to liquid chromatography is sensitive and advantageous. Detection by the mass spectrometry method can be carried out, for example, by labeling the protein in the aforementioned protein sample, fractionating the labeled protein, subjecting the fractionated protein to mass spectrometry, and confirming the MYT1 protein from the mass spectrometry value. As the label, known isotope labeling reagents in the technical field can be used, and appropriate labeling reagents can be obtained as commercially available products. Also, fractionation can be carried out using known methods in the technical field, for example, commercially available ion exchange columns, etc. can be used. In this specification, "having MYT1 inhibitory activity" means a situation where MYT1 activity is reduced in vitro, in a cell culture system, or in an animal. For example, the inhibitory activity IC of MYT1 measured 50 is preferably 10 μM or less, 5 μM or less, or 1 μM or less. More preferably, the MYT1 inhibitory activity (IC 50 ) is a compound of 100 nM or less, 10 nM or less, 3 nM or less, 100 pM or less, or 10 pM or less. Even more preferably, the MYT1 inhibitory activity (IC 50 ) is a compound of 1 nM to 1 μM, 1 nM to 750 nM, 1 nM to 500 nM, or 1 nM to 250 nM. Particularly preferably, the MYT1 inhibitory activity (IC 50 ) is a compound of less than 20 nM, or 1 nM to 20 nM. The higher (lower IC 50 ) the MYT1 inhibitory activity of the compound, the more effective it can be selected for the treatment or prevention of cancer in patients who test positive for RB1 gene mutation or have reduced expression of the RB1 gene or protein. The compound selected by the method according to this embodiment can improve the treatment efficacy more by being used in combination with a chemotherapeutic agent in the treatment of cancer in patients who test positive for RB1 gene mutation or have reduced expression of RB1 gene or protein. [Examples] Hereinafter, the present disclosure will be described in more detail based on examples, but the present disclosure is not limited to the following examples. NMR analysis was performed using AVANCE III HD400 (400 MHz) manufactured by BRUKER. NMR data is expressed in ppm (parts per million) (δ), and the deuterium lock signal from the sample solvent was referenced. Mass spectrometry data can be obtained using a single quadrupole mass spectrometer (LCMS-2020) attached with ultra-high performance liquid chromatography (Nexera UC) manufactured by Shimadzu Corporation, or a single quadrupole mass spectrometer (SQD or SQD2) attached with Acquity ultra-high performance liquid chromatography (UPLC or UPLC I-Class) manufactured by Waters. Analysis of high performance liquid chromatography was performed using any of the analysis conditions A to W shown in Tables 1 and 2 below. In Tables 1 and 2 below, "TFA" refers to trifluoroacetic acid, "FA" refers to formic acid, "AA" refers to ammonium acetate, and "AC" refers to ammonium bicarbonate. [Table 1] [Table 2] The microwave reaction was carried out using Initiator manufactured by Biotage. Also, in the microwave reaction, a snap cap reaction vial was used. The operation of the machine was carried out in accordance with the attached operation manual. The photoredox catalyst reaction was carried out using Penn PhD M2 Integrated Photoreactor (ACS Cent. Sci. 2017, vol. 3, issue 6, p. 647-653 (Non-patent Document 20)). The operation of the machine was carried out in accordance with the attached operation manual. Commercially available reagents were used without further purification. All non-aqueous reactions were carried out using commercially available dehydrated solvents.减压浓缩或溶媒馏除是使用旋转蒸发器进行。 Concentration under reduced pressure or solvent distillation was carried out using a rotary evaporator. In this specification, "room temperature" refers to a temperature of about 20°C to about 25°C. Compound a-1 4-bromo-7-chloro-2-(oxan-2-yl)indazole [Chemical Formula 22] 3,4-Dihydro-2H-pyran (32.68 g, 388 mmol) and pyridinium p-toluenesulfonate (9.77 g, 38.9 mmol) were added to a DCM solution (900 mL) of 4-bromo-7-chloro-1H-indazole (44.97 g, 194 mmol) in a reaction vessel, and the mixture was stirred at room temperature for 6 hours. A saturated aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted twice with DCM. The organic layer was dried over anhydrous sodium sulfate, the desiccant was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was suspended in a mixture of hexane / ethyl acetate (3 / 1), and the solid was filtered out. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography and combined with the previously obtained solid to give the title compound as a yellow solid (55.17 g, yield 90%). LCMS: m / z 315 [M+H] + HPLC retention time: 4.97 minutes (analysis condition J) Compound a-2 7-chloro-2-(oxan-2-yl)-1H-indazole-4-carboxylic acid (2,4,6-trichlorophenyl) ester [Chemical formula 23] Triethylamine (15.5 g, 153.18 mmol) was added to a toluene solution (340 mL) of 4-bromo-7-chloro-2-(oxan-2-yl)-1H-indazole (Compound a-1, 24.16 g, 76.55 mmol) in a reaction vessel. The reaction vessel was degassed under reduced pressure and replaced with nitrogen. Xantphos Pd G4 (3.69 g, 3.83 mmol) was added to the mixture, and the reaction vessel was further degassed under reduced pressure and replaced with nitrogen. After the reaction mixture was heated to 65 °C, a toluene solution (54 mL) of 2,4,6-trichlorophenyl formate (19.85 g, 88 mmol) that had been degassed under reduced pressure and replaced with nitrogen was added dropwise over 3 hours. The reaction mixture was further stirred at 65 °C for 20 minutes under a nitrogen atmosphere, then cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product of the title compound (46.69 g). LCMS: m / z 459 [M+H] + HPLC retention time: 4.86 minutes (analysis condition K) Compound a-3 7-chloro-2-(oxan-2-yl)-1H-indazole-4-carboxylic acid [Chemical formula 24] 2M aqueous sodium hydroxide solution (230 mL, 460 mmol) was added to a THF suspension (470 mL) of the crude product (46.69 g) of 7-chloro-2-(oxan-2-yl)-1H-indazole-4-carboxylic acid (2,4,6-trichlorophenyl) ester (Compound a-2) in a reaction vessel, and the mixture was stirred at 60 °C for 16 hours. The reaction mixture was cooled to room temperature, ethyl acetate, water, and aqueous phosphoric acid solution were added, and the pH was adjusted to 4. Then, the mixture was extracted twice with ethyl acetate. After washing the organic layer with water (500 mL), the mixture was extracted four times with saturated aqueous sodium hydrogen carbonate solution (400 mL) and 5% aqueous sodium hydrogen carbonate solution (400 mL). The combined aqueous layers were cooled to 5 °C, and aqueous phosphoric acid solution was added to adjust the pH to 4. The mixture was extracted four times with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and the desiccant was filtered off. The same operation was performed on other batches of the synthesized organic layers, which were combined and concentrated under reduced pressure to obtain the title compound as a pale yellow solid (38.76 g). LCMS: m / z 281 [M+H] + HPLC retention time: 2.79 minutes (Analysis condition K) Compound a-4 7-Chloro-N-methoxy-N-methyl-2-(oxan-2-yl)-1H-indazole-4-carboxamide [Formula 25] Triethylamine (55.89 g, 552 mmol), N,O-dimethylhydroxylamine hydrochloride (26.94 g, 276 mmol), and HATU (68.25 g, 180 mmol) were added to a THF solution (388 mL) of 7-chloro-2-(oxan-2-yl)-1H-indazole-4-carboxylic acid (Compound a-3, 38.76 g, 138 mmol) in a reaction vessel, and the mixture was stirred at room temperature for 15 hours. The reaction mixture was added to water and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and dried over anhydrous sodium sulfate. After filtering off the desiccant, the mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate) to obtain the title compound as a colorless solid (31.74 g, yield 71%). LCMS: m / z 324 [M+H] + HPLC retention time: 0.66 minutes (Analysis condition A) Compound a-5 4-Bromo-5-fluoro-2-iodoaniline [Formula 26] N-Iodosuccinimide (19.18 g, 85.248 mmol) was added to a solution of 4-bromo-3-fluoroaniline (15.43 g, 81.2 mmol) in acetic acid (200 mL) in a reaction vessel. The mixture was stirred at room temperature for 1 hour under a nitrogen atmosphere. The reaction mixture was cooled to 0 °C, and the solid was filtered off and washed with water. The resulting solid was dissolved in DCM and washed with saturated aqueous sodium carbonate. The organic layer was dried over anhydrous sodium sulfate, and after filtering off the desiccant, it was concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (hexane / ethyl acetate) to give the title compound as a brown solid (22.01 g, yield 86%). LCMS: m / z 316 [M+H] + HPLC retention time: 4.55 minutes (analysis condition J) Compound a-6 (E)-N'-(4-bromo-5-fluoro-2-iodophenyl)-N,N-dimethylmethanimidamide [Chemical Formula 27] 4-Bromo-5-fluoro-2-iodoaniline (Compound a-5, 28.58 g, 190.47 mmol) in the reaction vessel was dissolved in EtOH (180 mL), and N,N-dimethylformamide dimethyl acetal (43.12 g, 361.9 mmol) was added. The mixture was stirred at 80 °C for 1.5 hours. After cooling the reaction mixture to room temperature, it was concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (hexane / DCM) to give the title compound as a light red solid (31.7 g, yield 95%). LCMS: m / z 371 [M+H] + HPLC retention time: 2.59 minutes (analysis condition J) Compound a-7 (E)-N'-[4-bromo-2-[7-chloro-2-(oxan-2-yl)indazole-4-carbonyl]-5-fluorophenyl]-N,N-dimethylmethanimidamide [Chemical Formula 28] Cool the toluene solution (164 mL) of (E)-N'-(4-bromo-5-fluoro-2-iodophenyl)-N,N-dimethylformamidine (Compound a-6, 16.39 g, 44.18 mmol) in the reaction vessel to -40 °C. After dropping 1.3 M isopropylmagnesium chloride-lithium chloride complex THF solution (34 mL, 44.2 mmol), stir for 1 hour. Dropwise add the toluene solution (110 mL) of 7-chloro-N-methoxy-N-methyl-2-(oxan-2-yl)indazole-4-carboxamide (Compound a-4, 11.14 g, 34 mmol) to the reaction mixture over 30 minutes, and then stir at 0 °C for 1 hour. Add saturated aqueous sodium bicarbonate solution to the reaction mixture and extract 3 times with ethyl acetate. Dry the organic layer with anhydrous sodium sulfate, filter off the desiccant, and then concentrate under reduced pressure to obtain the crude product (22.38 g) of the title compound. LCMS: m / z 507 [M+H] + HPLC retention time: 3.65 minutes (Analysis condition J) Compound a-8 (2-Amino-5-bromo-4-fluorophenyl)-[7-chloro-2-(oxan-2-yl)indazol-4-yl]methanone [Chemical formula 29] Dissolve the crude product of (E)-N'-[4-bromo-2-[7-chloro-2-(oxan-2-yl)indazole-4-carbonyl]-5-fluorophenyl]-N,N-dimethylformamidine (Compound a-7, 22.38 g) in DMSO (220 mL) in the reaction vessel, add 5 M aqueous sodium hydroxide solution (20.4 mL), and stir at room temperature for 30 minutes. Add saturated aqueous ammonium chloride solution (300 mL) and water (1 L) to the reaction mixture. Filter out the solid and wash it with water. Purify the obtained solid by silica gel column chromatography 3 times to obtain the title compound as a yellow solid (7.41 g, yield 48%). LCMS: m / z 452 [M+H] + HPLC retention time: 5.42 minutes (Analysis condition J) Compound a-9 N-[4-bromo-2-[7-chloro-2-(oxan-2-yl)indazole-4-carbonyl]-5-fluorophenyl]-2-chloroacetamide [Chemical formula 30] Cool the DMA solution (120 mL) of (2-Amino-5-bromo-4-fluorophenyl)-[7-chloro-2-(oxan-2-yl)indazol-4-yl]methanone (Compound a-8, 7.41 g, 16.37 mmol) in the reaction vessel to 0 °C, add chloroacetyl chloride (1.96 mL, 24.64 mmol), and stir at room temperature for 1 hour to obtain the DMA solution of the title compound. LCMS: m / z 528 [M+H] + HPLC retention time: 5.57 minutes (analysis condition J) Compound a-10 6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-3-pyridin-1-ium-1-yl-1H-quinolin-2-one; chloride [Chemical formula 31] Pyridine (74 mL) was added to a DMA solution of N-[4-bromo-2-[7-chloro-2-(oxan-2-yl)indazole-4-carbonyl]-5-fluorophenyl]-2-chloroacetamide (Compound a-9) in a reaction vessel, and the mixture was stirred at 60 °C for 4 hours. The reaction mixture was cooled to room temperature to obtain a DMA / pyridine solution of the title compound. LCMS: m / z 553 [M] + HPLC retention time: 3.44 minutes (analysis condition J) Compound a-11 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1H-quinolin-2-one [Chemical formula 32] Hydrazine monohydrate (8.2 g, 163.8 mmol) was added to a DMA / pyridine solution of 6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-3-pyridin-1-ium-1-yl-1H-quinolin-2-one; chloride (Compound a-10), and the mixture was stirred at 60 °C for 4 hours and further stirred at room temperature for 13 hours. After adding water to the reaction mixture, the resulting solid was filtered off and washed with water. The obtained solid was purified by silica gel column chromatography (hexane / ethyl acetate) to obtain the title compound as a colorless solid (7.3 g, yield 91%). LCMS: m / z 491 [M+H] + HPLC retention time: 4.65 minutes (analysis condition J) Compound a-12 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1-[(4-methoxyphenyl)methyl]quinolin-2-one [Chemical formula 33] Suspend 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)-1H-indazol-4-yl]-7-fluoro-1H-quinolin-2-one (Compound a-11, 7.3 g, 14.84 mmol) and potassium carbonate (5.13 g, 37.12 mmol) in the reaction vessel in NMP (73 mL), add p-methoxybenzyl chloride (2.83 mL, 20.78 mmol), and stir at 70 °C for 2 hours. Cool the reaction mixture to room temperature, add water. Filter out the solid and wash it with water and hexane. Purify the obtained solid by silica gel column chromatography to obtain the title compound as a pale yellow solid (4.79 g, yield 53%). LCMS: m / z 611 [M+H] + HPLC retention time: 5.76 minutes (Analysis condition J) Compound a-13 3-Amino-4-[7-chloro-2-(oxan-2-yl)-1H-indazol-4-yl]-7-fluoro-6-hydroxy-1-[(4-methoxyphenyl)methyl]quinolin-2-one [Chemical formula 34] Add 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)-1H-indazol-4-yl]-7-fluoro-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-12, 500 mg, 0.817 mmol) and tBuBrettPhos Pd G3 (69.8 mg, 0.0817 mmol) to the reaction vessel, and degas the reaction vessel under reduced pressure and replace it with argon. Add DMA (8 mL) and 8M potassium hydroxide (245.1 μL, 1.961 mmol), degas the reaction vessel under reduced pressure and replace it with argon, then stir at room temperature for 21 hours. Add potassium dihydrogen phosphate (445 mg) and water, and filter out the resulting solid. Extract the filtrate with ethyl acetate, dry the organic layer with anhydrous sodium sulfate, filter off the desiccant, and concentrate under reduced pressure. Combine the residue with the previously obtained solid and purify by silica gel column chromatography to obtain the title compound as a light brown solid (308 mg, yield 68.7%). LCMS: m / z 549 [M+H] + HPLC retention time: 4.49 minutes (Analysis condition J) Compound a-14 3-Amino-4-[7-chloro-2-(oxan-2-yl)-1H-indazol-4-yl]-7-fluoro-1-[(4-methoxyphenyl)methyl]-6-(propan-2-yloxy)quinolin-2-one [Chemical formula 35] Suspend 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-6-hydroxy-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-13, 210 mg, 0.383 mmol) and potassium carbonate (265 mg, 1.917 mmol) in the reaction vessel in DMF (4.4 mL), add 2-iodopropane (190.2 μL, 1.913 mmol), and stir at room temperature for 18 hours. Add water to the reaction mixture and extract with ethyl acetate. Wash the organic layer with water and saturated aqueous sodium bicarbonate solution, dry over anhydrous sodium sulfate, filter off the desiccant, and then concentrate under reduced pressure. Purify the obtained residue by silica gel column chromatography (hexane / ethyl acetate) to obtain the title compound as a yellow solid (201 mg, yield 89%). LCMS: m / z 591 [M+H] + HPLC retention time: 5.60 minutes (analysis condition J) Compound A1 3-amino-4-(7-chloro-1H-indazol-4-yl)-7-fluoro-6-propan-2-yloxy-1H-quinolin-2-one [Formula 36] Add TFA / water (3 / 1, 3 mL) to 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1-[(4-methoxyphenyl)methyl]-6-propan-2-yloxyquinolin-2-one (Compound a-14, 201 mg, 0.34 mmol) in the reaction vessel and stir at 100 °C for 4 hours. Cool the reaction mixture to room temperature and concentrate under reduced pressure. Add MeOH to the residue and further concentrate. Add MeOH (4 mL) and 12 M hydrochloric acid (100 μL) to the residue and stir at room temperature for 20 hours. After concentrating the reaction mixture, dissolve the obtained residue in MeOH, add triethylamine. Concentrate the reaction mixture under reduced pressure and purify the obtained residue by silica gel column chromatography (hexane / ethyl acetate) to obtain the title compound as a pale yellow solid (48.3 mg, yield 37%). LCMS: m / z 387 [M+H] + HPLC retention time: 0.67 minutes (analysis condition A) Compound a-15 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-(3,3-difluoropropoxy)-7-fluoro-1-[(4-methoxyphenyl)methyl]quinolin-2-one [Formula 37] A 0.5 M solution of cyanomethylenetrimethylphosphonium in THF (2.53 mL, 1.265 mmol) was added to 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-6-hydroxy-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-13, 231 mg, 0.421 mmol) and 3,3-difluoropropan-1-ol (123 mg, 1.28 mmol) in a reaction vessel. The reaction vessel was degassed under reduced pressure and replaced with argon, and then stirred at 80 °C for 2.5 hours. The reaction mixture was cooled to room temperature, water (231 μL) was added, and the mixture was stirred at 80 °C for 15 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. THF was added to the resulting residue and the mixture was further concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to obtain the title compound as a pale yellow solid (233 mg, yield 88%). LCMS: m / z 627 [M+H] + HPLC retention time: 5.40 minutes (Analysis condition J) Compound A2 3-Amino-4-(7-chloro-1H-indazol-4-yl)-6-(3,3-difluoropropoxy)-7-fluoro-1H-quinolin-2-one [Formula 38] The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-(3,3-difluoropropoxy)-7-fluoro-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-15) under the same conditions as in the production example of Compound A1. LCMS: m / z 423 [M+H] + HPLC retention time: 0.65 minutes (Analysis condition A) Compound a-22 3-Amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1-(2-trimethylsilylethoxymethyl)quinolin-2-one [Formula 39] Cool the THF solution (25 mL) of 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1H-quinolin-2-one (Compound a-11, 1.732 g, 3.522 mmol) in the reaction vessel to 0 °C, add 60% sodium hydroxide / mineral oil (564 mg, 14.08 mmol), and stir for 30 minutes. Add 2-(chloromethoxy)ethyltrimethylsilane (1.86 mL, 10.6 mmol) to the reaction mixture, and further stir for 30 minutes. Add saturated aqueous sodium bicarbonate to the reaction mixture, and extract twice with ethyl acetate. Dry the organic layer over anhydrous sodium sulfate, filter off the desiccant, and concentrate under reduced pressure. Purify the obtained residue by silica gel column chromatography (hexane / ethyl acetate) to obtain the title compound as a pale yellow solid (1.87 g, yield 85%). LCMS: m / z 621 [M+H] + HPLC retention time: 6.33 minutes (analysis condition J) Compound a-23 3-Amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-6-hydroxy-1-(2-trimethylsilylethoxymethyl)quinolin-2-one [Formula 40] Synthesize the title compound from 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1-(2-trimethylsilylethoxymethyl)quinolin-2-one (Compound a-22) under the same conditions as in the production example of Compound a-13. LCMS: m / z 559 [M+H] + HPLC retention time: 5.35 minutes (analysis condition J) Compound a-24 3-Amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-cyclobutyloxy-7-fluoro-1-(2-trimethylsilylethoxymethyl)quinolin-2-one [Formula 41] Synthesize the title compound from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-6-hydroxy-1-(2-trimethylsilylethoxymethyl)quinolin-2-one (Compound a-23) under the same conditions as in the production example of Compound a-14. However, use bromocyclobutane instead of 2-iodopropane used in the production example of Compound a-14. In addition, heat the reaction mixture at 70 °C to carry out the reaction. LCMS: m / z 613 [M+H] + HPLC retention time: 5.00 minutes (analysis condition K) Compound A7 3-Amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclobutyloxy-7-fluoro-1H-quinolin-2-one [Chemical Formula 42] Anisole (125 mg, 1.15 mmol) and TFA (0.8 mL) were added to a DCM solution (0.8 mL) of 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-cyclobutyloxy-7-fluoro-1-(2-trimethylsilylethoxymethyl)quinolin-2-one (Compound a-24, 70.8 mg, 0.115 mmol) in a reaction vessel, and the mixture was stirred at room temperature for 3.5 hours. The reaction mixture was concentrated under reduced pressure, MeOH was added, and further concentration under reduced pressure was carried out. The resulting residue was purified by reverse-phase column chromatography (0.1% aqueous TFA / 0.1% TFA in acetonitrile). The fraction containing the title compound was collected, and saturated sodium bicarbonate was added for neutralization. The mixture was concentrated under reduced pressure, the resulting solid was filtered out, washed with water, and the title compound as a yellow solid (10.7 mg, yield 23%) was obtained. LCMS: m / z 399 [M+H] + HPLC retention time: 0.69 minutes (Analysis condition A) Compound A72 3-Amino-4-(7-chloro-1H-indazol-4-yl)-7-fluoro-6-[(1-fluorocyclopropyl)methoxy]-1H-quinolin-2-one [Chemical Formula 43] The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-6-hydroxy-1-(2-trimethylsilylethoxymethyl)quinolin-2-one (Compound a-23) under the same conditions as in the production examples of Compound a-15 and Compound A7. However, (1-fluorocyclopropyl)methanol was used instead of 3,3-difluoropropan-1-ol used in the production example of Compound a-15. LCMS: m / z 417 [M+H] + HPLC retention time: 0.65 minutes (Analysis condition A) Compound a-16 6-Bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-3-amine [Chemical Formula 44] 3-Amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1H-quinolin-2-one (Compound a-11, 1.496 g, 3.042 mmol) and silver carbonate (1.26 g, 4.57 mmol) were suspended in 1,2-dichloroethane (37 mL), then p-methoxybenzyl chloride (705 μL, 5.18 mmol) was added, and the mixture was stirred at 95 °C for 16 h. The reaction mixture was cooled to room temperature, filtered through diatomaceous earth, and washed with ethyl acetate. The resulting filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give the title compound (765 mg, yield 41%). Compound a-17 3-Amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol [Chemical Formula 45] The title compound was synthesized from 6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-3-amine (Compound a-16) under the same conditions as in the production example of Compound a-13. LCMS: m / z 549 [M+H] + HPLC retention time: 4.39 min (Analysis condition L) Compound A3 3-Amino-4-(7-chloro-1H-indazol-4-yl)-6-(cyclopropylmethoxy)-7-fluoro-1H-quinolin-2-one [Chemical Formula 46] The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-17) under the same conditions as in the production examples of Compound a-14 and A7. However, (iodomethyl)cyclopropane was used instead of 2-iodopropane used in the production example of Compound a-14. LCMS: m / z 399 [M+H] + HPLC retention time: 0.67 min (Analysis condition A) Compound a-102 (1s,3s)-3-fluorocyclobutyl trifluoromethanesulfonate [Chemical Formula 47] Cool a solution of (1s,3s)-3-fluorocyclobutan-1-ol (200 mg, 2.22 mmol) in DCM (2 mL) in the reaction vessel to 0 °C, add pyridine (197 μL, 2.44 mmol) and trifluoromethanesulfonic anhydride (413 μL, 2.44 mmol), and stir at room temperature for 1 hour. Purify the reaction mixture by silica gel column chromatography (DCM) to obtain the title compound (540 mg). 1H- NMR (d 6 -DMSO) δ: 5.41 - 5.16 (1H, m), 5.28 - 5.16 (1H, m), 2.69 - 2.57 (4H, m) Compound a-103 (1s,3s)-3-cyanocyclobutyl trifluoromethanesulfonate [Chemical Formula 48] Synthesize the title compound using the corresponding alcohol under the same conditions as in the production example of compound a-102. 1H- NMR (d 6 -DMSO) δ: 5.22 - 5.12 (1H, m), 3.61 - 3.39 (1H, m), 2.79 - 2.55 (4H, m). Compound A4 3-amino-4-(7-chloro-1H-indazol-4-yl)-7-fluoro-6-((1r,3r)-3-fluorocyclobutyl)oxy-1H-quinolin-2-one [Chemical Formula 49] Synthesize the title compound from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-17) under the same conditions as in the production examples of compound a-14 and A7. However, use the (1s,3s)-3-fluorocyclobutyl trifluoromethanesulfonate compound (a-102) instead of 2-iodopropane used in the production example of compound a-14. LCMS: m / z 417[M+H] + HPLC retention time: 0.65 minutes (Analysis condition A) Compound A5 (1r,3r)-3-[[3-amino-4-(7-chloro-1H-indazol-4-yl)-7-fluoro-2-side-oxy-1H-quinolin-6-yl]oxy]cyclobutane-1-carbonitrile [Chemical Formula 50] The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)-1H-indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-17) under the same conditions as in the production examples of Compounds a-14 and A7. However, (1S,3S)-3-cyanocyclobutyl trifluoromethanesulfonate (Compound a-103) was used instead of 2-iodopropane used in the production example of Compound a-14. LCMS: m / z 424 [M+H] + HPLC retention time: 0.60 minutes (Analysis condition A) Compound A6 3-Amino-4-(7-chloro-1H-indazol-4-yl)-7-fluoro-6-(3-fluoropropoxy)-1H-quinolin-2-one [Chemical formula 51] The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)-1H-indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-17) under the same conditions as in the production examples of Compounds a-14 and A7. However, 1-fluoro-3-iodopropane was used instead of 2-iodopropane used in the production example of Compound a-14. LCMS: m / z 405 [M+H] + HPLC retention time: 0.64 minutes (Analysis condition A) Compound a-25 4-Bromo-5-chloro-2-iodoaniline [Chemical formula 52] The title compound was synthesized from 4-bromo-3-chloroaniline under the same conditions as in the production example of Compound a-5. LCMS: m / z 332 [M+H] + HPLC retention time: 4.42 minutes (Analysis condition N) Compound a-26 (E)-N'-(4-Bromo-5-chloro-2-iodophenyl)-N,N-dimethylformamidine [Chemical formula 53] The title compound was synthesized from 4-bromo-5-chloro-2-iodoaniline (Compound a-25) under the same conditions as in the production example of Compound a-6. LCMS: m / z 387 [M+H] + HPLC retention time: 2.60 minutes (Analysis condition N) Compound a-27 (E)-N'-[4-Bromo-5-chloro-2-[7-chloro-2-(oxan-2-yl)-1H-indazole-4-carbonyl]phenyl]-N,N-dimethylformamidine [Chemical formula 54] The title compound was synthesized from (E)-N'-(4-bromo-5-chloro-2-iodophenyl)-N,N-dimethylformamidine (Compound a-26) under the same conditions as in the production example of Compound a-7. LCMS: m / z 523 [M+H] + HPLC retention time: 3.88 minutes (Analysis condition J) Compound a-28 (2-Amino-5-bromo-4-chlorophenyl)-[7-chloro-2-(oxan-2-yl)indazol-4-yl]methanone [Chemical formula 55] The title compound was synthesized from (E)-N'-[4-bromo-5-chloro-2-[7-chloro-2-(oxan-2-yl)indazol-4-carbonyl]phenyl]-N,N-dimethylformamidine (Compound a-27) under the same conditions as in the production example of Compound a-8. LCMS: m / z 468 [M+H] + HPLC retention time: 5.66 minutes (Analysis condition J) Compound a-31 3-Amino-6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1H-quinolin-2-one [Chemical formula 56] The title compound was synthesized from (2-Amino-5-bromo-4-chlorophenyl)-[7-chloro-2-(oxan-2-yl)indazol-4-yl]methanone (Compound a-28) under the same conditions as in the production examples of Compounds a-9, a-10, and a-11. LCMS: m / z 507 [M+H] + HPLC retention time: 4.96 minutes (Analysis condition J) Compound a-32 3-Amino-6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1-[(4-methoxyphenyl)methyl]quinolin-2-one [Chemical formula 57] The title compound was synthesized from 3-Amino-6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1H-quinolin-2-one (Compound a-31) under the same conditions as in the production example of Compound a-12. LCMS: m / z 627 [M+H] + HPLC retention time: 4.14 minutes (Analysis condition O) Compound a-33 3-Amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-hydroxy-1-[(4-methoxyphenyl)methyl]quinolin-2-one [Chemical formula 58] Under the same conditions as in the production example of compound a-13, the title compound was synthesized from 3-amino-6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1-[(4-methoxyphenyl)methyl]quinolin-2-one (compound a-32). LCMS: m / z 565 [M+H] + HPLC retention time: 3.09 minutes (analysis condition O) Compound a-34 3-Amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1-[(4-methoxyphenyl)methyl]-6-propan-2-yloxyquinolin-2-one [Chemical formula 59] Under the same conditions as in the production example of compound a-14, the title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-hydroxy-1-[(4-methoxyphenyl)methyl]quinolin-2-one (compound a-33). LCMS: m / z 607 [M+H] + HPLC retention time: 3.98 minutes (analysis condition O) Compound A8 3-Amino-7-chloro-4-(7-chloro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-quinolin-2-one [Chemical formula 60] Under the same conditions as in the production example of compound A1, the title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1-[(4-methoxyphenyl)methyl]-6-propan-2-yloxyquinolin-2-one (compound a-34). LCMS: m / z 403 [M+H] + HPLC retention time: 0.72 minutes (analysis condition A) Compound a-35 3-Amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-(3,3-difluoropropoxy)-1-[(4-methoxyphenyl)methyl]quinolin-2-one [Chemical formula 61] Under the same conditions as in the production example of compound a-15, the title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-hydroxy-1-[(4-methoxyphenyl)methyl]quinolin-2-one (compound a-33). However, cyanomethylenebutylphosphine and THF were used instead of the 0.5M cyanomethylenetrimethylphosphine THF solution used in the production example of compound a-15. LCMS: m / z 643 [M+H] + HPLC retention time: 3.68 minutes (analysis condition O) Compound A9 3-Amino-7-chloro-4-(7-chloro-1H-indazol-4-yl)-6-(3,3-difluoropropoxy)-1H-quinolin-2-one [Chemical formula 62] Under the same conditions as in the production example of Compound A1, the title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-(3,3-difluoropropoxy)-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-35). LCMS: m / z 439 [M+H] + HPLC retention time: 0.69 minutes (analysis condition A) Compound a-36 6-Bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-2-[(4-methoxyphenyl)methoxy]quinolin-3-amine [Chemical formula 63] Under the same conditions as in the production example of Compound a-16, the title compound was synthesized from 3-amino-6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1H-quinolin-2-one (Compound a-31). LCMS: m / z 627 [M+H] + HPLC retention time: 5.04 minutes (analysis condition O) Compound a-37 3-Amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol [Chemical formula 64] Under the same conditions as in the production example of Compound a-13, the title compound was synthesized from 6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-2-[(4-methoxyphenyl)methoxy]quinolin-3-amine (Compound a-36). LCMS: m / z 565 [M+H] + HPLC retention time: 2.98 minutes (analysis condition O) Compound A10 3-Amino-7-chloro-4-(7-chloro-1H-indazol-4-yl)-6-cyclobutyloxy-1H-quinolin-2-one [Chemical formula 65] The title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-37) under the same conditions as in the production examples of Compounds a-15 and A7. However, cyanomethylenebutylphosphine, THF, and cyclobutanol were use...

Claims

1. A compound represented by formula (1), a salt thereof, or a solvate thereof: [In the formula, R 4 is selected from the group consisting of a C 6 -C 10 aryl (R 4A ), a 4- to 10-membered heterocyclic group which may be substituted, and a 5- to 10-membered heteroaryl (R 4HA ); R 5 and R 6 together with the atoms to which they are bonded form an optionally substituted D ring; the D ring is selected from the group consisting of a 3- to 10-membered monocyclic alicyclic ring, a benzene ring, a 3- to 12-membered monocyclic heterocycle, and a 5- to 6-membered monocyclic aromatic heterocycle (D HA ); any two adjacent substituents on the D ring may together with the atoms to which they are bonded form an optionally substituted E ring].

2. The compound or its salt or their solvate according to claim 1, wherein the D ring is a benzene ring or a 5- to 6-membered monocyclic aromatic heterocycle (D HA ).

3. The compound or its salt or their solvate as described in claim 1 or 2, wherein, The D ring is unsubstituted or substituted by one or more Rs D wherein one or more Rs D are each independently selected from the group consisting of halogen, cyano, hydroxy, C 1 -C 6 alkylthio, C 1 -C 6 acylamino, mono-C 1 -C 6 alkylamino, C 1 -C 6 alkylsulfonylamino, C 3 -C 8 cycloalkylsulfonylamino, C 1 -C 6 alkoxy, halo-C 1 -C 6 alkoxy, hydroxy-C 1 -C 6 alkoxy, C 1 -C 6 alkoxy-C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl-C 1 -C 6 alkoxy, 4- to 10-membered heterocyclic-C 1 -C 6 alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclic oxy, C 1 -C 6 acyl, mono-C 3 -C 8 cycloalkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl, di-C 1 -C 6 alkylphosphonyl, C 1 -C 6 alkyl, halo-C 1 -C 6 alkyl, hydroxy-C 1 -C 6 alkyl, di-C 1 -C 6 alkylaminocarbonyl-C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl, C 2 -C 6 alkenyl, hydroxy C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, hydroxy C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and a group consisting of 5- to 10-membered heteroaryl, the C 1 -C 6 alkylthio, C 1 -C 6 alkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl C 1 -C 6 alkoxy, 4- to 10-membered heterocyclic group C 1 -C 6 alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclic oxy group, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may be further independently substituted by one or more substituents selected from the group consisting of halogen, cyano, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, side oxy group, halo C 1 -C 6 alkyl, and C 3 -C 8 cycloalkyl.

4. The compound or its salt or their solvate as described in any one of claims 1 to 3, wherein, The D ring is unsubstituted or substituted by one or more Rs D wherein one or more Rs D are each independently selected from the group consisting of halogen, C 1 -C 6 alkoxy, halo C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl C 1 -C 6 alkoxy, C 3 -C 8 cycloalkoxy, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, and C 3 -C 8 cycloalkyl.

5. The compound or its salt or their solvate as described in any one of claims 1 to 4, wherein, Any two adjacent substituents on the D ring together with the atoms to which they are bonded form an optionally substituted E ring.

6. The compound or its salt or their solvate as described in any one of claims 1 to 5, wherein, The D ring and the E ring form a bicyclic ring represented by the following formula: (wherein, * represents the carbon bonded to R in formula (1), ** represents the carbon bonded to R in formula (1)). In the formula, the D ring is represented by "D ring" and the E ring is represented by "E ring"). 5 The carbon bonded to R in formula (1), ** represents the carbon bonded to R in formula (1). 6 In the formula, the D ring is represented by "D ring" and the E ring is represented by "E ring".

7. The compound or its salt or their solvate according to claim 1, which is represented by the formula (2): [wherein, R 4 is selected from the group consisting of optionally substituted C 6 -C 10 aryl (R 4A ), optionally substituted 4- to 10-membered heterocyclic group, and optionally substituted 5- to 10-membered heteroaryl (R 4HA ); X 5 is CR x5 or N, X 6 is CR x6 or N, X 10a is CR x10a or N, R x5 、 R x6 、R 6a and R x10a are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, and the hydroxyl, sulfhydryl, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl may be further substituted, or R x5 and R x6 , R x6 and R 6a , or R 6a and R x10a may together with the atoms to which they are bonded form an optionally substituted E ring].

8. The compound or its salt or their solvate as described in claim 7, wherein, X 5 is CH, X 6 is CR x6 , X 10a is CR x10a .

9. The compound or its salt or their solvate as described in claim 7 or 8, wherein, R 6a selected from the group consisting of hydrogen, halogen, cyano, halo-C 1 -C 6 -alkoxy, and C 1 -C 6 -alkyl.

10. The compound or its salt or their solvate as described in any one of claims 7 to 9, wherein, R x10a selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, and C 3 -C 8 -cycloalkyl.

11. The compound or its salt or their solvate as described in any one of claims 7 to 10, wherein, The E ring is represented by the following formula: (where * represents the carbon bonded to R in formula (2), ** represents the carbon bonded to R in formula (2), and in the formula, the E ring is denoted as "E ring"). 6a The carbon bonded to R in formula (2), x10a The carbon bonded to R in formula (2), and in the formula, the E ring is denoted as "E ring".

12. The compound or its salt or their solvate as described in any one of claims 1 to 11, wherein, The E ring is unsubstituted or substituted by one or more Rs E wherein one or more Rs E are each independently selected from the group consisting of halogen, C 1 -C 6 alkoxy, boranyl, and C 1 -C 6 alkyl.

13. The compound or its salt or its solvate according to claim 1 or 7, which is represented by the formula (3): [In the formula, R 4 is selected from the group consisting of optionally substituted C 6 -C 10 aryl (R 4A ), optionally substituted 4- to 10-membered heterocyclic group, and optionally substituted 5- to 10-membered heteroaryl (R 4HA ); X 5 is CR x5 or N, X 6 is CR x6 or N, X 7 is CR x7 or N, X 8 is CR x8 or N, X 9 is CR x9 or N, X 10 is CR x10 or N, R x5 、 R x6 、R x7 、R x8 、R x9 and R x10 are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, and the hydroxy, mercapto, amino, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, carbonyl, carboxyl, sulfonyl, phosphoryl, boron, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and 5- to 10-membered heteroaryl may also be further substituted.

14. The compound or its salt or their solvate as described in claim 13, wherein, X 5 is CH, X 6 is CR x6 , X 7 is CR x7 or N, X 8 is CR x8 or N, X 9 is CR x9 or N, X 10 is CR x10 or N.

15. The compound or its salt or their solvate as described in claim 13 or 14, wherein, X 7 is N, X 8 is Cr x8 , X 9 is Cr x9 , X 10 is Cr x10 ; X 7 is Cr x7 , X 8 is N, X 9 is Cr x9 , X 10 is Cr x10 ; X 7 is Cr x7 , X 8 is Cr x8 , X 9 is N, X 10 is Cr x10 ; X 7 is Cr x7 , X 8 is Cr x8 , X 9 is Cr x9 , X 10 is N; X 7 is N, X 8 is Cr x8 , X 9 is Cr x9 , X 10 is N; X 7 is Cr x7 , X 8 is N, X 9 is Cr x9 , X 10 is N; or X 7 is N, X 8 is N, X 9 is Cr x9 , X 10 is Cr x10 .

16. The compound or its salt or their solvate as described in any one of claims 7 to 15, wherein, R x6 selected from hydrogen, halogen, hydroxyl, C 1 -C 6 alkylthio, C 1 -C 6 amide group, single C 1 -C 6 alkylamino, C 1 -C 6 alkylsulfonamide, C 3 -C 8 cycloalkylsulfonamide, C 1 -C 6 alkoxy, halogenated C 1 -C 6 alkoxy, hydroxyl C 1 -C 6 alkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl C 1 -C 6 alkoxy, 4- to 10-membered heterocyclic group C 1 -C 6 alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclic oxy, C 1 -C 6 acyl, single C 3 -C 8 cycloalkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl, di C 1 -C 6 alkylphosphonyl, C 1 -C 6 alkyl, halogenated C 1 -C 6 alkyl, hydroxyl C 1 -C 6 alkyl, di C 1 -C 6 alkylaminocarbonyl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, C 2 -C 6 alkenyl, hydroxyl C 2 -C 6 alkenyl, C 2 -C 6 Alkynyl, hydroxy C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and a group consisting of 5- to 10-membered heteroaryl, the C 1 -C 6 Alkylthio, C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclic group C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, 4- to 10-membered heterocyclic group oxy, C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl, 4- to 10-membered heterocyclic group, C 6 -C 10 Aryl, and 5- to 10-membered heteroaryl may further be independently substituted by one or more substituents selected from the group consisting of halogen, cyano, hydroxy, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, side oxy, halo C 1 -C 6 Alkyl, and C 3 -C 8 substituted by one or more substituents selected from the group consisting of cycloalkyl.

17. The compound or its salt or their solvate as described in any one of claims 7 to 16, wherein, R x6 selected from the group consisting of hydrogen, methoxy, ethoxy, propoxy, propane-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yloxy], [(2R)-butan-2-yloxy], methyl, ethyl, propyl, propane-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl.

18. The compound or its salt or their solvate as described in any one of claims 13 to 17, wherein, R x7 is hydrogen, halogen, C 1 -C 6 -alkoxy or C 1 -C 6 -alkyl.

19. The compound or its salt or their solvate as described in any one of claims 13 to 18, wherein, R x8 is hydrogen, halogen, C 1 -C 6 -alkoxy or C 1 -C 6 -alkyl.

20. The compound or its salt or their solvate as described in any one of claims 13 to 19, wherein, R x9 selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkoxy, C 1 -C 6 alkyl, and boronyloxy.

21. The compound or its salt or their solvate as described in any one of claims 13 to 20, wherein, R x10 is hydrogen, halogen, C 1 -C 6 -alkoxy or C 1 -C 6 -alkyl.

22. The compound or its salt or their solvate as described in any one of claims 1 to 21, wherein, R 4 is a 5- to 10-membered heteroaryl group that can be substituted (R 4HA ).

23. The compound or its salt or their solvate as described in claim 22, wherein, 5- to 10-membered heteroaryl (R 4HA ) is selected from the group consisting of pyrimidinyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridinyl.

24. The compound or its salt or their solvate as described in claim 22 or 23, wherein, 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or substituted by one or more R a , where one or more R a are each independently selected from the group consisting of halogen, cyano, hydroxy, amino, C 1 -C 6 -alkyl, halo-C 1 -C 6 -alkyl, hydroxy-C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, halo-C 1 -C 6 -alkoxy, and alkylsulfonamide.

25. The compound or its salt or their solvate as described in any one of claims 22 to 24, wherein, 5- to 10-membered heteroaryl (R 4HA ) is 1H-indazol-4-yl, or 1H-indazol-4-yl substituted with one or more halogens.

26. A compound selected from the following compounds, or a salt thereof, or a solvate of the same: 3-amino-7-chloro-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-benzo[h]quinolin-2-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclopropyl-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methyl-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propan-2-yl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclopropyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclobutyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-ethyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(5-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(5-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, (S)-3-amino-6-cyclopropyl-4-(5-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-ethyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-ethoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-cyclopropyl-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propoxy-1H-1,7-phenanthroline-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthroline-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-ethoxy-1H-1,7-phenanthroline-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthroline-2-one, 3-amino-6-ethoxy-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthroline-2-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthroline-2-one, 3-amino-6-ethyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthroline-2-one, 3-amino-6-cyclobutyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthroline-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,10-phenanthroline-2-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,10-phenanthroline-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,10-phenanthroline-2-one, 3-amino-6-ethyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,10-phenanthroline-2-one, 3-amino-9-fluoro-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthroline-2-one, 3-amino-9-fluoro-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthroline-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-9-fluoro-6-methoxy-1H-1,7-phenanthroline-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-9-fluoro-6-methyl-1H-1,7-Phenanthrolin-2-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methoxy-10H-pyrido[2,3-f]quinolin-9-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-(propan-2-yloxy)-10H-pyrido[2,3-f]quinolin-9-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methyl-10H-pyrido[2,3-f]quinolin-9-one, 8-amino-5-cyclopropyl-7-(7-fluoro-1H-indazol-4-yl)-10H-pyrido[2,3-f]quinolin-9-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methyl-10H-pyrido[3,2-h]quinazolin-9-one, 8-amino-5-cyclopropyl-7-(7-fluoro-1H-indazol-4-yl)-10H-pyrido[3,2-h]quinazolin-9-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,8-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5,6-dimethyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-5-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-1H-1,7-phenanthrolin-2-one, 3-amino-4-(5,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-methyl-4-(1H-pyrazolo[4,3-c]pyridin-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(1H-benzotriazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, and 3-amino-6-(tert-butyl)-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one., 27. A pharmaceutical composition comprising the compound or its salt or their solvate as described in any one of claims 1 to 26 as an active ingredient.

28. A pharmaceutical composition which is combined with a chemotherapeutic agent and contains, as an active ingredient, a MYT1 inhibitor for treating or preventing cancer in cancer patients positive for detection of an RB1 gene mutation or having low expression of the RB1 gene or protein, and the aforementioned MYT1 inhibitor is the compound or its salt or their solvate as described in any one of claims 1 to 26.